



Serena Dato, Mette Sørensen and Giuseppina Rose
www.mdpi.com/journal/genes
Edited by
Printed Edition of the Special Issue Published in Genes
Genetic Determinants of Human
Longevity













Danish Aging Research Center









This is a reprint of articles from the Special Issue published online in the open access journal
Genes (ISSN 2073-4425) in 2019 (available at: https://www.mdpi.com/journal/genes/special issues/
Genetic-Determinants-Human-Longevity).
For citation purposes, cite each article independently as indicated on the article page online and as
indicated below:




c© 2019 by the authors. Articles in this book are Open Access and distributed under the Creative
Commons Attribution (CC BY) license, which allows users to download, copy and build upon
published articles, as long as the author and publisher are properly credited, which ensures maximum
dissemination and a wider impact of our publications.
The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons
license CC BY-NC-ND.
Contents
About the Special Issue Editors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Serena Dato, Mette Soerensen and Giuseppina Rose
Untangling the Genetics of Human Longevity—A Challenging Quest
Reprinted from: Genes 2019, 10, 585, doi:10.3390/genes10080585 . . . . . . . . . . . . . . . . . . . 1
Giusi Taormina, Federica Ferrante, Salvatore Vieni, Nello Grassi, Antonio Russo and
Mario G. Mirisola
Longevity: Lesson from Model Organisms
Reprinted from: Genes 2019, 10, 518, doi:10.3390/genes10070518 . . . . . . . . . . . . . . . . . . . 5
Paolo Abondio, Marco Sazzini, Paolo Garagnani, Alessio Boattini, Daniela Monti,
Claudio Franceschi, Donata Luiselli and Cristina Giuliani
The Genetic Variability of APOE in Different Human Populations and Its Implications
for Longevity
Reprinted from: Genes 2019, 10, 222, doi:10.3390/genes10030222 . . . . . . . . . . . . . . . . . . . 25
Jacob Hjelmborg, Pia Larsen, Jaakko Kaprio, Matt McGue, Thomas Scheike,
Philip Hougaard and Kaare Christensen
Lifespans of Twins: Does Zygosity Matter?
Reprinted from: Genes 2019, 10, 166, doi:10.3390/genes10020166 . . . . . . . . . . . . . . . . . . . 53
Daniela Scarabino, Martina Peconi, Franca Pelliccia and Rosa Maria Corbo
Analysis of the Association Between TERC and TERT Genetic Variation and Leukocyte Telomere
Length and Human Lifespan—A Follow-Up Study
Reprinted from: Genes 2019, 10, 82, doi:10.3390/genes10020082 . . . . . . . . . . . . . . . . . . . . 63
Francesco De Rango, Paolina Crocco, Francesca Iannone, Adolfo Saiardi,
Giuseppe Passarino, Serena Dato and Giuseppina Rose
Inositol Polyphosphate Multikinase (IPMK), a Gene Coding for a Potential Moonlighting
Protein, Contributes to Human Female Longevity
Reprinted from: Genes 2019, 10, 125, doi:10.3390/genes10020125 . . . . . . . . . . . . . . . . . . . 74
Paolina Crocco, Alberto Montesanto, Serena Dato, Silvana Geracitano, Francesca Iannone,
Giuseppe Passarino and Giuseppina Rose
Inter-Individual Variability in Xenobiotic-Metabolizing Enzymes: Implications for Human
Aging and Longevity
Reprinted from: Genes 2019, 10, 403, doi:10.3390/genes10050403 . . . . . . . . . . . . . . . . . . . 86
Mary Revelas, Anbupalam Thalamuthu, Christopher Oldmeadow, Tiffany-Jane Evans,
Nicola J. Armstrong, Carlos Riveros, John B. Kwok, Peter R. Schofield, Henry Brodaty,
Rodney J. Scott, John R. Attia, Perminder S. Sachdev and Karen A. Mather
Exceptional Longevity and Polygenic Risk for Cardiovascular Health
Reprinted from: Genes 2019, 10, 227, doi:10.3390/genes10030227 . . . . . . . . . . . . . . . . . . . 97
v

About the Special Issue Editors
Serena Dato obtained a Ph.D. in Molecular Bio-Pathology in 2004. Since September 2006, she has 
been an Assistant Professor in Genetics at the Department of Cell Biology of the University of 
Calabria, where she carries out research at the Genetics Laboratory. From the beginnning, her 
research interests have focused on the study of human longevity and in particular on the 
development of experimental designs and new analytical approaches for the study of the genetic 
component of longevity. With her group, she developed an algorithm for integrating demographic 
data into genetics, which enabled the application of a genetic-demographic analysis to cross-
sectional samples. She was involved in several recruitment campaigns for the collection of data and 
DNA samples from old and oldest-old people in her region, both nonagenarian and centenarian 
families. She has several international collaborations with groups involved in her research field in 
Europe and the USA. Since 2008, she has been actively collaborating with the research group of 
Prof. K. Christensen at the Aging Research Center of the Institute of Epidemiology of Southern 
Denmark University, where she spent a year as a visiting researcher in 2008. Up to now, her work 
has led to forty-eight scientific papers in peer reviewed journals, two book chapters and 
presentations at scientific conferences.
Mette Sørensen has been active within ageing research since 2006, with work ranging from 
functional molecular biological studies to genetic epidemiology and bioinformatics. She obtained a 
Ph.D. in genetic epidemiology of human longevity in 2012 and was appointed Associate Professor at 
the University of Southern Denmark in March 2019. Her main research interest is in the mechanisms 
of ageing, age-related diseases and longevity, with an emphasis on genetic and epigenetic variation. 
Her work is characterized by a high degree of international collaboration and interdisciplinarity. The 
work has, per September 2019, led to thirty-one scientific papers in peer reviewed journal, as well as 
popular science communications, presentations at scientific conferences, media appearances, and an 
independent postdoctoral grant from the Danish Research Council in 2013.
Giuseppina Rose is Associate Professor in Genetics at the University of Calabria. She graduated from 
the University of Calabria School of Natural Science in 1983 and served as a Research Assistant there 
from 1992–1999. In 1994 she achieved a Ph.D. in Biochemistry and Molecular Biology at the 
University of Bari, Italy. She became Assistant Professor of Genetics at the University of Calabria 
from 2000–2003 before becoming Associate Professor in 2003. From the very beginning of her career, 
she worked on human population genetics, with a special reference in the genetic variability in 
complex traits. From 1996, she focused her interests in the study of human longevity and age-related 
traits, exploring the influence of mitochondrial and nuclear variability on human survival but also on 
the genetic predisposition to age-related complex diseases. Her studies have provided significant 
contributions to the identification of genetic factors modulating rate and quality of human ageing 
and have also contributed to recognize main players in molecular mechanisms related to ageing 
phenotypes. She has participated in several European projects, coordinating the local research 
activity and collaborating with group leaders in longevity studies. She has published eighty-eight 
scientific papers in peer reviewed international journals, four book chapters and more than one 




G C A T
T A C G
G C A T
Editorial
Untangling the Genetics of Human
Longevity—A Challenging Quest
Serena Dato 1,*,†, Mette Soerensen 2,*,† and Giuseppina Rose 1,*,†
1 Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, Italy
2 The Danish Twin Registry and Epidemiology, Biodemography and Biostatistics, Department of Public
Health, University of Southern Denmark, 5000 Odense-C, Denmark
* Correspondence: serena.dato@unical.it (S.D.); msoerensen@health.sdu.dk (M.S.); pina.rose@unical.it (G.R.)
† All authors equally contributed.
Received: 23 July 2019; Accepted: 25 July 2019; Published: 31 July 2019
Keywords: genetic determinants of human longevity; genetic variation; genetic association study;
longevity-related genes; human lifespan
Human average life expectancy in developed countries has increased dramatically in the last
century, a phenomenon which is potentially accompanied by a significant rise in multi-morbidity and
frailty among older individuals. Nevertheless, some individuals appear someway resistant to causes
of death, such as cancer and heart disease, compared with the rest of the population, and are able to
reach very old ages in good clinical conditions, while others are not. Thus, during the last two decades
we have witnessed an increase in the number of studies on biological and molecular factors associated
with the variation in healthy aging and longevity. Several lines of evidence support the genetic basis of
longevity: from the species-specific maximum lifespan to the genetically determined premature aging
syndromes. Studies in human twins, that aimed to distinguish the genetic from the environmental
component, highlighted a heritability of life span close to 25%. In centenarian’s families, the offspring
of long-lived individuals not only exhibit a survival advantage compared to their peers, but also have
a lower incidence of age-related diseases. On the other hand, population studies found that genetic
factors influence longevity in age- and sex-specific ways, with a most pronounced effect at advanced
age and possibly in men compared to women. All this evidence indicates that a genetic influence on
longevity exists, laying the foundation for the search for the genetic components of extreme long life.
Consequently, over the past three decades, there has been a surge in genetic research, due in part to
advances in molecular technologies, starting as studies of single genetic variants in candidate genes
and pathways, moving on to array-based genome-wide association studies (GWAS) and subsequently
to next generation sequencing (NGS). However, despite a plethora of studies, only few variants (in the
APOE, FOXO3A and 5q33.3 loci) have been successfully replicated in different ethnic groups and the
emerging picture is complex. For instance, it is an understatement to think that long-lived people
harbor only favorable variants, completely avoiding risk alleles for major age-related diseases; indeed,
there is evidence that many disease alleles are present in long-lived people. It is more probable that the
longevity phenotype is the result of a particular combination of pro-longevity variants and risk alleles
for pathologies, likely interacting in networks in a sex- and age-specific way. Finally, characteristics of
aging are extremely heterogeneous, even among long-lived individuals, due to the complex interaction
among genetic factors, environment, lifestyle, culture and resiliency. Population and study specificity,
lack of statistical power for such a rather rare phenotype and missing heritability represent further
hard obstacles to overcome in genotype–phenotype association studies. Thus, many challenges remain
to be addressed in the search for the genetic components of human longevity. In this Special Issue we
included five original articles and two reviews covering different areas in the field of human longevity,
to help the reader take stock of the situation and point to future perspectives of the field.
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The two reviews in particular look closely at two main arguments of biogerontology research.
The paper by Taormina and co-workers gives an updated review of the lessons from model organisms,
where a substantial number of findings suggest that longevity could “directly” be promoted by
interventions in specific pathways, like inflammation, oxidative stress response, DNA repair, as well as
the use of nutrients [1]. The most relevant model systems used in biogerontology are discussed, as well
as significant discoveries confirmed in humans, advising the researchers to use different model systems
to avoid misinterpretation of the results due to confounding factors or model system peculiarities.
The paper by Abondio et al. [2] reviews the available literature on APOE and its involvement in
biological pathways related to human longevity, under an anthropological and population genetics
perspective, highlighting the evolutionary dynamics, which may have shaped the distribution of
its haplotypes across the globe and the potential adaptive role. Both of the two reviews are useful
compendia of reference papers in the field and, at the same time, provide good points of discussion for
future studies on the genetic aspects of human longevity.
The paper by Hjelmborg et al. discusses an interesting topic for demographical studies on human
longevity, i.e., the role of zygosity in a twin’s lifespan [3]. Twin cohorts have been analyzed in several
GWAS of common traits and diseases around the world. Although there is no evidence that the
gene–disease associations seen in singletons differ in twins, the question if selecting one individual
from a twin pair implies a selection in survival due to zygosity is still often questioned. The authors
compared the relative survival of monozygotic (MZ) with dizygotic (DZ) twins (from the 1870–1900
and the 1961–1990 birth cohorts), from one of the largest nationwide cohorts of twins with valid vital
status, the Danish Twin Registry; they found no correlation of mortality with zygosity, meaning that
MZ and DZ pairs appear to share the same mortality process. Thus, being a twin does not appear
to impact the basic biological processes and human development in adolescence and adulthood.
This is an interesting result for the studies on disease onset and other age-dependent traits which
use twins, because it implies that findings from twins are generalizable to the population as a whole,
especially when large sample sizes are used.
The three candidate gene association studies of longevity presented here (the papers by
Scarabino et al., De Rango et al. and Crocco et al.) directly deal with the search for the genetic
component of longevity and healthy aging. The response to external injuries is the leitmotif unifying
all three association studies.
As it is known, internal and external stresses disrupt telomere homeostasis. The contribution by
Scarabino and co-workers confirms the genetic determination of leukocyte telomere length (LTL) by
TERT variability, showing that shorter LTL at baseline may predict a shorter lifespan [4]. Furthermore,
they found that the reliability of LTL as a lifespan biomarker could be age-specific and act in specific
age-spans (age 70–79 in their study population).
The papers by De Rango et al. and Crocco et al. highlight the complexity of longevity, a highly
dynamic phenotype influenced by internal and external stresses, that makes the identification of genes
robustly associated with it very challenging. De Rango’s paper investigated for the first time the
contribution to the longevity phenotype of the genetic variability of IPMK (Inositol Polyphosphate
Multikinase), a potential moonlighting protein performing multiple functions in pathways affecting
the aging process, from nutrient-sensing to oxidative stress and telomere maintenance [5]. This paper
supports this gene as a novel gender-specific determinant of human longevity on one hand, and on
the other hand promotes pleiotropic proteins like IPMK, able to integrate cellular activities in space
and time, as crucial determinants of the complex connections among aging, health, and longevity.
Dynamic genetic effects on longevity were found in the paper by Crocco et al. who investigated the
variability of xenobiotic metabolizing genes, known to mediate the response/toxicity to xenobiotics [6].
They found lifelong changes in the frequency of alleles at CYP2B6, CYP3A5, COMT and ABCC2 genes,
following either linear or non-linear trajectories with respect to the chance of becoming long-lived.
Such findings underline once again that SNPs associated with longevity might behave either as
pro-longevity or killing variants but also as deleterious variants neutralized by the protective effect of
2
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pro-longevity genes (buffered variant), an important aspect to take into account in disentangling the
genetic contributors to human longevity.
Finally, the paper by Revelas and co-workers contributes to the open debate of whether extreme
longevity is coupled to risks for major diseases [7]. The authors built a polygenic risk score for
cardiovascular health, based on GWAS variants, cardiovascular-related risk factors (such as cholesterol
levels) and cardiovascular multi-morbidity disease (myocardial infarction, coronary artery disease,
stroke etc.). By exploring the genetic profiles of 95+ year old individuals, the authors found that these
extremely long-lived subjects did not have lower polygenic risk for cardiovascular health as compared
to younger subjects, thus supporting the theory that exceptional longevity does not necessarily imply
the absence of risk factors for major age-related traits.
Overall, we believe these papers, highlighting different facets and the complexity of the studies
on the genetics of human longevity, may help to understand the path research has taken in the field up
to now, and to explore some possible interventions, taking advantage of the pathways highlighted and
of the perspectives they are unveiling for the future.
So, where should the longevity genetic field go from here? Despite decades of genetic studies,
the variants consistently identified as associated to human longevity explain only a small part of the
estimated heritability. For facing the challenge of ‘missing heritability’, new and innovative approaches
are needed. First of all, more studies are needed to elucidate the effect of rare variants with larger effect
sizes, not captured by standard GWAS. The opportunity of high-throughput methodologies like NGS,
together with large multi-center collaborative studies of extremely long-lived cohorts, can contribute
to pave the way for untangling the networks involved in human longevity. In this sense, the study of
epistatic effects of different genetic markers in gene-set and pathway-enrichment analyses, as well as the
integration of several layers of biological variation (SNP, Copy Number Variants, epigenetic markers) in
polygenic risk scores could further help too. The application of a more functional genomic approach like
the collection of whole-exome sequencing, genome-wide epigenetic, cell-specific transcriptomic data
and the integration of all these layers of genomic information can help to disentangle the determinants
of lifespan. Finally, the collection of life-long environmental and lifestyle variables known to influence
an individual’s health (like microbiome and nutrition), can significantly improve our chance to untangle
the intricate interplay between genes and environment in determining the longevity phenotype.
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di rilevante Interesse Nazionale—2015, Prot. 20157ATSLF) to G.R. M.S. was supported by The Danish Council for
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Abstract: Research on longevity and healthy aging promises to increase our lifespan and decrease
the burden of degenerative diseases with important social and economic effects. Many aging theories
have been proposed, and important aging pathways have been discovered. Model organisms have
had a crucial role in this process because of their short lifespan, cheap maintenance, and manipulation
possibilities. Yeasts, worms, fruit flies, or mammalian models such as mice, monkeys, and recently,
dogs, have helped shed light on aging processes. Genes and molecular mechanisms that were
found to be critical in simple eukaryotic cells and species have been confirmed in humans mainly by
the functional analysis of mammalian orthologues. Here, we review conserved aging mechanisms
discovered in different model systems that are implicated in human longevity as well and that could
be the target of anti-aging interventions in human.
Keywords: model systems; aging; signal transduction; molecular senescence
1. Introduction
Aging is considered a natural and unavoidable “side effect” of life in spite of the observation that
life span can vary greatly between species and individuals. Researchers have developed many theories
on the cause of aging, but none of them prevailed. George Williams, an undisputed leader of the field,
proposed that natural selection fixes alleles in a population for their positive contribution to fitness early
in life, but that the selected alleles become deleterious later in life [1]. Around this idea, he developed
the antagonistic pleiotropy theory. According to this proposal, aging is the result of (a) casual selection
of late-acting deleterious alleles because of their advantage early in life and (b) the incapacity of natural
selection to filter the late-acting detrimental effect of these alleles. Corollary to this theory is that mutations
that are capable of increasing the life span must cause a disadvantage or a reduced fitness during the
early stages of life. Many mutations that are capable of increasing the life span of different model systems
confirmed this prediction, but the existence of long-lived mutants, such as the yeast Ras2 or the C. elegans
daf-2 that grow and reproduce at a normal rate [2], suggests that extended life doesn’t imply a reproductive
or growth rate fitness cost. However, these observation are made in laboratory conditions; therefore,
we cannot exclude that these mutants could also show a reduced fitness, but only in the wild.
The disposable soma theory proposes aging as a stochastic process driven by the progressive
accumulation of molecular damages within somatic cell lines. This damaging force can be
counterbalanced by repair systems that tend to maintain the cellular status quo at some energetic cost.
Therefore, the aging rate, which profoundly differs between species, is inversely associated with the
amount of energy used for somatic maintenance. According to this theory, periods of nutrients shortage
forced organisms to balance the energy used for germ line maintenance as well as reproduction and
somatic maintenance [3]. Programmed longevity theory has been proposed as an alternative [4].
It proposes that the healthy portion of life span is programmed to increase the fitness. The aging rate
wouldn’t be regulated by an energy-based trade-off between reproduction and longevity, but each
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species reaches an evolutionary stable strategy. According to this theory, most longevity-extending
mutations will cause a trade-off, but some won’t.
However, there is the possibility that the group instead of the individual is the object of evolution.
According to this theory, fitness is affected by either “group competition”, “individual competition”,
or both, depending on the conditions encountered. The advantage of the single individual is positively
selected only if it also confers a group advantage. Mathematical simulations and experimental
evidences suggest that at least in S. cerevisiae, aging under certain conditions can be programmed,
and an altruistic life span extension of the individual can provoke the extinction of the group [4].
None of these theories prevailed so far, which was probably because the complex forces of evolution
cannot be simplified by a single scheme. Evolution may be the result of multi-level selection where
individual fitness or group fitness are preferred, depending on ecological niche and population density.
Model systems have been widely used to confirm these theories. Their advantage relies on
reduced costs, easy maintenance in a laboratory facility, and affordable but rigorous manipulation
tools. In general, the simpler the organism we use as a model, the greater these advantages. The short
life span of simple organisms is another key advantage of model systems in aging research (Figure 1),
which allows both parallel and serial experiments to be performed in reasonable time. In addition,
rigorous genetic experiments can be performed in simple eukaryotes using the powerful possibilities
of modern molecular genetics, which permit simultaneously screening multiple congenic, or even
in some models such as yeasts or isogenic individuals at relatively low cost. The other side of
the scale is that some of the simpler systems cannot model alone all the aging phenotypes (e.g.,
immunosenescence can’t be modeled by yeasts). It is not surprising that, as in many other science
fields, biogerontologists thus widely take advantage from the usage of multiple model organisms to
explore their theories. In addition, ethical issues are of course much more limited in simple model
organisms making Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster, and Mus
musculus the most popular model systems used in aging research. Canis lupus familiaris is becoming an
interesting alternative to those model systems because, even though it has a similar ethical constraint
to that of humans, massive breed selection offer interesting genetic opportunities. We will describe
below the genes and pathways discovered thanks to these organisms that have shed light on possible
aging mechanisms in humans.
2. The Simplest Eukaryotic Model: Yeast Cells
Yeast has played a critical role in revealing the molecular genetics of many basic cellular
processes such as the cell cycle [5], protein folding [6], intracellular trafficking [7,8], and many
others. A short generation time, easy and cheap lab setups, powerful genetic approaches,
and high-throughput methodologies [9] are some of the attractive factors of this simple unicellular
eukaryote. Genome similarities (homologue and orthologue genes) between this very simple organism
and mammalians or even humans are surprisingly high, suggesting that this organism can be an
effective model of human diseases [10–12]. Two different paradigms of aging exist in yeast: replicative
life span (RLS) and chronological life span (CLS) [13]. The first one measures the replicative potential
of individual cells. Single cells can in fact be monitored for their ability to generate new cells.
Almost 60 years ago, Robert K. Mortimer used this characteristic to count the number of cell divisions
obtained from a single cell [14]. In this protocol, the emerging bud (daughter cell) is carefully removed
by micromanipulation as it appears until the mother cell stops dividing. The second paradigm (CLS)
measures instead the survival of a cellular population in the post-mitotic, non-dividing phase [15].
Thus, the yeast RLS resembles the Hayflick limit observed in cultured mammalian cells, measuring
essentially the doubling ability of cultured cells, while the CLS models better the ability to survive
and retain the doubling potential of post-mitotic tissues. It is interesting to note that in spite of
the clear differences of the two paradigms used to summarize aging in yeast, some pathways such
as Ras-PKA or Tor-Sch9 have a consistent role in CLS and RLS [13,16], while others do not (e.g.,
Sir2 [17]). The yeast life span is doubled through deletion of the gene encoding the small G-protein
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Ras2, showing a contemporary higher resistance to multiple stresses [18,19]. Ras proteins are molecular
switches that can cycle between the on–off state, which correspond to the GTP-bound and GDP-bound,
respectively [20]. Mutations on the human orthologue of the yeast Ras are found in 35% of human
cancers. The amount of the Ras on-state molecules is dependent on the availability of sugars [21].
Two different pathways are known to be dependent on Ras2 activation in yeast: protein kinase A (PKA)
and Mitogen-activated protein kinase (MAPK). Many data suggest a major role of the PKA pathway
as a longevity regulator [22]. Msn2/Msn4, two key stress resistance transcription factors, are in fact
inhibited by kinase A activity, and Msn2/4 deletion reverts the phenotype observed with Ras2 deletion.
In addition, mutations affecting adenylate cyclase, an activator of the kinase A pathway, also increased
the survival of yeast cells, confirming the role of the PKA pathway as a major Ras-dependent pathway
relevant to the aging processes. PKA activation leads to Rim15 inhibition which, in turn, positively
regulates the transcription factors Gis1 [23], Msn2, and Msn4, whose function is to bind respectively
the PDS (post-diauxic shift) and STRE (STress Responsive Element) sequences activating the expression
of genes involved in survival and stress response such as heat shock proteins, the cytoplasmic catalase,
and the two superoxide dismutase (SOD1, SOD2) [24,25], or in DNA repair such as the DDR2 gene [26].
A selection of stress-resistant mutants obtained by transposon mutagenesis was evaluated by
chronological life span to isolate long-lived mutants. In this study, the Sch9-Tor pathway emerged
as another pro-aging pathway [27,28]. Sch9 is a serine/threonine protein kinase that is homologous
to mammalian Akt and S6K. It has been isolated in yeast as a multicopy suppressor of Ras/PKA
through the conditional inactivation of the thermosensitive Ras exchange factor allele CDC25ts [29,30].
In addition, the increased G1 length of yeast cells bearing a Sch9 null allele is suppressed by a
hyperactive kinase A pathway. These and other data suggest that its function is partly overlapping
with the Ras/PKA pathway. The down-regulation of both signaling pathways obtained by specific
nutrients depletion results in the greater expression of genes involved in resistance to stresses [31].
The observation that SOD2 expression levels doubles in ras2Δ strains suggests that oxidative stress
is a major component of this response [32]. In addition, overactivation of the transcription factors
that respond to thermal (HSF1) and oxidative stresses (YAP1) increases survival [33,34]. In spite
of these observations, the over-expression of superoxide dismutases and catalases alone does not
allow the survival levels obtained by the deletion of RAS2 and SCH9, suggesting that modulation of
oxidative stress is not the only mechanism involved in longevity regulation. In addition, despite the
aforementioned functional overlap between the Ras and Sch9 pathways, the simultaneous deletion of
RAS2 and SCH9 has greater effect than their respective individual deletions. It is important to notice
once again that the mediators that are part of these pro-aging cell pathways find their functional or
structural orthologues in higher eukaryotes, and it has been confirmed that the mechanisms described
are conserved from yeast to mammals. In addition, it has been observed that in all organisms, these
pathways are influenced by nutrients, either directly or through insulin/insulin-like growth factor-1
(IGF-1) and growth hormone (GH) in multicellular eukaryotes [35–37].
3. Caenorabtidis elegans
Caenorhabditis elegans has been established as a model organism in 1965 by Sidney Brenner.
This small size (1.5-mm long adult) soil nematode has great potential for genetic analysis, is easy and
cheap at laboratory cultivation, and has a short life cycle: the generation time is only three to five days,
and the life span is two to three weeks. C. elegans can inbreed by self-fertilization (hermaphrodite).
Alternatively, hermaphrodites can cross with males (a possibility that is otherwise known only in
plant genetics where selfing and crossing can be manipulated at will). Other key features are the
anatomical simplicity (<1000 cells) and the small genome. The latter is about 101-Mbp long, consists
of six chromosomes, and contains 19,000 genes, of which 50% are conserved in the human genome.
The animal body is transparent, which is a characteristic that allows the tracking of cells in vivo over
time, and the fluorescent visualization of tagged proteins. It can be cultivated on agar plates or in
liquid media; therefore it is a good system for a wide variety of high-throughput manipulations.
7
Genes 2019, 10, 518
In addition, the researchers take advantage of its powerful and continuously expanding genetic and
imaging possibilities [38,39]. First, a multicellular organism is completely sequenced, revealing a
conservation of ~80% of its proteins with vertebrates [40]. RNA interference (RNAi) was the most
commonly used approach to address gene function; however, tissue-specific knockdowns have recently
been developed [41]. Another reason for its wide usage as a model system is that simple phenotypes
can be observed, easing the analysis of most genetic screens.
Many key factors that are capable of regulating longevity have been discovered using this model
organism [42,43]. In 1993, it was demonstrated that mutations at the daf-2 locus, which encodes an
ortholog of the insulin/IGF1 receptor, doubles the life span of the animal [44–46]. Further molecular
characterization revealed that the life-span extension observed with defective daf-2 alleles required
the activity of the daf-16 gene product [44]. The latter is a transcription factor of the FOXO (forkhead
box transcription factor O) family, giving the first example of transcriptionally regulated aging
modulation [47]. The FOXO family is an evolutionary conserved group of transcription factors that
target the protein kinase Akt. In the presence of growth stimuli, FOXO proteins are first exported
from the nucleus to the cytoplasm, and then degraded via the ubiquitin–proteasome pathway. On the
contrary, in the absence of growth stimuli, FOXO proteins are imported to the nucleus, where they
up-regulate a group of target genes, ultimately promoting cell cycle arrest, stress resistance, or apoptosis.
Stress stimuli also trigger the relocalization of FOXO factors into the nucleus, thus allowing an adaptive
response to stress stimuli. Additional studies identified the PI-3 kinase signaling pathway as the
downstream molecular cascade target of the DAF-2 receptor, provoking the nuclear localization of
the mentioned DAF-16 transcription factor [48–50]. HSF1, the C. elegans orthologue of the heat shock
transcription factor, plays a critical role in the DAF-2 observed regulation of longevity. It has also been
demonstrated that HSF-1 is capable of increasing the life span of DAF-2 pathway mutants, suggesting
that heat shock proteins may have a pleiotropic role on pathways other than the daf-2 molecular
cascade [51]. At the same time, mutations in daf-18, which is a homolog of PTEN (Phosphatase
and tensin homolog) phosphatase that normally negatively regulates the insulin-dependent signal,
suppress the increased survival due to mutations on DAF-2 and age-1 loci [52,53]. The latter codes
the C. elegans catalytic subunit of the phosphatidylinositol-3-OH kinase (PI(3)K), whose impairment
triggers constitutive Dauer status (the larva goes into a type of stasis and can survive harsh conditions),
and increases life span and stress resistance. The lengthening of the survival of these mutants has
been related to their increased resistance to oxidative stress; in fact, DAF-2 mutants express high
levels of antioxidant enzymes such as catalase and superoxide dismutase, as well as low levels of
free radicals. Mutants at the age-1 locus prevent the age-related decrease of catalase levels [54].
Other proteins that have been identified as important for longevity in nematode include the protein
kinase phosphatidylinositol-dependent 1 (PDK1), the kinase Akt, and the mitochondrial enzymes
Clk involved in ubichinone synthesis. In particular, the reduction in Clk-1 function produces smaller
worms that live 15–30% longer than wild types, which is probably thanks to a decrease in basal
metabolism and oxidative damage [55].
4. Drosophila melanogaster
Drosophila melanogaster has a 100 year-long history as an important model organism for studies
on genetics and molecular biology. In 1908, Thomas Hunt Morgan was the first to use Drosophila
as a model organism, demonstrating that genes are located on chromosomes. The fruit fly has also
been the first organism for which a genetic map was obtained, thanks to Alfred Sturtevant and
Calvin B. Bridges. Drosophila melanogaster has a generation time of 10–14 days and shows a high
rate of reproduction. Large numbers of flies can easily be cultivated. Maintenance is quite simple
and cost-effective. Drosophila’s genome is very simple: four pairs of chromosomes, 13,000 genes,
and about 170 Mbp; it is about 20-fold smaller than a typical mammalian genome, but in spite of
that, it encodes approximately the same number of gene families, thus making it easier to study
gene function. Furthermore, many pathways, tissues, and organ systems in Drosophila are shared
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by mammals; approximately 60% of the genes that are known to be involved in human diseases
have functional orthologues in the fruitfly. Thus, Drosophila represents one of the most useful and
popular model organisms for research on human diseases. Aging research further benefits from its
short life span (4–6 weeks), which allows manipulating and observing several generations while
monitoring the effect of drugs, nutrients, genetic manipulation, as well as environmental factors over
time. Other advantages are the wide range of tools to modulate gene function (such as mutagenesis
screens, RNA interference, and transgene expression in specific stages of life or in selected tissues) and
resources (cell lines, clone libraries, antibodies, microarrays, and databases) [56,57].
Studies on Drosophila show that longevity increases as a result of the over-expression of genes
involved in stress response such as hsp70 (which encodes the heat shock protein 70), MnSOD (producing
the superoxide dismutase), and mei-41 (involved in DNA repair) [58]; meanwhile, the loss of function
of the pathway that includes the hormone receptor Dts3 and the insulin receptor (InR), Chico (which is
the substrate of InR [59,60]), and the transcription factor dFOXO, greatly increases the life span [61].
Giannakou and Hwangbo in 2004 demonstrated that the tissue-specific overexpression of FOXO in gut
and fat extends the life span, which is likely through the transcriptional repressor aop [62], which shares
some targets with FOXO. Among these, Obp99b seems to have a key role, since it is upregulated in a
long-lived Drosophila model [63]. mTOR inhibition also by rapamycin administration [64] extends life
spans [65], but only in the presence of the s6 kinase [65,66]. The life extension by rapamycin treatment
also requires an intact autophagy pathway [64,67]. Dietary restriction can increase the longevity of
D. melanogaster by up to 30% as well as reduce the reproduction rate [68]. The restricted intake of
specific nutrients, particularly proteins, may mediate the benefits as well as alter the macronutrients
ratio. Amino acids and some amino acids sensors, such as Gcn2, seem to have a key role in life-span
extension by dietary restriction [69].
5. Mouse
Domestic mouse is the most widely used mammalian model. Its genome is almost the same
size as the human one (2.5 Gbp and 40 chromosomes), and encodes essentially the same number of
genes. Most (85%) of protein-coding regions of the mouse genome are identical to human genome; in
addition, 99% of the 25,000 genes have a human orthologue. Compared to other model organisms,
working with mice is more difficult in every respect. They are bigger, have a generation time of
about 8–10 weeks, and produce, on average, only six to eight young per brood. These numbers
are interesting when compared to other mammals, but aren’t when compared to simpler model
organisms. Colonies of mice are expensive to maintain, and their genetic manipulation is quite
difficult. However, unlike the fruit flies and nematodes, mice have an immune system, musculoskeletal
apparatus, endocrine system, digestive system, and even nervous system similar to humans both in
function and architecture. A fundamental tool to explore the genetics of aging in mammals is the
identification of single-gene mutations that increase life span. The first of these was discovered in
1996 studying the Ames dwarf mouse [70]. Ames dwarf mice produce a reduced amount of growth
hormone (GH), prolactin, and thyroid-stimulating hormone; they have a recessive point mutation in
the Prop1 gene leading to hereditary dwarfism [71]. Prop1 encodes a protein required for the pituitary
activation of Pou1f1, which is a member of the POU family of transcription factors implicated in
mammalian development [72]. In 1996, Brown-Borg et al., following the life span of 62 Ames dwarf
mice, showed a mean life span increased of 49% and 68% in males and females respectively, and a
maximal life span extension of 20% and 50%, respectively [70]. This was the first demonstration that
a single gene mutation can extend the life span in mammals. The Snell dwarf mouse was described
in 1929; it has a recessive spontaneous point mutation in the Pou1f1 gene that causes hereditary
dwarfism [73]. Flurkey et al. in 2001 followed the life span of 24 Snell dwarf mice together with
33 normal controls. He discovered that the mean life span was extended in the dwarf group by 48%,
and some of the common age-related declines were delayed [74,75]. Other studies highlight that
the dwarf mice have alterations in insulin/IGF-1 signaling: both Ames and Snell dwarf mice have
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severely reduced circulating levels of insulin, IGF-1, and glucose [76,77]. In addition, the dwarf mice
show a slower metabolism [78]. Most of the dwarf mice are also infertile [79], but they display a
lower spontaneous mutation frequency [80] and a very low incidence of malignant lesions compared
to controls at the time of death [81]. Notably, dwarf mice have reduced levels of DNA and protein
oxidation in the liver compared to control mice [82], according to increased levels or activity of catalase
and Cu/Zn superoxide dismutase in various tissues at different ages [83,84], which makes these mice
resistant also to the effects of chemical stressors [85], and shows low levels of reactive oxygen species.
However, the importance of oxygen concentration as a driver of protein and DNA damages leading
to cellular senescence has recently been challenged [86]. In fact, it has been demonstrated that while
lab mice-derived primary fibroblasts are sensitive to oxygen concentration, primary fibroblasts from
wild-caught mice are not. In addition, cells from other wild-caught rodents have lower oxygen
sensitivity than lab mice-derived cells [86]. This observation underlines the need to use multiple model
systems and the necessity, when possible, to confirm the results on wild-caught animals, since the
repeated breeding and the laboratory condition of lab animals may trigger unwanted genetic drift.
An example of the results confirmed in multiple systems are the metabolic pathways involved in
the aging of Drosophila and C. elegans, which were confirmed in mice thanks to genetic manipulation.
Among the genes whose deletion significantly increases the survival of mice, some of the genes
involved in stress resistance have been identified, such as for example GPx4, which codes for
glutathione peroxidase, and some that are part of the insulin pathway, such as FIRKO (insulin receptor
in adipose tissue) [87]. Animals that have mutations in the growth hormone receptor also live longer
and show a lower incidence of age-related cognitive impairment and improved insulin sensitivity [88],
while those who over-express GH show signs of accelerated aging [77]. Also, female Irs-1 knock-out
mice (Irs-1 is the major intracellular effector of insulin) live 32% longer than the wild-type counterpart.
Finally, inhibition of the mTOR (mammalian target of rapamycin) pathway, which was obtained by
rapamycin administration through S6 kinase deletion, increases survival and reduces the incidence
of age-related diseases, including immune dysfunction and insulin resistance [89]. Inactivation of
the PKA pathway also increases survival and causes a reduction of tumor incidence and insulin
resistance over time. Another key aging gene in mice is klotho. This protein is a circulating factor
that inhibits the intracellular insulin/IGF-1 signaling cascade, but its function is still controversial.
Homozygous klotho-deficient mice display a syndrome similar to human progeria and anomalies in
different tissues. These mice are short-lived and infertile; they show growth retardation, premature
thyme involution, ectopic calcification, skin atrophy, arteriosclerosis, osteoporosis, and pulmonary
emphysema [90]. On the other hand, klotho gene over-expression extends mice life span by 20–30% [91].
Higher levels of klotho are associated with longer life span, reduced atherosclerosis risk, and better
hearing than other mouse strains [92]. Some mutants with mutations in DNA maintenance, stability,
and repair exhibit premature aging phenotypes. Wrn knock-out mice lightly display characteristics of
premature aging, including the contemporaneous deletion of the Terc gene, which encodes the RNA
component of the telomerase enzyme, and brings Werner’s phenotype [93].
6. Domestic Dog
The domestic dog is a very interesting aging model for different reasons. Dogs allow us to observe
them in their natural environment while being investigated; notably, they often share lifestyle and
sometimes exercise habits with humans. Canine life span can vary greatly [94]. Interestingly, it has
been observed that life span inversely correlates with body size. Larger breeds live almost six to
seven years, while smaller breeds can reach up to 16 years [95–97]. Dogs share the same diseases with
humans, in particular age-related diseases such as congestive heart failure, renal and hepatic disease,
sarcopenia, diabetes, obesity, joint disease, neurodegeneration, cataracts, immune-mediated illnesses,
and cancer [97–101]. In addition, it is the only species where massive breed selection has led to large
numbers of individuals with very small phenotypic and genotypic differences within a specific breed,
but with very large differences between different breeds. Maybe as a result of this strong selection for
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specific traits, some pure breeds of dogs are more prone to specific age-related diseases than others [97].
For example, the analysis of cancer incidence in different pure breeds confirmed that larger breeds
have a higher incidence of cancer but revealed also that each breed has increased incidence for specific
cancer types, suggesting that anatomic differences and genomic differences between breeds can explain
these differences. It is also interesting to know that as a companion animal, dogs often share part of
their lifestyle with their owners, including physical exercise. At the same time, dogs receive medical
treatments from veterinarian specialists during their life as it happens for humans, and that contributes
to increase the life span of these companion animals. The domestic dog has a well-annotated genome
that was fully sequenced 10 years ago [102–104]. The size of the diploid genome is 4900 Mbp, which is
organized in 38 pairs of autosomes and two sex chromosomes. Different genetic resources are applied
in canine genetic research. Furthermore, genetic pedigrees are registered for many generations [105].
Greer et al. (2007) reported a correlation between body size and longevity. They noticed that smaller
members (Chihuahua) live longer than larger members (e.g., Great Dane) [95]. Similar data have been
obtained from studies in a murine system in which the IGF/GH axis resulted involved in longevity and
body size determination [106]. Notably, circulating IGF-1 levels correlate with the body size of adult
dogs; in fact, IGF-1 levels increase with body weight. Therefore, the data is consistent with previous
work by Eigenmann et al. (1988), indicating that adult dogs have a high correlation between circulating
IGF-1 and adult body size [107]. Furthermore, IGF-1 decreases over time as a function of age [108].
In addition, a reduction of the insulin/insulin-like growth factor-1 (IGF-1) signaling cascade significantly
extends life span [109]. Interestingly, Greer et al. described that serum IGF-1 levels decrease at a
higher rate in intact females than in spayed females. Similarly, there is a significant difference in the
serum IGF-1 levels between neutered and intact males. For both intact males and females, an increase
in overall body weight was significantly associated with higher levels of IGF-1. These data suggest
relevant hormonal effects on IGF-1 action [104]. Interestingly, Waters et al. (2009) demonstrated that
dogs with four years or more of ovarian hormone exposure live longer than ovariectomized dogs [110].
Therefore, higher body weight is related to high level of serum circulating IGF-1, which in turn seems
to be deleterious for aging. Accordingly, the maintenance of lean body mass and reduced accumulation
of body fat have been associated with attaining a longer than average life span [111]; thus, dog’s
weight may be more predictive of life span than height, as reported by Greer et al. [95]. A dietary
restriction of 25% has been reported to increase life span by about two years [112,113], improving
metabolic health [114,115] and delaying immune senescence in Labrador retrievers maintained in a
laboratory environment [114,115]. Further studies will be necessary to discriminate as to whether
increasing the health and life span after CR in dogs is the effect of weight loss or depends on the
down-regulation of pro-aging pathways such as previously demonstrated in simple model organisms
such as yeast. Actually, studies carried out by Jimenez et al. suggest that large breed dogs may have
higher glycolytic rates, and an increased DNA mutation rate, which could be responsible for their
decreased life span compared with small breed dogs, despite reactive oxygen species (ROS) production
showing no differences across size and age classes [116]. Likewise, Alexander et al. observed a decline
in the heat shock protein 70 response after heat stress with age, suggesting a role of oxidative stress in
dog’s aging [117].
7. Non-Human Primates
The models closest to humans are non-human primates. In fact, the chimpanzee genome has more than
98% homology with the human genome, while the rhesus monkey (Macaca mulatta) has 93% DNA homology
with the human genome [118,119]. The Macaca mulatta genome is 3146 Mbp and codes 21,000 different
proteins [120]; Pan troglodytes, a common chimpanzee, has a 3385-Mbp genome coding for 23,534 proteins.
Interestingly, they have a similar inter-individual variability to humans and share eating and sleeping
behavior, physiology, neurology, endocrinology, immunology, as well as anatomy [121]. Their average
life span ranges from 7 to 30 years depending on the species considered, while the maximum life span
of the commonly used macaque reaches 40 years, and the chimpanzees can reach up to 65 years [122].
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Similarly to humans, monkeys exhibit signs of physical decline and many age-associated diseases,
including [123]: sarcopenia [124], osteoporosis [125], cataracts, cardiovascular diseases, and cancer [123].
In fact, the incidence of these diseases is similar to that in humans. Researchers take advantage of two
important resources: the Internet Primate Aging Database, which collects data such as body weight and
blood chemistry measurements on many non-human primate species during aging, and the Nonhuman
Primate Tissue Bank. Another advantage is the possibility to fully control the environment, dietary intake,
and medical history. On the other hand, non-human primates require specialized care, have high cost,
and require ethical considerations. However, they represent the ideal model to summarize the complex
in vivo physiology of human aging. Even though research such as direct manipulation of the monkey
genome are not possible for ethical reasons, observational studies and dietary interventions may give us
very useful information, especially to validate in the closest to human system what has been previously
discovered in simpler organisms. To this purpose, three major studies have been performed in non-human
primates to evaluate the efficacy and safety of calorie restriction and aging: one was performed at the
University of Maryland [126], one was at NIA (National institute of Aging) [127], and the last one was
at the Wisconsin National Primate Research Center [128]. All of them confirmed the benefits of CR on
health. The University of Wisconsin study confirmed that CR reduces disease incidence and prolongs
life span [129–131], while the NIA study doesn’t observe a different survival between CR and control
monkeys. Differences in feeding protocol, diet composition, and the timing of CR onset may explain the
observed differences [132]. However, data from both studies suggest that many of the beneficial effects
of CR reported in rodents also occur in primate models, thus suggesting a possible role also in human
aging [131].
From comparative genetics studies between non-human primates and humans, it is deducible that
some of the genetic regulatory processes that are important during development are less subjected to
selective pressure and may became adverse later in life [133]. Blalock et al. analyzed gene expression in
two major hippocampal subdivisions that are critical for memory/cognitive function in rhesus monkeys,
identifying genes that changed expression with aging, and showed that increased gene expression
of the glucocorticoid receptor happens with aging in rhesus macaques, linking the age-dependent
metabolic syndrome to aging changes in the brain [134]. Epigenetic changes occur during aging in
monkeys. In rhesus macaque brains, aging is associated with a global increase in H3K4me2 and
H3K4me3 transcriptional activation; in addition, SETD7 and DPY30 (H3K4me2 methyltransferases)
show elevated expression [135]. A role in aging has been ascribed to miRNA; in particular, Mohan
et al. identified the miR-34a-SIRT1-acetylp65 axis as a potential mediator of “inflammaging” in the
intestine [136].
8. Discussion
Humans are not an easy-to-study system both for ethical as well as for practical reasons,
and have required the support of simpler organisms to model their physiology and pathology.
Epidemiology, one of the most used approaches to investigate humans, is the branch of science that tries
to count how often a certain pathology occurs in different population groups, hopefully identifying
the risk or protective factors against certain pathologies. It is an essential methodology to study
humans, but can fall short because it often requires a very large cohort of people, is normally very time
and budget consuming, and can potentially be affected by many confounding factors. Clinical trials
often use small groups of people to be cost effective and test specific hypotheses ranging from the
safety/effectiveness of selected drugs to specific devices. Of course, obvious ethical as well as practical
issues limit the potential of this approach in humans. Therefore, although both approaches are essential
for the understanding of human physiology and pathology, they unlikely may suggest alone new
branches of science or help to develop breakthrough ideas [137]. On the other hand, human genetics
has been very successful, and revealed the genetic cause of more than 6000 monogenic diseases in
humans, but it is hard to imagine the development of this science without the seminal discoveries
in plants, fruitfly, fungi, etc., also in humans. The identification of genes and pathways relevant for
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human longevity has acquired deep advantages from model systems and discoveries, which can be
grouped in four functional categories:
• Genes related to stress resistance: their role in longevity has first been demonstrated in many different
model systems [18,24,25,32–34,51,54,58,82–85] and eventually confirmed in centenarians who show a
low degree of oxidative stress as well as high antioxidant protection [138,139]. A high level of oxidative
stress is also an important risk factor of other age-related diseases such as hypertension, atherosclerosis,
and diabetes. SNP (single nucleotide polymorphisms) studies have identified Tp53, coding for tumor
suppressor p53 [140–142], EXO1 [143], GPX1 (glutathione peroxidase1) [144], SOD2 (manganese
superoxide dismutase) [145], heat shock proteins genes HSPA1A, HSPA1B, and HSPA1L [146–148],
GSTZ1 (glutathione S-transferase zeta 1) [149], NOS1, NOS2 (nitric oxide synthase 1 and 2) [150],
and UCPs (uncoupling proteins) [147,151,152] as susceptibility genes.
• Genes involved in telomeres length: they have been found to be associated with human longevity
such as TERT and TERC (telomerase reverse transcriptase, telomerase RNA component) [153], SIRT1,
and SIRT3 (sirtuins) [154,155]. The first discoveries were made in yeasts and tetrahymena by Elizabeth
Blackburn, finding the role of TERT and TERC ([156] and references within). In Caenorhabditis elegans
over-expressing a protein involved in telomere length regulation leads to the elongation of telomeres
and extends the life span, making the organism more resistant to heat stress [157]. The over-expression
of TERT also extends the life span of mice [158]. In yeast, sirtuins promote longevity [159]; in
particular, it has been reported that Sir2 mediates life-span extension due by calorie restriction [160].
These findings have been replicated in other model organisms [161], but their role in longevity is not
consistent for all species, and therefore is still under debate [162].
• Genes involved in metabolism and cellular division: APOE (apolipoprotein E) [163], TXNRD1
(thioredoxin reductase 1), XDH (xanthine dehydrogenase) [163], MAP3K7 (mitogen-activated
protein kinase kinase kinase 7) [149], AKT kinase, and TOR [164]. The association of APOE with
human longevity have been replicated in different populations: [165–167]. Apolipoprotein E
(apoE) exhibits three isoforms: apoE2, apoE3 and apoE4. They are involved in inflammation,
elevated lipid levels, and oxidative stress; furthermore, these are risk factors for cardiovascular
disease and Alzheimer’s disease, as reported by Huebbe et al. (2011) [168]. APOE2 has been
defined as a longevity gene for its putative protective function; it is abundant in long-lived people,
while APOE4, that differs from e3 allele at a single aa (112cys), and has been considered a frailty
allele [169]. In fact, it increases the risk of Alzheimer’s disease and cardiovascular diseases, maybe
for a putative interaction with the β amyloid protein, and it is almost absent in centenarians.
• Genes belonging to the IGF/GH and insulin pathway: mutations in genes belonging to the insulin
or insulin-like signaling pathway extend the life span of Caenorhabditis elegans [170,171], Drosophila
melanogaster [59,109,172], and mice [69,173]. In humans, it has been observed that insulin sensitivity
normally decreases during aging. On the other hand, centenarians are more sensitive to insulin
than other people, and often show lower IGF-1 plasma levels [174]. SNP studies have found an
association of particular alleles or haplotypes for INS (insulin) [175], INSR (insulin receptor) [176],
IGF1 (insulin growth factor 1) [177], IGF1R (insulin growth factor 1 receptor); in fact, a specific
haplotype of the IGF-I receptor and the kinase PI3KCB is frequently found in individuals living
longer together with low plasma levels of IGF-1 [178], IGF2 (insulin growth factor 2) [179], IGF2R
(insulin growth factor 2 receptor) [180], IRS1 (insulin receptor substrate 1) [177], GH1 (growth
hormone 1) [177], GHSR (growth hormone secretagogue receptor type 1) [175], FOXO1A (forkhead
box protein O1 A), and FOXO3A (forkhead box protein O3 A) transcription factor, which contains
alleles that are associated with longevity in multiple Asian and European populations [181–185].
FOXO is a transcription factor that is conserved in all eukaryotic organisms and is negatively
regulated by the insulin-signaling pathway. When insulin or insulin-like growth factor signaling is
low, FOXO is activated, and life-span extension occurs [182].
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Studies on all of the model organisms cited above have thus contributed to the discovery of the
fundamental mechanisms of aging in humans. The essential conservation of these mechanisms throughout
evolution has been strikingly confirmed in all the model organisms that have been tested so far. The series of
similarities found in the mechanisms of regulation of aging in all the model organisms and in humans make
us believe that these mechanisms have been preserved during the evolution from yeast to mammals [36,186].
For example, the protein sequence of DAF-2 (the C. elegans insulin/IGF receptor ortholog) shows 34%
identity with the IGF-IR of mammals, nematode’s AGE-1 is 27% identical to its ortholog PI3KCB kinase,
and DAF-16 is 49% identical to FOXO1A, while IRS-1 has 30% identity with Drosophila’s insulin receptor
substrate 1 (CHICO). In addition, these factors regulate similar processes in all organisms such as resistance
to oxidative stress, metabolism, nutrient utilization, and of course life span [187]. A 2007 study compared
genes whose transcription varies with the inhibition of the insulin/IGF-1 pathway in three different
species—C. elegans, Drosophila, and mouse—and it was demonstrated that there are significant similarities
concerning in particular two main categories of genes. The first one includes genes involved in protein
synthesis that are hypoexpressed (this was also independently observed in yeast [188]), the second one
includes genes involved in detoxification that are over-expressed, (e.g., the gene coding for glutathione
S-transferase [189]). Consistent with the latter observation, the over-expression of transcription factors that
regulate xenobiotics metabolism increases survival in Caenorhabditis and Drosophila [190]. The considerable
affinities that were found confirm that the mechanism of aging, which is specifically mediated by the
insulin-dependent pathway, has been preserved during the evolution in all eukaryotes from yeast to humans.
In addition, it has been also confirmed that these pathways may be regulated mainly by nutrients [191].
Calorie restriction, protein restriction, fasting, and a fasting-mimicking diet are in fact becoming interesting
alternatives to manipulating our genome structure [192]. Again, it has been so far confirmed that simple
model systems, despite their clear morphological differences with humans, can be effectively used as a
model to pave the way to future relevant discoveries in humans. Therefore, we believe that model systems
will continue to be an essential tool for aging research and for the usage of high-throughput methodologies
However, the observation that wild-caught animals may behave differently than lab animals stresses the
need to confirm the results obtained with one organism in other species or in wild-caught animals in
order to avoid the possibility that lab condition and repeated breeding may have favored genetic drift or
epigenetic changes.
Figure 1. Comparative analysis of the most used model systems in aging research. Genome informations
are from NCBI.
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Abstract: Human longevity is a complex phenotype resulting from the combinations of context-
dependent gene-environment interactions that require analysis as a dynamic process in a cohesive
ecological and evolutionary framework. Genome-wide association (GWAS) and whole-genome
sequencing (WGS) studies on centenarians pointed toward the inclusion of the apolipoprotein E
(APOE) polymorphisms ε2 and ε4, as implicated in the attainment of extreme longevity, which refers
to their effect in age-related Alzheimer’s disease (AD) and cardiovascular disease (CVD). In this
case, the available literature on APOE and its involvement in longevity is described according to
an anthropological and population genetics perspective. This aims to highlight the evolutionary
history of this gene, how its participation in several biological pathways relates to human longevity,
and which evolutionary dynamics may have shaped the distribution of APOE haplotypes across the
globe. Its potential adaptive role will be described along with implications for the study of longevity
in different human groups. This review also presents an updated overview of the worldwide
distribution of APOE alleles based on modern day data from public databases and ancient DNA
samples retrieved from literature in the attempt to understand the spatial and temporal frame in
which present-day patterns of APOE variation evolved.
Keywords: apolipoprotein E; APOE; longevity; populations; genomics
1. Introduction
The study of APOE and its isoforms has spread in all the studies about the genetics of human
longevity and this is one of the first genes that emerged in candidate-gene studies and in genome-wide
analysis in different human populations. The pleiotropic roles of this gene as well as the pattern of
variability across different human groups provide an interesting perspective on the analysis of the
evolutionary relationship between human genetics, environmental variables, and the attainment of
extreme longevity as a healthy phenotype. In the present review, the following topics will be discussed.
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1. APOE gene and protein structure and function, including the latest theoretical models describing
its mechanism of action
2. The role of APOE in human longevity, its physiological functions, and the involvement in
pathological traits in modern populations
3. APOE evolution and variability among human populations, including a novel analysis of modern
and ancient data
4. The evolutionary mechanisms that maintained APOE deleterious variants in modern
human populations.
2. APOE Structure and Models
Human APOE is a 299-amino acid long protein (34 kDa in weight) belonging to the family of
amphiphilic exchangeable apolipo-proteins that is expressed in hepatocytes, monocytes/macrophages,
adipocytes, astrocytes, and kidney cells [1–4]. Structural studies have shown two independently-folded
domains for the lipid-free protein: an N-terminal elongated domain (residues 1–167) forms a 4 α-helix
cluster in which non-polar residues face the inside of the protein, while the C-terminal domain (residues
206–299) has a more relaxed structure, with α-helices generating a largely exposed hydrophobic
surface [5,6]. These domains are connected by an unstructured hinge that provides a large degree of
mobility, which is necessary for the protein to fulfill its primary function in the hepatic and extra-hepatic
uptake of plasma lipoprotein and cholesterol [7].
The N-terminal domain contains the low-density-lipoprotein receptor (LDLR) binding region,
which is a cluster of basic arginine and lysine residues, spanning between positions 135 and 150
in helix 4 (an Arg-172 residue in the hinge is also necessary for the binding function [8]).A stretch
of hydrophobic residues at the end of the C-terminal domain (residues 260–299) is deemed to be
responsible for binding the protein to lipids as well as for directing oligomerization of lipid-free ApoE.
Since the monomer is the form that binds to lipids, oligomer dissociation appears to be the rate-limiting
step of protein lipidation [9,10].
The gene itself is located on chromosome 19:q13.3, together with the apoC genes APOC1, APOC2,
and APOC4, which are members of the exchangeable lipoprotein family, and in proximity to the
mitochondrial translocase of the outer membrane gene (TOMM40). This is another locus involved in
the development of AD [11–15].
As represented in Figure 1, the combination of two mutations at the APOE gene (rs7412 C/T
and rs429358 C/T) gives rise to the three main protein variants, called ε2, ε3, and ε4 (or, alternatively,
APOE2, APOE3 and APOE4) [16–18]. Isoform ε3 has a cysteine in position 112 and an arginine residue
in position 158, while isoform ε2 has two cysteine residues and isoform ε4 has two arginine residues.
Several other mutations can act on this background to nuance the effects of the three main variants
and are involved in diverse cardiovascular pathologies, as reported, for example, in a recent review by
Matsunaga and Saito [19].
While the difference in sequence is limited to a couple of residues, this has a great impact on the
protein biophysical and, consequently, functional properties, since the change in structural features of
APOE provides insight on the different behavior of its isoforms [20–26].
In particular, the Arg158Cys mutation in isoform ε2 reduces the affinity of the protein for the
LDLR 50-to-100-fold [27] due to the removal of a crucial electrostatic interaction with Asp154. Mutating
this residue to a neutral alanine has shown that the isoform fully recovers its functionality [28].
The mutation Cys112Arg in isoform ε4 does not change its affinity for the receptor but its
preference for lipoprotein binding shifts from HDL (as do ε3 and ε2) to LDL/VLDL. This occurs
because charged residues that should be buried in the protein core are, instead, propelled outwards
and can establish trans-domain interactions that modify the protein structure and, therefore, lipoprotein
preference, possibly by hindering overall dynamics [29,30]. Mutagenesis experiments proved effective
in re-establishing the preference of isoform ε4 for HDL [17,29,31,32].
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Both domain interactions and intermolecular interactions have been recently confirmed by using
Forster Resonance Energy Transfer assay (FRET), which is a method to quantify the exchange of energy
between two fluorescent tags attached to the ends of the APOE protein. These experiments showed
that there is a consistently significant difference among isoforms, with ε4 showing a higher degree of
energy transfer for both domain interaction and polymerization. However, a different study asserted
that conformational changes appeared to reduce the propensity of this isoform to self-stabilize in
tetramers [33,34].
Denaturation experiments aimed at testing protein stability again showed different behaviors for
the three isoforms, with the ε2 N-terminal domain being the most resistant and being followed by ε3
and ε4, which is the least resistant isoform, but shows a higher number of stable intermediates between
its folded and unfolded forms [35–39]. This has been interpreted as isoform ε4 assuming partially
unfolded stable states at different pH in basic environments, facilitating large conformational changes
and, in doing so, increasing the remodeling rate of lipoprotein particles. This has also been noted
with other exchangeable apolipo-proteins, such as APOAI and APOAII [38–41]. Higher ε4 catabolism,
although being not an index of overall increased efficiency in plasma lipoprotein clearance, may justify
why APOE4 homozygotes have a lower plasma APOE concentration [42–45]. On the other hand, it has
been suggested that partially folded APOE is more sensitive to proteolysis of the domain-connecting
hinge and that isoform ε4 may be more easily flagged as “misfolded” due to domain interaction,
particularly in the brain [46–50].
Figure 1. Polymorphisms underlying the three main APOE variants in humans. (A) Chromosome
location, gene structure, identity of the mutating sites in the gene, and the corresponding mutating
residues in the context of the protein structure. In yellow, it is indicated as the receptor-binding
region in helix 4 and, in green, it is the lipid-binding region in the C-terminal domain. Red and black
dots indicate the genetic variants in APOE and their position in the genomic and protein sequences,
respectively. (B) Table reporting the haplotypes and corresponding residue combination associated to
each APOE allele.
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It is also important to remember that no definitive mechanism for how APOE binds to lipids
has been elucidated even though different hypotheses have emerged over the years, especially in
relation to the implication of its isoforms in pathological traits. Starting from the concept of “molten
globule” [36,51], a hairpin model has been proposed assuming that the protein bends itself so that
the LDLR-binding motif is exposed at one extremity of the structure [31,52–55]. Other studies have
suggested a conformational heterogeneity of bound apoE, observing that LDLR binding affinity, while
higher in the bound protein than in the lipid-free protein, is modulated by the particle size, its lipid
composition, and the presence of other bound lipoproteins [31,52,56–58].
A revised model has been recently proposed and considers the high proportion of intrinsically
disordered regions in the protein (up to a third of the whole molecular structure), multiple interactions
between the two domains, the presence of evolutionarily conserved residues, and structural differences
that may justify the lipid-binding preferences of isoforms ε3 and ε4 [20,59]. The authors of this work
also argue that most structural studies on lipid-bound apoE make use of the hepatocyte-secreted
protein and plasma lipids, but that the lipid composition in the brain is different and the current
models may fail to address lipidation mechanisms of astrocyte-synthesized APOE [59].
3. APOE Function and Pathology
Multiple lipid-related physiological functions are associated with APOE. In particular, isoform
ε3 helps in maintaining the structural integrity of cholesterol-rich lipoproteins and enhances their
solubilization in blood plasma, regulates lipid homeostasis of both hepatic and non-hepatic tissues,
facilitates lipid internalization in cells and, when expressed by lipid-laden macrophages after cellular
clearance, activates the reverse cholesterol transport, redirecting any excess of cholesterol to the liver
for elimination [60–63].
The APOE genotype accounts for the vast majority of AD risk and AD pathology: inheriting
one copy of APOE4 raises a person’s risk of developing the disease fourfold, while, with two copies,
the risk increases 12-fold [64]. Raber and colleagues and, at the same time, Saunders and colleagues
reported that clinical data regarding the association of the ε4 allele with AD suggests that 50% of AD is
associated with the ε4 allele in the United States [65,66]. APOE4 may be responsible for the accelerated
formation of β-pleated amyloid, as supported by studies showing that individuals with two copies
of the APOE ε4 allele have a higher risk and earlier onset than heterozygous subject [67]. Moreover,
a significant increase in risk of EOAD (early-onset Alzheimer’s disease) was found for individuals
homozygous for APOE4 regardless of family history of dementia, but an increase in EOAD risk for
APOE4 heterozygotes could only be shown in subjects with a positive family history [68].
Experiments with knock-out mice have proven that failed expression of APOE leads to a shortened
lifespan due to the emergence of typically age-related phenotypes like an altered lipoprotein profile
(the forefront of atherosclerosis and cardiovascular disease), neurological disorders, type II diabetes,
deficits in immune response, and elevated markers of oxidative stress [69–75]. Moreover, the APOE
variants determining the three isoforms ε2, ε3, and ε4 have also been associated with the modulation
of body mass index (BMI) at statistical significance (p < 10−3) in a meta-analysis including 27,863
individuals from seven longitudinal cohort studies [76]. This highlights, on one hand, that APOE is a
pleiotropic gene that simultaneously affects multiple phenotypes, depending on the site of protein
synthesis (in particular, liver and brain). On the other hand, this emphasizes that the manifestations of
its impairment fit the definition of aging as a general decline in biological functions, decreased stress
resistance, and elevated susceptibility to disease that leads to an increase in mortality with age [77–79].
Most of the research conducted at this point focused on isoform ε4 as the “functionally altered”
form of APOE in the brain since this is one of the most consistent candidates associated with human
longevity and the onset of AD, according to GWAS and whole genome sequencing studies [62,66,68,80].
The finding of unexpectedly large proportions of C-terminal APOE in β-amyloid plaques of
ε4/ε4 homozygous AD subjects leads to the hypothesis that the partially folded protein is highly
sensitive to proteolysis [46–50] and this prevents APOE in helping Aβ clearance, favoring instead
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its deposition [81]. By folding into a more helical structure, truncated ε4-165 was shown to have
deleterious effects on this same process, which stresses that structural integrity is important for AD
pathogenesis [82–84]. The link with Aβ has also been associated with a higher degree of lysosome
leakage in neurons, primarily due to the enhanced lipid remodeling activity of isoform ε4 on the
lysosomal membrane at a low pH [85,86].
Experiments on mice have highlighted how isoform ε4 can also cause behavioral deficits in the
absence of amyloid accumulation and, as with AD in humans, spatial and memory impairments
increase with age and are observed primarily in females [87–90]. Regarding neuronal plasticity,
similar studies showed that isoform ε3 associated with VLDL clearly stimulates neurite extension
in developing neurons by feeding their membrane with lipids, while isoform ε4 inhibits branching
likely due to effects on microtubule stability mediated by the LDLR-protein signaling pathway. The ε4
isoform also inhibits GABAergic input in newly formed neurons [91–94].
Furthermore, this isoform has been associated with decreased cerebral glucose metabolism that
occurs even decades before the cognitive impairment becomes apparent, which suggests an interaction
with the mitochondrial membrane and components of the respiratory complexes III and IV at very early
stages of the disease [95–100]. An interesting observation is that mitochondria and the endoplasmic
reticulum (ER) are intimately connected via mitochondria-associated membranes (MAMs) and the
protein miofusin-2, so that mitochondrial dysfunction may propagate to the ER and affect the secretory
pathway [12,101]. If the protein is recognized as unfolded, the pathways of the unfolded protein
response can activate an inflammatory process by stimulating NF-kB, which is a transcription and
cytokine regulator that mediates the immune response in cell survival [102–104].
Isoform ε4 also shows a decrease in the anti-oxidative properties of APOE as a metal cation
binding protein. In fact, APOE4 genotype correlates with a higher degree of lipid oxidation and
presence of hydroxyl radical levels in the blood of post-mortem patients [71,105]. Macrophages
overexpressing ε4 also display membrane oxidation and generate anion radicals and, as a stress
response, an increase of the anti-inflammatory protein heme oxygenase 1, was observed [106].
Moreover, it has been noted that, because of the cholesterol binding property of APOE and
the fact that cholesterol is the main component of the envelope of many human-infecting viruses,
the different behaviors of isoforms ε3 and ε4 may, respectively, impede or ease infections. For example,
extensive work in the last 20 years showed that herpes simplex virus HSV-1 is frequently found in the
brain of elderly normal patients as well as AD-affected patients, and it is thought that isoform ε4 can
facilitate the process of colonization and repeated activation of latent colonies through inflammation,
which exacerbates neural decay at a younger age. It is also suggested that an antiviral therapy may be
effective in slowing AD progression (see comprehensive reviews in References [107–109]). The hepatitis
C virus, on the other hand, needs APOE for assembling and the host lipid metabolism is directly
involved in the viral infection [110–115]. Lastly, an interesting set of studies tried to investigate a
link between APOE and the modulation of HIV infection as a chronic disease, now that the affected
individuals can live to older ages thanks to anti-retroviral therapy. Even though the overall results
are somewhat contrasting, isoform ε4 seems to correlate in different cases with the development of
HIV-associated neurocognitive disorders, impaired cognition, dyslipidaemia, premature brain aging,
and increased chance of debilitating opportunistic infections [116–120] (see also a comprehensive
review in Reference [121]).
However, one of the most notable associations to be examined is between APOE alleles and
cardiovascular disease (CVD). A study carried out on nine cohorts (eight of European and one
of Chinese ancestry) of middle-aged men recruited by the World Health Organization MONICA
(Monitoring of Trends and Determinants in Cardiovascular Disease) Project showed how variation
in the relative frequency of the ε4 allele could predict 40% to 75% of the variation in coronary heart
disease (CHD) fatalities among populations and how a 0.01 increase in the frequency of this allele could
increase CHD death rates by 24.5/100,000 [122]. A study on follow-up data for almost 1000 Danish
and Finnish heart attack survivors similarly denoted that carrying this variant can be a prognostic
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element, as these subjects have an 80% increased risk of dying [123]. A similar conclusion is presented
by a post-mortem study, performed at the Oslo University Hospital, on over 1500 individuals who
died of natural causes. In the cohort of patients presenting a cardiovascular disease (35% of the total),
there were significantly more ε4 carriers (34% against 29%) and significantly less ε2 carriers (12%
against 14%) than in the rest of the group (p < 0.05) [124]. It has also been recently recognized that,
not only APOE is associated to cardiovascular risk, but also with the level of unsaturated and saturated
circulating fatty acids, so that some light is being shed on how environmental and dietary factors can
mediate the association between APOE variants and adverse cardiovascular events [125].
The common APOE alleles ε2, ε3, and ε4 are located in a CpG island and the related SNPs
impact on the quantity of CpG dinucleotide, which impacts the gene DNA methylation. A recent
study showed that the DNA methylation profile of this genomic region differentiates AD brain if
compared to that of control subjects [126]. Moreover, a recent study on lymphocytes showed that DNA
methylation in the APOE gene is associated with age and shaped by genetic variants in the gene [114].
A different study in African Americans also suggested that DNA methylation in blood cells may be an
early indicator of individuals at risk for dementia [127].
4. APOE and Human Longevity
Many studies have attempted to grasp the complexity of the genetics of human
longevity [128–133]: recent findings suggest that alleles associated with this phenotype are
population-specific and, at the same time, that the achievement of extreme longevity is modulated by
mechanisms shared among populations [134–136]. One of the most relevant loci identified by many
studies (if not all) is the APOE gene.
Candidate gene studies, genome-wide association studies (GWAS) on geographically diverse
populations, and, more recently, whole-genome sequencing approaches have been aimed at uncovering
the genetic variants that influence the longevity phenotype and APOE possibly due to its involvement
in several post-reproductive pathologies, which has emerged as a strong candidate in most of them.
In this section, a brief overview of the studies on human longevity conducted in relation to the three
main variants of APOE is presented, with special attention to its isoforms ε2, ε3, and ε4 arising from
the combination of two mutations (rs7412 C/T and rs429358 C/T) [16–18].
Several GWAS supported the association between APOE and the longevity trait. For example,
a Japanese study including 743 centenarians and 822 middle-aged controls found a novel positive
association between variant rs16835198-G of the gene FNDC5 (which synthetizes a pro-hormone
that is upregulated by muscular exercise) and APOE alleles in individuals with extreme longevity,
which further highlights the polygenic nature of this trait [137]. A recent meta-analysis of GWAS
examined data from 6036 individuals at least 90 years old against a control group of 3757 subjects
that died between the ages of 55 and 80. A replication of known variants at APOE and FOXO3
genes was obtained, but the authors also pointed out the difficulty in locating new alleles associated
with survival past the age of 90, possibly because of heterogeneous genetic influences combined
with the fact that rare variants are not usually picked up by GWAS [80]. A novel statistical method
for evaluating genome-wide associations starting from previous knowledge of age-dependent and
disease-related traits that overlap with longevity (i.e., informed GWAS, or iGWAS) was applied to
reduce the background SNPs possibly associated with extreme ages and to amplify potential signals
that could be difficult to pick up in small centenarian cohorts [138]. Accordingly, 92 SNPs at eight
independent loci (including the APOE/TOMM40 locus) were found to be associated with longevity at
GWAS significance (p < 10−8) and four of these were further replicated in three different validation
cohorts including the APOE/TOMM40 rs4420638 variant [138].
However, other studies failed to identify significant associations. For example, a study involving a
Chinese cohort of 312 individuals with at least one long-lived parent (i.e., aged over 90) and 298 controls
without a familial history of longevity found no significant correlation between APOE isoforms, age,
and the levels of blood cholesterol (HDL-C) even though HDL-C levels themselves are significantly
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higher in the longevity group (p = 0.0001) [139]. The first study on a Brazilian cohort, including
220 individuals of at least 85 years of age and 232 controls averaging 72 years, was recently performed
to investigate the association between FOXO3, SOD2, SIRT1, and APOE known variants and several
phenotypes in oldest-olds. Only an association of two FOXO3 alleles with gender and triglyceride
levels was confirmed in this case and the authors suggested expansion of the number of samples in
order to perform a more powerful analysis [140].
A similar pattern emerged from candidate gene studies, as some have highlighted putative
associations between APOE and extreme lifespan, while others have not. For example, a study focused
on three independent cohorts of centenarians from Italy, Spain, and Japan compared with healthy,
younger controls confirmed the ε4 allele being negatively associated with extreme longevity in all
three cases after adjustment for sex, while allele ε2 was positively associated with the same trait in the
Japanese and Italian cohorts only. This highlighted that the ε4 variant appears to decrease the likelihood
of reaching extreme ages across ethnicity and geographic origin [141]. A recently published paper
on 450 individuals of Ashkenazi Jewish ancestry at least 95 years of age contrasted with 500 controls
without a history of familial longevity, which undertook a full analysis of the coding and regulatory
regions of APOE. Two common regulatory variants were, thus, found in the proximal promoter of the
gene (rs405509 and rs769449), which is significantly depleted in the elderly group (p < 0.036). Moreover,
a significant enrichment of the ε2 allele (p = 0.003) and the ε2/ε3 genotype (p = 0.005), as well as a
reduction of the ε3/ε4 genotype (p = 0.005) were observed in the same group [142]. Two recent
reviews and meta-analyses of polymorphisms associated with human longevity recovered genomic
data of European and Asiatic cohorts involving centenarians (i.e., 13 cohorts [141,143–153] for the 2014
review [154], 12 cohort s [141,143,144,148,149,155–158] for the 2018 review [130]), and added newly
generated data to obtain groups of at least 2700 centenarian cases and 11,000 younger controls. The first
study highlighted how the likelihood of reaching extreme longevity is negatively associated with
carrying the ε4 allele, the ε4/ε4, ε3/ε4, or ε2/ε4 genotypes (all p < 0.001), while the trait is positively
associated with the ε2/ε3 genotype (p = 0.017) [154]. The second study ascertained the homogeneity
between the European and Asian groups when accounting for ethnicity. It also confirmed a significant
negative association of the ε4 allele with longevity and a positive association of the ε2 variant with
the same trait (which was not supported by the 2014 meta-analysis [154]) when compared to the
ε3 allele (p < 0.0001) [130]. In another meta-analysis, data of over 28,000 individuals born between
1880 and 1975 were collected from seven studies on population longevity and familial healthy aging,
with cases ranging from 96 to 119 years and controls from 0 to 99 years. Three genetic models (i.e.,
standard genotypic model, additive model for the effects of the ε2 allele, grouping of genotypes
containing and not containing ε4) and two definitions of longevity (i.e., age at death, age reached by
less than 1% of the population) were applied. Results showed that carrying the ε2 allele, but not ε4,
is associated with significantly increased odds of reaching extreme longevity, with decreased risk of
death when compared to the most common genotype ε3/ε3, but modest risk reduction at the most
extreme ages. The opposite is observed for ε4, which acts independently from ε2 and associates with
decreased odds for extended lifespan and an increased death risk that persists even at extreme ages in
all groups. Furthermore, a joint haplotype analysis of five SNPs at the PRVL2-TOMM40-APOE-APOC1
gene cluster revealed that three haplotypes were individually associated with extreme lifespan when
compared to the most common haplotype. The first one, containing ε2, was associated with a 34%
increase in odds of extreme longevity (p = 7.8 × 10−7). The second one, containing ε4, was associated
with a 50% decrease in the same odds (p = 10−8). The last one was, instead, an uncommon haplotype
containing ε3 and was associated with a 20% decrease in odds for extreme longevity (p = 0.04), which
suggests that there are SNPs at this locus that can exert a negative effect on longevity independently
from the influence of the APOE ε4 allele [159].
A more extensive collection of GWAS and candidate gene studies performed in the last 8 years
and describing APOE gene variants in human longevity is reported in Supplementary Table S1.
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A recently published paper about genetic variants affecting viability over generations in large
cohorts applied a method for testing the variability in allele frequency across different ages, after
considering individual ancestry. When applied to the Genetic Epidemiology Research in Adult health
and Aging (GERA) cohort and to parents of the UK Biobank participants, few common variants
significantly related to mortality at specific ages were found across the genome, all tagging the APOE
ε4 allele and the CHRNA3 gene. When testing for viability effects of genetic variant sets, strong signals
(p < 10−3) were found relating delayed puberty with longer parental lifespan, as well as later age
of first birth with longer maternal lifespan and, lastly, cholesterol levels and risk of coronary artery
disease, with a marked difference between male and female participants [160].
It is worth noting that recent data from Northern European populations [148,161] clarified that
APOE variation is associated with the likelihood of reaching extreme longevity not because it is a
‘longevity gene’ that ‘ensures’ a long life by itself, but due to the fact that it is rather a ‘frailty gene’ that
slightly influences mortality and, particularly, ε4 is associated with an increased risk for death that
persists even beyond ages reached by less than 1% of the population [159].
5. APOE Evolution and Variability among Human Populations
Human APOE clusters with members of the groups APOA and APOC in the superfamily
of exchangeable apolipoproteins. These are structurally and functionally distinct from the
non-exchangeable apolipoproteins APOB48 and APOB100, which make up the core of the lipoprotein
particles [162,163].
Phylogenetic reconstruction using apolipoprotein sequences from representative eukaryotic
species has shown that an ancestral form of this protein already existed before Metazoan evolution (i.e.,
approximately 750 Mya) and that divergence between the exchangeable and non-exchangeable families
is equally ancient [162]. Focusing on the human exchangeable superfamily, a similar analysis showed
that APOE clusters specifically with APOA1, APOA4, and APOA5 (the most recently identified human
apolipoprotein), are separated from the cluster including APOA2, APOC3, APOC2, and APOC1
(the oldest in the cluster). It is also noteworthy that the length of the synthetized protein increases
from the oldest to the youngest gene [162]. When including the insect apolipo-protein ApoLpIII in
the analysis, it was found to group by sequence similarity within the human APOE cluster, instead
of being an outgroup to all human exchangeable proteins. This suggests that the divergence of
exchangeable apolipo-proteins occurred at an early evolutionary stage, possibly with the advent of
bilateral symmetry (i.e., approximately 650 Mya), while the origin of ApoLpIII has dated back to
the emergence of flying insects (i.e., 500 Mya) [162,164,165]. Nevertheless, an extensive review of
phylogenetic relationships among eukaryotic apolipo-proteins is not the purpose of this review [162].
Focusing on the investigation of human-specific apolipo-proteins characteristics, comparison of
the protein sequence of human and primate APOE reveals that the non-human apolipo-protein has
arginine in position 112, like human isoform ε4. This suggests that ε4 is the ancestral variant and
recent analyses of Denisovan DNA (a specimen of archaic human found in 2010 in the Denisova cave,
in the Altai Mountains in Siberia) also corroborate such a hypothesis [166,167]. Unfortunately, this
information is not yet fully disentangled for the Neanderthal genomes. The other non-synonymous
variants detected among the species do not alter the size or charge of the residues and are not located in
functional domains [162]. The only fundamental difference, then, involves residue 61, where humans
present an arginine, while all other primates have a threonine. The Thr61Arg substitution introduces
a bulkier, positively charged residue near the equally charged Arg112, by which it is projected out
of the N-terminal helix bundle. This repositioning allows for Arg61 in ε4 to be involved in domain
interactions that affect the isoform structure, which makes the protein less stable, but readier in binding
large, lipid-rich lipoproteins. It is, however, unclear how the mutation that originated human ε4 from
an ancestral APOE could provide a net evolutionary advantage. Theories including the consumption
of cholesterol-rich meat, the presence of pathogens in uncooked foods, and increasing brain size during
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human evolution have been proposed as well as random DNA photooxidation following the loss of
body hair [162,168].
One of the most intriguing hypotheses for the development of longevity despite the presence
of a deleterious APOE isoform, however, postulates a link with increased physical activity, over the
evolutionary history of the genus Homo, that helped in counterbalancing a higher risk of cardiovascular
disease [169]. Haplotype analysis revealed that the origin of isoforms ε2 and ε3 in humans can be
dated back to 200,000 to 300,000 years ago [170], while the increase in physical exercise occurred much
earlier in time, possibly around 1.8 Mya, when Homo erectus abandoned the sedentary lifestyle of
the forests to become a hunter-gatherer. Long foraging distances and the ability to run for extended
periods of time, to either follow prey or flee from danger, require endurance and increased levels
of aerobic activity, which is related to the conversion of body fat into usable energy and is in stark
contrast with the cardiovascular effects induced by the ε4/ε4 haplotype [171–173]. This likely relaxed
the limitation on lifespan imposed by the deleterious allele and is in accordance with fossil dating and
palaeodemographic analyses that testify an increase in the number of older individuals throughout the
evolution of H. erectus and then H. sapiens [174], as well as the extension of post-reproductive lifespan
in concert with the development of a hunter-gatherer lifestyle [169,175,176].
However, in modern populations, isoform ε4 is only the second-most common APOE variant,
which shows the highest frequency in indigenous populations of Central Africa (40% in Aka Pygmies,
38% in Tutsis, 33% in Zairians, and 29% in Fon), Oceania (49% in the Hui population of New Guinea,
26% in the Mowanjum aboriginal tribe of Western Australia and in Polynesians from American
Samoa) and Mexico (27% for the Huychol in Nayarit [177]). Isoform ε3, instead, shows peaks of
94% in the Alberta Hutterite people of Canada, 90% in Mexican Mayas, 88% in the Basque and
Sardinian populations of Europe, and 86% in Han Chinese. As highlighted in Figure 2 and reported in
Supplementary Table S2, a distinct latitudinal gradient for ε4 can be observed across Europe (5% to
10% in Spain, Portugal, Italy, and Greece, up to 16% in France, Belgium, and Germany, up to 23%
in the Scandinavian peninsula, with peaks of 31% in the Saami population of Finland) and it has
been also reported in China (5% to 17.5% in 19 distinct populations) [178–181]. In the context of the
present review, data have been also gathered for a cohort of 134 Italian centenarians and 350 healthy,
younger controls, so that 484 samples were enrolled in three Italian areas (North, Center, and South
Italy) and clustered according to their place of birth. DNA samples were recovered after approval
by the Ethical Committee of Sant’Orsola-Malpighi University Hospital (Bologna, Italy). As shown in
Supplementary Tables S3 and S4, when individuals from both groups were separately clustered by
macroareas [182,183], a definite gradient could be observed for the ε4 allele in both centenarians and
controls, with frequencies of 0.125 and 0.124, respectively, in Northern Italy, 0.052 and 0.063 in Central
Italy, and 0.026 and 0.039 in Southern Italy. Although sample size is relatively small in the latter group,
the increase in frequency from South to North at both a regional and a continental level follows a pattern
that has been already observed. For example, in Italy and in Europe, for other genes involved in lipid
metabolism [182,184,185], this suggests that isoform ε3 may be selected against ε4 at lower latitudes,
but this does not explain the evolutionary advantage of the single amino acidic mutation Arg112Cys
provided in giving rise to the now most frequent APOE variant worldwide [178–180,186]. Studies on
this topic report a higher structural stability and functional flexibility of isoform ε3, which can also be
associated with metal binding, oxidative stress resistance, micronutrient uptake, enhanced neuronal
repair following damage, and an energy-conserving phenotype [187–191] (see a comprehensive
review on adaptation to dietary changes in Reference [192]). However, being more adaptive and
responsive to environmental changes does not justify that all the ailments of isoform ε4 is associated
with, tend to be post-reproductive. Theories have been recently introduced that several derived
alleles (including those at the APOE gene) with a protective effect on cognition after menopause
may result from late-life selection through an increase in younger kin survival. The proposal of this
“grandmother effect” may explain the predominance of the ε3 allele in a trans-generational way by
assessing that the extension of the post-reproductive lifespan as a healthy phenotype requires the
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prevention of age-related cognitive decline to increase the survival of younger kin under grandparental
care. Moreover, cultural transmission through generations is known to shape the social structure of
modern foraging populations, which enhances the survival probability of the individuals belonging to
networks that are enriched in multi-generational sharing of knowledge [175,176,193,194].
Figure 2. Frequency distribution of APOE alleles in 82 countries. Data from the 1000 Genome Project
have been integrated with those published in Singh et al. 2006. (A) Frequency distribution of the ε2
variant. (B) Frequency distribution of the ε3 variant. (C) Frequency distribution of the ε4 variant.
6. APOE Trade-Offs
Human longevity is a complex phenotype in which small contributions from a high number
of genetic variants participate to define most age-related traits in later life. Isoform ε4 of APOE is
involved in several cardiovascular and neural pathologies that become apparent at a post-reproductive
age. Many studies in the last decade tried to find explanations as to why such a deleterious variant has
been maintained at high frequency in many human groups, particularly in indigenous populations of
Africa and Oceania [178]. The main collected findings suggest an association between isoform ε4 and
a number of population-specific and environment-related beneficial effects that compensate for the
damage induced by the same variant in later life [175,176,187,189,193].
The observation that the most detrimental effects of APOE (CVD, AD, reduced lifespan) mainly
affect individuals of affluent populations, while most African groups do not develop significant
impairment despite presenting the highest frequencies of isoform ε4, prompted a study on a rural
Ghanaian population characterized by high levels of mortality from widespread infectious diseases.
The analyses conducted pinpointed an association between the exposure of fertile women to high
pathogen levels and a higher degree of fertility (ε4 carriers have one more child than non-carriers, while
ε4 homozygous women have 3.5 more children on average). Such polymorphism may be maintained
because it favors reproduction in a context where limited survival at older ages spontaneously
delays the detrimental effects of the isoform. Conversely, individuals living in modernized societies,
less affected by pathogens and capable of reaching an older age, have no need for the positive
reproductive advantage conferred by this allele and have, instead, more probability to manifest the
related negative repercussions [195]. Moreover, several candidate gene studies conducted on cohorts
from industrialized countries (e.g., Iran, Turkey, United States) seem to highlight a positive relationship
between cardiovascular disease and thrombophilia, as induced by lipid clearance dysfunction through
the ε4 variant, and occurrences of two or more consecutive miscarriages before the 20th week of
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gestation. These studies compared groups of affected women and fertile negative controls with at least
two successful pregnancies. In all cases, a statistically significant enrichment in the ε4 variant was
found for the cohorts affected by recurrent pregnancy loss as well as a significant positive association
of the ε3/ε4 and ε4/ε4 genotypes with the analyzed phenotype [196–200].
Another study relating pathogen exposure to the preservation of the deleterious isoform was
performed on the Tsimane population of Amazonian foragers. Results highlighted that ε4 carriers
with a high eosinophil count (a sign of parasitic infection) perform better in cognitive tests than the
non-infected carriers, irrespective of their age [201,202].
Some publications also support the thesis that the extremely long span of human survival beyond
fertile age is an exception in the world of primates and mammals and is tightly linked to the practice
of inter-generational cooperative child rearing, which potentially developed early in hunter-gatherer
societies. The role of the grandmother is, in this case, equally parted in practices of active support,
information transfer, and building of social networks that can result in extensive sharing of resources,
which favor the survival and growth of the younger individuals. In this case, the positive effects
of differential survival and reproductive success in early life are mirrored by deleterious cognitive
deficiencies at an older age, when natural selection is absent [175,193].
Other studies have proposed that the main advantage provided by isoform ε3 when it first
emerged, around 200,000 years ago, relates to an early shift in dietary habits. More organized hunting
methods and the use of fire enhanced the quantity of fat-rich meat introduced with diet, which
ultimately helped extend the human lifespan. Survival to reproductive age and beyond would,
in this case, require both an efficient clearance of excess cholesterol from the blood and a stronger
inflammatory response to food-borne pathogens, which is provided by the more ancient isoform
ε4 [168,192].
The ε4 allele is an independent risk factor in age-related mortality and all-cause mortality. Since
it hampers longevity, one would expect a general reduction of allele frequency with increasing age.
However, the disease risk association seems to vary in an ethnic-related way. For example, hypertension
and brain hemorrhage risks are increased only in Asian and European ε4 carriers [203,204], while
African and Hispanic Americans show an increased risk for Alzheimer disease even in the absence
of ε4, which allows for its accumulation in older age cohorts, because it is less detrimental [178,205].
Other studies have shown how this variant may exert negative pleiotropy, which grants protection to
the infant brain and against infections at a younger age. This counterbalances the deleterious effects
that may be induced later in life [206–209].
Lastly, isoform ε2 has a worldwide frequency of around 7% and a patchy distribution, with
peaks in Southeast Asia, Australia, and some African populations (up to 19%) and absence in most
indigenous American groups [178]. The effects of this isoform are opposite to those of ε4. Carriers show
a lower risk and delayed onset of cognitive decline and a significantly reduced risk of cardiovascular
disease, but increased infection rates at a young age [208,210–214]. Given the opposite effects of the
two isoforms, the only current explanation for their simultaneous high frequency in several indigenous
African populations is that selection acts for ε2 and ε4 against ε3, but no definitive selective mechanism
has been described so far [162].
Other possible explanations for the latitudinal distribution of APOE variants and the maintenance
of ε4 relate to its role in immunity. As highlighted by ecological and biogeographical research, there is
a clear relationship between the current distribution of human infectious diseases, latitude, average
temperature, humidity, and population density, with harmful bacteria flourishing in hot, wet climates
and in densely populated areas of the world [215,216]. Studies involving knock-out chimeras in mice
suggest that APOE deficiency (also mimicking reduced functionality of ε4) leads to cholesterol build-up
in dendritic cell membranes, which enhances antigen presentation via lipid rafts and increasing T-cell
activity (hampering macrophage function [106,217]) regardless of ensuing hypercholesterolemia. This
has also been directly observed in humans, where subjects expressing the ε4 isoform have a higher
activated T-cell count when compared to carriers of the other isoforms [218]. However, earlier studies
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on mice also highlighted that APOE-deficient specimens may show a significantly reduced immune
response to specific pathogens by becoming more susceptible to Lysteria monocytogenes and Klebsiella
pneumoniae infections [72,73,219]. As described in paragraph 3.2, several viruses require the most
common form of APOE to build their particles and invade human cells. In fact, it has been observed
that isoform ε4 may hamper virion synthesis and compete with the hepatitis C virus for access to
LDL receptors, which reduces liver damage in exposed populations. For example, in the Italian
peninsula, the North-South gradient of hepatitis C incidence overlaps with a reverse gradient in ε4
distribution [220,221]. It is less clear how the different isoforms of APOE interact with the herpes
simplex virus and HIV even though the mechanisms proposed in a review by Kuhlman et al. (2010)
suggest that ε4, in this case, poses less competition to cell entry, which is also helped by the enhanced
presence of lipid rafts in the cell membrane [222]. A relationship between APOE4 conservation,
enhanced immune response, and pathogen distribution can be further justified by studies highlighting
how carriers of this allele show higher levels of the anti-parasitic cytokine interleukin-3 (IL-3) and the
pro-inflammatory tumor necrosis factor (TNFα) when exposed to endotoxins [223,224]. This seems
to be especially important in the extreme case of Gram-negative infections since their toxins are
membrane lipopolysaccharides (LPS) that can be collected by lipoproteins and redirected by APOE to
the liver for inactivation. Reduced functionality of this protein can, thus, lead to hampered endotoxin
clearance, overstimulation of macrophages, overproduction of inflammatory cytokines, and a stronger
immune response leading to sepsis in the afflicted subject [225].
While local accumulation of the ε4 isoform in indigenous populations can be justified by the
prevalence of infections in the absence of medical care, it can also be associated with a stronger
inflammatory response to food-borne pathogens [168,192]. Other dietary factors, such as vitamin
D and bone calcium assimilation, which were proven to be higher in both humans and transgenic
mice carrying the ε4 allele [188,191], may have been crucial in the adaptation of populations living at
extreme latitudes to the reduced amount of UV radiation. This justifies the North-South distribution of
ε4 observable in Europe [188].
Many recent studies also considered a relationship between APOE and the gut microbiota, since,
in this context, APOE can simultaneously exert its double role in lipid assimilation and immunity.
Several experiments using APOE knock-out mice have shown that the diet can modulate gut microbiota
composition such as with an enrichment in Firmicutes when mice were fed a typically Western diet.
In turn, this relates to the amount of metabolic endotoxins in the bloodstream that stimulated a
chronic inflammatory state [226,227]. On the other hand, if mice feeding on a hyperlipidic diet were
immunized against their own gut microbiota, a significant decrement in serum inflammatory cytokines
could be observed together with a reduction in atherosclerotic plaques, which suggests an interesting
trade-off mechanism that balances the immune response against the resident microbiota with immune
regulation of inflammation mediated by apolipoprotein E [228]. Other studies on obese mice and
knock-out mice fed on regular chow versus a Western diet discovered that mending the loss of
specific bacteria strains (e.g., Akkermansia muciniphila) caused by a hyperlipidic diet contrasted the
enhanced permeability of the gastrointestinal tract to endotoxins and reduced vessel inflammation,
fat dysmetabolism, and atherosclerosis both in normal and obese specimens [229–231]. Taking into
consideration the immunomodulatory function of APOE, not only against bacteria, but also toward
oxidized LDL found in sclerotic vessels, these observations highlight how both local and systemic
responses can shape the overall arrangement of the intestinal biome [228].
Trade-off mechanisms may explain, in certain cases, issues regarding the replication of association
signals for the same allele in different human populations and that several studies deem it more
likely that a proportion of genetic influence on longevity (and of complex traits in general) may be
explained through polygenic effects [232–234]. Furthermore, the studies performed until now did not
fully address the role of rare mutations [235] nor the interaction between rare variants and APOE that
seems to have a relevant impact on the phenotypic outcome, as supported by a recent study on the
Hong Kong Chinese population [236]. Lastly, in this review, we did not address a potential limitation
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of trade-off mechanisms: the fact that they may be time-dependent and may be influenced by specific
environmental (internal and external) conditions.
The contrast between APOE4 and APOE3 frequency distributions in current populations, with
the former being prevalent in foraging communities and the latter being predominant in regions
with relevant agricultural economy, led to the theory that the ε4 variant is a relic of a hunter-gatherer
genetic background that has not adapted to the modern, energy-rich, and exercise-poor lifestyle [237].
To assess the possibility of observing the temporal scale of this transition, in the context of the present
review, we built a panel of 1149 publicly available ancient genomes and selected 97 of them, with both
rs7412 and rs429358 already directly genotyped (the original works including the selected samples can
be found at References [238–258]). This has been done in order to avoid the introduction of bias in the
dataset by imputing variants from highly deteriorated DNA, which usually presents extended regions
of missing data. The samples, mapped in Figure 3 and listed in Supplementary Table S5 with details
on the place of discovery and cultural context, cover the Euro-Mediterranean area and range from 1500
to 42,000 years ago. The ε3/ε3 genotype was found to be the most frequent (83%), followed by the
ε4/ε4 genotype (13%), and the ε2/ε2 genotype (3%). The only heterozygote ε3/ε4 was represented by
the Ust’Ishim sample, a 42,000-year old specimen of early hunter-gatherer human found in Siberia.
In more detail, the ε2/ε2 individuals are Northern European samples from the Bronze Age. Despite
carrying the ancestral genotype, all ε4/ε4 individuals are less than 8000 years old, with most of them
being even more recent than 5000 years, while a conspicuous number of ε3/ε3 samples are much older
than this, especially in the areas of Caucasus, between the Black Sea, the Caspian Sea, and the Middle
East. This temporal and spatial distribution may be coherent with Palaeolithic alleles, like APOE4,
having been reintroduced in Europe at higher frequency with the Yamnaya migration from the Steppe
during the Bronze age and APOE3 being present at higher frequencies in the Fertile Crescent prior to
the Neolithic Revolution, even though both alleles were already present in the European populations
as well, as highlighted by the older local specimens [238,243,245]. However, the limited number of
samples available across such an extended geographic area and the chance of genotyping errors due
to the highly deteriorated ancient DNA hinder the possibility of a thorough factual discussion of the
results. In order to draw more elaborate conclusions, it would be useful to recover more complete and
evenly distributed ancient data, both in space and in time.
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Figure 3. Distribution and approximate age of the analyzed ancient samples. Those coming from the
same location and belonging to the same culture have been clustered together and share the same label.
The number of grouped individuals is given in brackets.
7. Conclusions
This review reports and summarizes relevant considerations regarding APOE and its pivotal role
in the genetics of human longevity. Both candidate-gene studies and genome-wide analysis reveal its
involvement in the attainment of an extreme lifespan by exerting a pleiotropic effect in a polygenic
context. In this review, some new data (on the geographic distribution of APOE isoforms ε2, ε3 and ε4
in centenarians and in healthy individuals from the Italian population and on public available dataset
on ancient genomes) have also been considered and evaluated in the light of the most recent findings
on this gene, with particular attention to the variability across human populations. In fact, the study
of the variability across different human groups is crucial to understand the differences that can be
observed in the association between this gene and longevity and age-related diseases. The patterns
can be justified by considering the multitude of biological pathways this gene belongs to and the
different environmental conditions human populations must deal with especially with regard to
pathogen exposure and dietary changes. An evolutionary perspective is also crucial to understand the
conservation and current worldwide distribution of APOE isoforms ε2, ε3, and ε4. New data regarding
DNA methylation variability in different tissues will also help more clearly define the role of this gene.
Moreover, the relation between population specific cultural/ecological traits and APOE variability
(as well as other genes) are needed to disentangle the devious way from genotype to phenotype. Given
the high amount of data available on this gene, we think that an evolutionary approach, such as the
one proposed by evolutionary medicine [259–263], will help interpret and clarify the link between
even distant (or apparently not connected) results for this gene in different populations.
Supplementary Materials: The following is available at http://www.mdpi.com/2073-4425/10/3/222/s1.
Table S1: Summary of the studies published in the last eight years investigating the association between APOE
variants and human longevity. Table S2: APOE allele frequencies in different human populations. Data used
for Figure 2. Table S3: number of APOE alleles and haplotypes in geographically divided groups of 484 Italian
centenarians and controls. Table S4: frequency of APOE alleles and haplotypes in geographically divided groups
of 484 Italian centenarians and controls. Table S5: Summary of APOE haplotypes in ancient genomes. Data used
for Figure 3.
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Abstract: Studies with twins provide fundamental insights to lifespans of humans. We aim to clarify
if monozygotic and dizygotic twin individuals differ in lifespan, that is, if zygosity matters. We
investigate whether a possible difference in mortality after infancy between zygosities is stable
in different age cohorts, and whether the difference remains when twins with unknown zygosity
are taken into account. Further, we compare the distribution of long-livers, that is, the upper-tail
of the lifespan distribution, between monozygotic and same-sex dizygotic twin individuals. The
Danish Twin Registry provides a nationwide cohort of 109,303 twins born during 1870 to 1990
with valid vital status. Standard survival analysis is used to compare mortality in monozygotic
and dizygotic twin individuals and twin individuals with unknown zygosity. The mortality of
monozygotic and dizygotic twin individuals differs slightly after taking into consideration effects of
birth- and age-cohorts, gender differences, and that twins are paired. However, no substantial nor
systematic differences remain when taking twins with unknown zygosity into account. Further, the
distribution of long-livers is very similar by zygosity, suggesting the same mortality process. The
population-based and oldest twin cohort ever studied suggests that monozygotic and dizygotic twins
have similar lifespans.
Keywords: lifespan; mortality; twins; zygosity; unknown zygosity; cumulative incidence curves;
age-stratification; long-livers
1. Introduction
One of the advantages of using twins in quantitative genetic modelling is the assumption of
comparability (of trait means and distribution of variances) of the monozygotic (MZ) and dizygotic
(DZ) twins with respect to the studied trait or disease when considering the twins as individuals [1].
However, for studies on disease onset and other age-dependent traits, an important factor to study is
the relative survival of MZ twins compared to DZ twins [2]. One may speculate whether MZ twins
in general show better survival in comparison to same-sex and opposite-sex DZ twins as an effect
of greater closeness and social support. On the other hand, MZ twins show lower birth weights,
higher risk of prematurity and greater neonatal mortality than DZ twins, which may affect long term
survival [3]. Genetic and environmental effects on mortality are well studied [4,5], showing a modestly
higher concordance of overall mortality in MZ twin pairs than DZ twin pairs. However, the effect of
zygosity on concordance in mortality might integrate social factors beneficial for a longer life. It may
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be difficult to disentangle such factors, and many studies points towards little or no difference in twins
as individuals across zygosity for many outcomes related to survival [6,7].
Compared to the background population, twin individuals have higher perinatal and infant
mortality [8], however the relatively high mortality in twins occurs soon after birth [2], and after the
age of six mortality of twins is similar to that of the background population [6]. A recent study on
Danish twin birth cohorts from 1870–1900, left truncated at age 10, suggested that MZ twin individuals
have better survival than same-sex DZ twin individuals at nearly all ages [9]. The paper applied
a two-process model, assuming independence between all subjects, and partitioned mortality into
an intrinsic process, where death follows from cumulative and incremental degradation of survival
capacity, and an extrinsic process, where death results from an acute environmental challenge [9]. No
formal statistical tests were made, but explorative results indicated that MZ female twins may have
better overall survival than same-sex DZ female twins, due to greater extrinsic survival. Monozygotic
male twins may have better overall survival than same-sex DZ male twins, where the improved
survival was ascribed to greater extrinsic survival until age 65–70, and to greater intrinsic survival
from age 65–70. Based on these results, we seek here to study rigorously mortality after infancy in MZ,
same-sex DZ, and opposite-sex DZ twin individuals, accounting for the dependency within twin pairs,
in birth cohorts ranging from 1870 until 1990 and using the most recent follow-up data on vital status
in the Danish Twin Registry [10,11].
The Danish Twin Registry was established in 1954, identifying twin pairs prospectively as well as
retrospectively from church records and classifying zygosity through questionnaires and interviews
with surviving twins and family [11,12]. The register includes Danish twin pairs from birth cohorts
1870 onwards and is regarded almost complete from birth cohort 1960 [11,13]. For some same-sex
twin pairs the zygosity is not determined, in particular in the early birth cohorts and among twin
pairs with early mortality. In the early birth cohorts from 1870 to 1960, more same sex twins with early
mortality are likely to be registered as unknown zygosity (UZ) due to the ascertainment method, and
consequently, mortality of UZ twins from birth cohorts 1870–1960 may be expected to be higher than
for twins registered as MZ or DZ. From birth cohorts 1960, it may be assumed that the registration
of UZ twins due to death after infancy is negligible [10]. Although the true zygosity of UZ twins is
unknown, it is expected that UZ twin pairs are a mixture of MZ and same-sex DZ twin pairs.
The objectives of this study are to compare mortality after infancy in MZ, same-sex DZ, and
opposite-sex DZ twin individuals, to examine whether possible differences in survival between
zygosities are stable in different and age cohorts, and to investigate differences in mortality in MZ,
same-sex DZ, and opposite-sex DZ under different assumptions on the true zygosity of UZ twin pairs.
A further objective was to explore the upper-end of the lifespan distribution in MZ and same-sex DZ
twin individuals.
2. Materials and Methods
2.1. The Danish Twin Registry
As the first nationwide twin registry, the Danish Twin Registry was established in 1954, identifying
twin pairs prospectively as well as retrospectively from church records of all 2200 Danish parishes
and all calendar years 1870–1930. Also, regional population registers and other public sources were
used to identify twins and close relatives of twins. All twins, or their closest relatives, were sent
questionnaires, including questions on similarity between the twins to determine the zygosity of
same-sex twin pairs [6,11,12,14,15]. If one or both twins had died or emigrated before the age of six, the
twin pairs were not followed up. Twins, who did not reply to the questionnaires, as well as a minority
providing inconsistent responses, were classified as UZ [10]. Later comparisons of the zygosities of
same-sex twins determined from the questionnaires with results determined from blood samples
indicated that more than 95% of twin pairs were classified correctly [16].
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For the birth cohorts 1930–1990, the ascertainment procedure was based on the civil registration
system introduced in 1968 and hence the criterion for inclusion was survival of both twins until 2 April
1968, which resulted in complete registration of all twins born from that date [10].
2.2. Study Population
The study includes population-based birth cohorts from the Danish Twin Registry including
information about mortality. The Danish Twin Register comprises total of 126,489 individuals from
multiple births from birth cohorts 1870–1990. Excluding triplets, quadruplets, twin pairs with
inconsistent zygosities, twin individuals with invalid or missing vital status, and twin individuals
who died before age six, leaves a total of 109,303 twin individuals from 57,313 twin pairs. For our
primary analyses on differences in mortality between zygosities, we use all twin individuals with
known zygosity from birth cohorts 1870–1990 (n = 96,338), and for our secondary analyses we include
UZ twins and restrict the birth cohorts to 1961–1990 (n = 39,504) where there is virtually complete vital
status follow-up of the twin individuals [10] (Figure 1).
 
Figure 1. Flowchart.
The project was approved, and data were provided by, the Danish Twin Registry (ref. no.
17/64840) in an anonymized fashion. Access to the data requires application to this registry. According
to Danish law, no ethical approval is required for registry-based studies.
2.3. Statistical Analyses
Individual twins were excluded in case of missing data on vital status or date of vital status,
or in case of death before age six years old (Figure 1). For the general population, it is well known
that life expectancy has improved over the period 1870–1990. To be able to handle this period-effect
and the differences in ascertainment methods, the birth cohorts are divided into four cohorts within
which the same ascertainment method was used, and within which mortality rates are assumed
to be homogeneous in the background population: In the first two cohorts, church records were
used for identification of twins; this cohort was further divided into two separate cohorts, due to
the pronounced increase in life expectancy in the Danish background population during this period,
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increasing from an average life expectancy in males between 46–49 years in 1870–1900 to an average
life expectancy in males between 53–61 years in 1901–1930 (StatBank Denmark, Statistics Denmark). In
the third cohort, including birth cohorts 1931–1960, the ascertainment of twins was based on survival
of both twins until April 1968 and the average life expectancy in the background male population
ranged between 62–70 years. From 1960, virtually all twins surviving infancy were included, and
the average life expectancy in the background male population was between 70–72. Descriptive
analyses were conducted for each cohort separately. Mortality was compared between zygosities (MZ:
monozygotic, SSDZ: same-sex dizygotic, OSDZ: opposite-sex dizygotic) separately within each cohort
using Kaplan-Meier plots and cumulative incidence curves [17] of death by age, stratified on sex. Due
to non-proportional hazards and statistically significant interaction between zygosity and age, the
models were stratified on three age-intervals (0–50 years, 50–75 years and 75+ years) by introducing a
time-varying interaction term with cut-points at ages 50 years and 75 years. Within each age-interval,
the proportional hazards assumptions were satisfied when assessed using Schoenfeld residual tests. To
combine survival analyses across the four cohorts, the baseline hazards were stratified on the cohorts
in the age-stratified Cox proportional hazard models. In analyses on both sexes combined, the baseline
hazards were further stratified on sex. The mortality analyses were conducted on twins regarded
as individuals. However, as the two twins within a twin pair are not independent, cluster robust
standard errors were used in the statistical models to account for the lack of independence between
observations [18]. All analyses were conducted on both sexes combined and for each sex separately.
Registration of twins surviving infancy is assumed to be complete in the Danish Twin register
from 1960 onwards. Therefore, the fourth cohort (birth cohorts 1961–1990) was used in three sensitivity
analyses including all twin individuals with known or unknown zygosities. The cohort comprises a
total of 39,504 twin individuals of which 5178 have UZ. In the first sensitivity analysis, all UZ twin
pairs were treated as MZ, in the second UZ twin pairs were randomized 1:1 as either MZ or SSDZ
twins, and in the third, UZ twin pairs were randomized 1:2 as either MZ or SSDZ twins. In the cohort
1961–1990, the follow-up time was at most 56 years (from 1 January 1960 until end of follow-up 1
October 2016), and most twin individuals were alive at the time of follow-up. Age-stratified (0–50
years and 50+ years) Cox proportional hazard regression analyses with cluster robust standard errors
were conducted. In analyses on both sexes combined, the baseline hazards were stratified on sex.
The analyses were conducted on both sexes combined and for each sex separately. Assumptions on
proportional hazards were assessed using Schoenfeld residual tests and were satisfied for both sexes
and in both age-groups.
Finally, we explored whether the distribution of the lifespans of long-livers, that is, twin
individuals reaching very high ages, differ between MZ and SSDZ twin individuals, by comparing the
upper-tail of the lifespan distributions. To do this, the generalized extreme value distribution (GEV)
was applied to model the upper-tail of the lifespan distribution for twins born between 1870–1930 [19].
The GEV is a three-parameter model with a location parameter μ, estimating the center of the lifespan
distribution for twin individuals, a scale parameter σ, estimating the deviations around the location
parameter, and finally a shape parameter ξ, estimating the heaviness of the upper-tail lifespan, i.e., the
distribution of lifespan among the long-livers: twins reaching very high ages. An increasing shape
parameter corresponds to a higher probability of reaching very long lifespans. A negative value of
the shape parameter indicates a light upper-tail, i.e., that there is a final limit to the highest possible
lifespan, which is in accordance with human lifespans [20]. The shape parameter of the GEV to be
reported for MZ and SSDZ for each gender was estimated by the moments method and inference was
obtained by parametric bootstrap using the R-package ExtRemes [21].
3. Results
Characteristics of twin individuals with known zygosities in each of the four cohorts are shown
in Table 1. The age at follow-up (FU) was lower in the third and fourth cohorts due to censoring at end
of the study period (1 October 2016). In the third cohort, the proportions of MZ twins and females
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were lower than in the other cohorts. In the second cohort, the proportion of OSDZ twins was lower
than in the other cohorts.












Total, n (pairs) 96,338 (49,390) 9037 (4907) 15,645 (8060) 37,330 (19,114) 34,326 (17,309)
Age at FU a, mean (SD) 58.5 (18.3) 69.0 (19.8) 74.0 (16.8) 65.3 (11.2) 41.2 (9.2)
Sex, n (%)
Male 49,100 (51.0) 4496 (49.8) 7480 (47.8) 20,133 (53.9) 16,991 (49.5)
Female 47,238 (49.0) 4541 (50.3) 8165 (52.2) 17,197 (46.1) 17,335 (50.5)
Zygosity, n (%)
MZ 23,888 (24.8) 2247 (24.9) 4613 (29.5) 7122 (19.1) 9906 (28.9)
SSDZ 39,728 (41.2) 4029 (44.6) 9156 (58.5) 14,440 (38.9) 12,103 (35.3)
OSDZ 32,722 (34.0) 2761 (30.6) 1876 (12.0) 15,768 (42.2) 12,317 (35.9)
Dead during FU a, n (%)
No/censored 62,459 (64.8) 208 (2.3) 959 (6.1) 27,806 (74.5) 33,486 (97.6)
Yes 33,879 (35.2) 8829 (97.7) 14,686 (93.9) 9524 (25.5) 840 (2.4)
a FU is defined as time until death, censoring (emigration) or end of study period (1 October 2016). SD: standard
deviation; MZ: monozygotic; SSDZ: same-sex dizygotic; OSDZ: opposite-sex dizygotic.
Kaplan-Meier survival curves indicate non-proportional hazards in the two first cohorts for both
male and female twins (Supplementary Figures S1 and S2). For younger ages, the mortality of OSDZ
twin individuals appears much higher than both MZ and SSDZ twin individuals in the first two
cohorts, while at higher ages the survival is similar for all three zygosities.
In all three age-intervals, OSDZ twin individuals have significantly higher mortality than MZ twin
individuals for both males and females (Table 2). For males, SSDZ twin individuals have significantly
higher mortality than MZ twin individuals in all three age-intervals, and for females SSDZ twin
individuals have significantly higher mortality than MZ twin individuals in the two younger age
intervals. For both males and females, the difference in mortality between MZ and DZ twin individuals
is largest in the youngest age interval (0–50 years) and weakens with age (Table 2).
Secondary analyses were conducted on the birth cohorts 1961–1990 including UZ twin pairs.
Population characteristics of the twin individuals are shown in Table 3.
Kaplan-Meier survival curves (Figure S3) suggest a higher mortality in UZ twin individuals than
twin individuals with known zygosity, mainly among male twins. Age stratified analyses on the
birth cohorts 1961–1990 in Table 4 show that the increased mortality among UZ male twin individuals
mainly exists in the younger age group (up to 50 years of age), while there are no statistically significant
differences in mortality in twin individuals aged above 50.
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Table 2. Associations between mortality and zygosity in individual twins from all birth cohorts
1870–1990 and surviving to age 6; among individual twins at ages up to 50 years, between 50–75 years,
and from 75 years.
All Ages,
n = 96,338 a
Ages ≤50,
n = 96,338 a
Ages 51–75,
n = 65,107 a
Ages >75,
n = 20,839 a
Both sexes HR (95%-CI) HR (95%-CI) HR (95%-CI) HR (95%-CI)
Zygosity, n (%)
MZ Ref. Ref. Ref. Ref.
SSDZ 1.09 (1.06, 1.12) *** 1.19 (1.11, 1.29) *** 1.11 (1.06, 1.17) *** 1.04 (1.00, 1.09) *
OSDZ 1.17 (1.13, 1.21) *** 1.53 (1.41, 1.66) *** 1.12 (1.06, 1.18) *** 1.09 (1.04, 1.15) ***
Males
Zygosity, n (%)
MZ Ref. Ref. Ref. Ref.
SSDZ 1.11 (1.07, 1.16) *** 1.23 (1.11, 1.36) *** 1.11 (1.04, 1.18) *** 1.07 (1.00, 1.13) *
OSDZ 1.16 (1.11, 1.21) *** 1.44 (1.30, 1.60) *** 1.10 (1.03, 1.18) ** 1.11 (1.03, 1.19) **
Females
Zygosity, n (%)
MZ Ref. Ref. Ref. Ref.
SSDZ 1.07 (1.03, 1.12) ** 1.20 (1.11, 1.30) *** 1.12 (1.07, 1.17) *** 1.04 (1.00, 1.08)
OSDZ 1.18 (1.13, 1.24) *** 1.52 (1.40, 1.64) *** 1.11 (1.06, 1.17) *** 1.09 (1.04, 1.15) ***
a Baseline hazard stratified on cohort group (analyses on both sexes stratified on sex as well). HR: hazard ratio; CI:
confidence interval; * p < 0.05, ** p < 0.01, *** p < 0.001.







Total, n (pairs) 39,504 (20,232) 19,964 (13,266) 19,540 (13,000)
Age at FU a, mean (SD) 40.3 (9.6) 40.2 (9.5) 40.5 (9.6)
Sex, n (%)
Male 19,964 (50.5) 19,964 (100.0) -
Female 19,540 (49.5) - 19,540 (100.0)
Zygosity, n (%)
MZ 9906 (25.1) 4689 (23.5) 5217 (26.7)
SSDZ 12,103 (30.6) 6159 (30.9) 5944 (30.4)
OSDZ 12,317 (31.2) 6143 (30.8) 6174 (31.6)
UZ 5178 (13.1) 2973 (14.9) 2205 (11.3)
Dead during FU a, n (%)
No 38,519 (97.5) 19,334 (96.8) 19,185 (98.2)
Yes 985 (2.5) 630 (3.2) 355 (1.8)
a FU is defined as time until death, censoring (emigration) or end of study period (1 October 2016).
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Table 4. Associations between mortality and zygosity in individual twins, birth cohorts 1961–1990,







Both sexes a HR (95%-CI) HR (95%-CI) HR (95%-CI)
Zygosity
MZ Ref. Ref. Ref.
SSDZ 1.07 (0.89, 1.13) 1.10 (0.91, 1.34) 0.80 (0.46, 1.40)
OSDZ 1.21 (1.01, 1.45) * 1.23 (1.02, 1.48) * 1.05 (0.61, 1.79)
UZ 1.83 (1.47, 2.28) *** 1.89 (1.51, 2.37) *** 1.25 (0.49, 3.20)
Males
Zygosity
MZ Ref. Ref. Ref.
SSDZ 1.01 (0.80, 1.28) 1.06 (0.83, 1.35) 0.63 (0.29, 1.37)
OSDZ 1.22 (0.97, 1.53) 1.23 (0.97, 1.55) 1.14 (0.56, 2.29)
UZ 1.86 (1.43, 2.42) *** 1.92 (1.46, 2.51) *** 1.26 (0.39, 4.11)
Females
Zygosity
MZ Ref. Ref. Ref.
SSDZ 1.17 (0.88, 1.56) 1.19 (0.88, 1.62) 1.04 (0.46, 2.31)
OSDZ 1.19 (0.90, 1.58) 1.23 (0.91, 1.67) 1.14 (0.56, 2.28)
UZ 1.71 (1.13, 2.60) * 1.78 (1.15, 2.75) ** 1.18 (0.26, 5.45)
a Baseline hazard stratified on sex. * p < 0.05, ** p < 0.01, *** p < 0.001.
There are no interactions between zygosity and age-group among male or female twins (all:
p = 0.696, males: p = 0.519, females: p = 0.902). In all three sensitivity analyses, treating all UZ twin
pairs as MZ, randomizing UZ twin pairs 1:1 as MZ or SSDZ twin pairs, or randomizing UZ twin
pairs 1:2 as MZ or ss-DZ twin pairs, there are no differences in mortality between MZ and DZ twin
individuals in neither age group (Supplementary Tables S1–S3).
For MZ and SSDZ twin individuals, the upper-tail of lifespan distributions are similar for both
male and female twins. Overall for the birth cohorts 1870–1930, the estimated values of the shape
parameters, reflecting the probability of reaching very long lifespans, are very similar for MZ males
and DZ males (MZ: ξ (95%-CI) = −0.74 (−0.76, −0.69); DZ: ξ (95%-CI) = −0.75 (−0.77, −0.72)), and
for MZ and DZ females (MZ: ξ (95%-CI) = −0.86 (−0.88, −0.81); DZ: ξ (95%-CI) = −0.84 (−0.86,
−0.81)). Hence, the shape of the upper-tail of lifespans are very similar by zygosity suggesting the
same mortality process regarding the probability of reaching very long lifespans.
4. Discussion
4.1. Main Findings
Using mortality information for the 1870–1990 Danish twin cohorts, we find that the mortality
after infancy of MZ and DZ twin individuals differ slightly after taking age, sex, and birth cohort
into account. However, when further taking into consideration that some twin pairs have unknown
zygosity, we find no indication of a substantial or systematic difference in survival between MZ and
DZ twin individuals. Sensitivity analyses, treating UZ twin pairs as MZ twins or randomizing UZ
twin pairs as either MZ or DZ twins, indicate that any apparent differences in mortality after infancy
between MZ and DZ twin individuals disappear when accounting for UZ twins, suggesting that the
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differences in mortality between MZ and DZ twins may be explained by selection due to unknown
zygosity of some twins. Finally, we find that the distribution of long-livers, that is, the upper-tail of the
lifespan distribution, is very similar in MZ and SSDZ twin individuals suggesting the same mortality
process regarding the probability of reaching very long lifespans.
4.2. Comparisons with Other Studies
In line with the results of Sharrow and Anderson [9], survival analyses, not accounting for UZ
twins, suggest better survival of MZ than DZ twin individuals in the younger age groups. However,
these results might reflect a deselection of UZ twins with higher mortality than twins with known
zygosity. The differences in mortality after infancy between MZ and DZ twin individuals vanish when
UZ twins are merged with twins with known zygosities under different conditions. The analyses in
the present paper as well as the paper by Sharrow & Anderson [9] are based on left truncated data,
conditioning on both twins surviving to age six (present paper) or 10 (Sharrow and Anderson [9]), and
may thus include only the most robust twin pairs where both of them were strong enough to survive
their youngest childhood. Including the individual surviving twin from all pairs in which one twin
died under the age of six would enhance the comparability with the general population on mortality
after infancy. Unfortunately, there are no data to enable follow-up of such surviving twins from the
early cohorts.
That MZ and DZ twins derive from the same base population with respect to lifespan is consistent
with other literature indicating no or little differences between MZ and DZ twin individuals, and
between twins and singletons in adulthood with respect to mortality, lifestyle, and incidence of common
diseases [6,22–26]. Data from multiple twin cohorts around the world have formed a substantial part
of genome-wide association studies of common traits and complex diseases and there is no evidence
to show that the gene–disease associations seen in singletons and twins differ. Thus, being a twin
does not appear to impact the basic biological processes and human development in adolescence and
adulthood. This implies that findings from twins are generalizable to the population as a whole. Given
that twin studies often have response rates higher than surveys in the population at large, twin studies
can be considered more representative when based on large, population-derived twin cohorts such as
the Danish Twin Registry and other Nordic cohorts.
4.3. Strengths and Weaknesses
The results in this paper are based on a very large dataset comprising more than 90,000 individual
twins with information of high quality on zygosity and vital status. The mortality of individual twins
is analyzed using an empirical approach and semiparametric models to conduct statistical inference,
testing hypotheses and estimating hazard ratios, while accounting for the dependency within twin
pairs and adjusting for birth cohorts by stratifying the baseline hazard function.
Although the Danish Twin Registry was established in 1954, it includes birth cohorts from 1870
onwards. For twins in the earlier birth cohorts, before the register was established, zygosity of the
twins was determined late in their lives, or even posthumously, leading to a relatively large proportion
of twin pairs with UZ in the early cohorts. Due to the structure in church records, retrospective
identification of opposite-sex twins was more difficult than identification of same-sex twins, which
may explain why some of the earlier birth cohorts in the Danish Twin Registry do not capture as large
a proportion of opposite-sex twins as same-sex twins. In the third cohort, birth cohorts 1930–1960, the
presence of MZ and female twin individuals are lower than in the other cohorts which might lead to
selection bias. To address potential confounding due to this bias in the survival analyses, all baseline
hazards were stratified on cohorts and, in analyses combing both sexes, the baseline hazards were
further stratified on sex. The criterion on survival until 1968 for all birth cohorts from 1930–1968 could
introduce a healthy-survivor effect, although this effect is likely to be comparable for MZ and DZ
twin individuals.
60
Genes 2019, 10, 166
In the 19th and first part of the 20th century, infant mortality was high overall and especially
high for twins due to low birth weight. In the current paper as well as the paper by Sharrow and
Anderson [9], twin pairs were included only if both had survived to age 6, respectively age 10, thus
selecting only the hardiest twin pairs. This could lead to biased results on survival in favour of MZ
twins over DZ twins because MZ twins have higher infant mortality. Another possible selection bias
in the earlier cohorts may have been difficulties in classifying the zygosity of twins dying young since,
in many cases, also their parents had died and they could not act as informants about zygosity. Thus,
the high mortality seen in UZ twins in the early cohorts might be related to high mortality in the
population in general rather than implying high early mortality in UZ twins.
5. Conclusions
The population-based and oldest twin cohort ever studied suggests that although direct
comparisons of MZ and DZ twin individuals may indicate that they differ slightly in mortality,
no substantial nor systematic difference in survival between MZ and DZ twin individuals is found
when taking twins with unknown zygosity into consideration and accounting for the effects of birth-
and age-cohorts, gender differences, and that twins are paired.
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Abstract: We investigated the possible influence of TERC and TERT genetic variation and leukocyte
telomere length (LTL) on human lifespan. Four polymorphisms of TERT and three polymorphisms of
TERC were examined in a sample of elderly subjects (70–100 years). After nine years of follow-up,
mortality data were collected, and sub-samples of long-lived/not long-lived were defined. TERT
VNTR MNS16A L/L genotype and TERT rs2853691 A/G or G/G genotypes were found to be
associated with a significantly higher risk to die before the age of 90 years, and with a significantly
lower age at death. The association between lifespan and LTL at baseline was analyzed in a subsample
of 163 subjects. Age at baseline was inversely associated with LTL (p < 0.0001). Mean LTL was greater
in the subjects still living than in those no longer living at follow-up (0.79 T/S ± 0.09 vs. 0.63 T/S ±
0.08, p < 0.0001). Comparison of age classes showed that, among the 70–79-year-olds, the difference
in mean LTL between those still living and those no longer living at follow-up was greater than
among the 80–90-year-olds. Our data provide evidence that shorter LTL at baseline may predict
a shorter lifespan, but the reliability of LTL as a lifespan biomarker seems to be limited to a specific
age (70–79 years).
Keywords: human lifespan; genetic variation; TERC; TERT; leukocyte telomere length
1. Introduction
The dramatic increase in rates of survival to an advanced old age over the past century
has prompted extensive research in the attempt to identify the mechanisms involved in lifespan
determination. Among the most extensively studied biological processes associated with longevity are
those involved in cell maintenance/senescence. Telomeres, the structures at the ends of eukaryotic
chromosomes with a protective action against genome instability, have been widely studied as
a possible determinant of lifespan [1]. Human telomeres are composed of repeated TTAGGG nucleotide
sequences located at the ends of each chromosome. Because telomere sequences are not fully replicated
during DNA replication due to the inability of DNA polymerase to replicate the 3′ end of the DNA
strand, telomeres shorten as cells divide. In the absence of special telomere maintenance mechanisms,
telomeres (and chromosomes) become shorter with each cell division. Once a critically short telomere
length is reached, the cell is triggered to enter replicative senescence, ultimately leading to cell death.
Telomerase, a cellular ribonucleoprotein enzyme complex, counteracts telomere shortening [2]. Human
telomerase is constituted by a DNA reverse transcriptase polymerase (telomerase reverse transcriptase,
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TERT), which uses an RNA template (telomerase RNA component, TERC) to add telomeric DNA
onto telomeres, thus compensating for the telomere shortening caused by cell divisions [3]. The two
components of human telomerase are encoded by the TERT gene on 5p15.33 (OMIM:187270) and by the
TERC gene on 3q26 (OMIM:602322). Since telomerase is almost totally absent in adult tissues, including
the skin, kidney, liver, blood vessels, and peripheral leukocytes, the telomeres of replicating cells
shorten progressively. This mechanism is thought to underlie aging and age-associated diseases [4–6].
Average leukocyte telomere length (LTL) is generally used as a marker of overall telomere length, since
TLs have been found to be strongly correlated across different cell types within the same individual [7,8].
Population studies that have applied analysis of LTL support the hypothesis that leucocyte telomere
shortening is associated with aging and lifespan [4–6,9,10]; however, the associations with age-related
chronic diseases (cardiovascular and metabolic disease, cancer) are not always concordant [8,9,11,12].
As fully functional telomerase is critical for telomere maintenance, genetic variations of human
TERT and TERC genes may alter the stability of the telomerase complex or directly affect its enzymatic
activity [13]. Studies assessing the possible effect of genetic polymorphisms of human TERT and
TERC genes on LTL [13–16], and on aging and lifespan [17–19], have produced mixed results. While
some TERC or TERT SNPs were found to be associated with longevity, the relation was not always
mediated by the association with telomere length. Similar contradictory results have come from genetic
association studies of TERT polymorphisms and common diseases [8].
In the present study, we investigated the possible impact on the human lifespan of four polymorphisms
of the TERT gene (MNS16A, rs2853691, rs33954691, rs2736098) and three polymorphisms of the TERC
gene (rs12696304, rs3772190, rs16847897). MNS16A is a minisatellite (variable number of tandem repeats,
VNTR) located downstream of exon 16 of the TERT gene and upstream in the putative promoter region of
an antisense TERT transcript. It shows two common alleles (VNTR-302 or L and VNTR-243 or S on the
basis of the PCR fragment size) [20]. It has been studied in relation to longevity and cancer risk [18,21–23].
The detection of antisense TERT mRNA suggested its possible role in regulating human telomerase
expression [20]. TERT rs2853691 is located in an intronic region and shows two common alleles, A and
G, while rs33954691 is located in exon 14, where a C to T substitution does not result in a change of
the amino acid (Histidine) at codon 1013. These two TERT SNPs have been reported to be associated
with both LTL and lifespan [13,17]. rs2736098 is located in exon 2, where a G to A substitution does not
result in a change of the amino acid alanine at codon 305; it has shown a strong association with some
cancer types (see OMIM %613059). The TERC SNPs rs12696304, rs3772190, and rs16847897 are all located
downstream of TERC in a noncoding region [14,17] and have been consistently associated with variation
of LTL [14,16,17,24]. In addition, in the attempt to gain a better understanding of the relationships between
telomere length and lifespan, in the present study, we analyzed LTL in a subsample of elderly subjects who
had been genotyped for TERT and TERC polymorphisms.
The association between LTL and TERT and TERC polymorphisms and longevity was investigated
by means of a follow-up study. The study sample was originally recruited in 2000. After collecting
mortality information in 2009, we defined a sample of long-lived subjects as those who died after
the age of 90 years, and a sample of not-long-lived subjects composed of those who had died before
reaching 90 years of age.
2. Materials and Methods
2.1. Materials
The sample was recruited in 2000 for the multidisciplinary LONCILE (Longevity of Cilento) study
on the anthropological and biological characteristics of the elderly population of the Cilento area in
the district of Salerno, southern Italy [25]. As previously reported [26], it consisted of 277 unrelated
individuals (43.7% males) born between 1900 and 1930 (mean age, 82.9 ± 5.7 years ± standard deviation
[SD]), enrolled without selection criteria, except age (>70 years) and birth place; they had no manifest
pathologies and were healthy, consistent with age. Mortality data on 267 subjects were collected in 2009.
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In 2000, 14.5% were aged 90 years old or older. During the nine-year follow-up period, the mortality
rate was 62.5% (51.5% men), and 44.9% of the subjects died after the age of 90 years, including those
aged 90 at baseline. As the mean life expectancy in this geographic area in 2000 for subjects 83 years
old was seven years for women and six years for men (ISTAT, http://demo.istat.it/unitav/index.html),
we defined as long-lived those subjects who, at follow-up in 2009, had died at an age of more than 90
years (≥90 years). The sample of the long-lived (n = 75) comprised 100% of subjects aged 90 years or
older in 2000 and 36.3% of those aged over 80 years in 2000. The sample of the not long-lived (n = 89)
was made up of individuals who had died between 2000 and 2009 before reaching the age of 90 years.
The protocol for the collection of biological material for the scientific studies was approved
by the institutional committees (Local Health Unit, Salerno 3). The study was approved by the
Department Board (12/06/2009 session) of the former Department of Genetics and Molecular Biology
of La Sapienza University, Rome. Written, informed consent was obtained from all subjects.
2.2. Laboratory Methods
Genomic DNA was extracted according to the salting out procedure described by Miller et al. [27]
from venous blood drawn in EDTANa2 as anticoagulant from all subjects after overnight fasting.
TERT VNTR MNS16A was genotyped according to the allelic-specific PCR method, as previously
reported [20,23]. Genotyping revealed, in addition to the most common alleles corresponding to
243 bp band and 302 bp band, less frequent but still polymorphic alleles corresponding to 274 bp
band and 333 bp band. The genotypes were then classified according to Wang et al. [20]: short allele
(S) corresponds to 243 and 274 bp bands and long allele (L) to 302 and 333 bp bands. The MNS16A
genotypes were L/L, L/S, and S/S. TERT SNPs (rs2853691 and rs33954691) were investigated by
polymerase chain reaction amplification followed by restriction fragment length polymorphism
(PCR-RFLP), as previously reported [23]. Genotyping of the TERT SNP (rs2736098) and the TERC SNPs
(rs12696304, rs3772190, and rs16847897) was carried out by allelic discrimination using predesigned
TaqMan SNP genotyping assays (Applied Biosystems), as previously reported [23]. The genotyping
techniques are reported in detail in Supplementary Materials (Figures S1–S3).
The average (of triplicate) telomere length in leukocytes was measured by real-time PCR
quantitative analysis (qPCR) on a 7300 real-time PCR instrument (Applied Biosystems). This method
allows the determination of the number of copies of telomeric repeats (T) compared to a single
copy gene (S) used as a quantitative control (T/S ratio) [28]. The telomere and single-copy gene
β-globin (HGB) were analyzed on the same plate in order to reduce inter-assay variability. DNA
(35 ng) was amplified in a total volume of 20 μl containing 10 μl of SYBER Select Master Mix (Applied
Biosystems); primers for telomeres and the single-copy gene were added to final concentrations
of 0.1 μM (Tel Fw), 0.9 μM (Tel Rev), 0.3 μM (HGB Fw), and 0.7 μM (HGB Rev), respectively. The
primer sequences were: Tel Fw 5′-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3′;
Tel Rev 5′-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3′; HGB
Fw 5′-GCTTCTGACACAACTGTGTTCACTAGCAAC-3′; and HGB Rev
5′-CACCACCAACTTCATCCACGTTCACCTTGC-3′ [29]. The enzyme was activated at 95 ◦C
for 10 min, followed by 40 cycles at 95 ◦C for 15 s and 60 ◦C for 1 min. In addition, two standard
curves (one for HGB and one for telomere reactions), were prepared for each plate using a reference
DNA sample (Control Genomic Human DNA, Applied Biosystems) diluted in series (dilution factor =
2) in order to produce five concentrations of DNA ranging from 50 to 6.25 ng in 20 μL. Measurements
were performed in triplicate and are reported as the T/S ratio relative to the calibrator sample to allow
for comparison across runs.
2.3. Statistical Analysis
Allelic frequencies were determined by the gene-counting method. Agreement between the
observed genotype distributions and those expected according to the Hardy-Weinberg equilibrium
was verified with a chi square test. Linkage disequilibrium (LD) between the TERT and TERC SNPs
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and haplotype frequencies were estimated by the maximum likelihood method using the EH program
(http://www.genemapping.cn/eh.htm) [30]. The differences in allele, genotype, and haplotype
frequencies between patients and controls were analyzed with a chi square test. The probability of
living to an age over 90 years (≥90 years) or not associated with TERT genotypes was estimated by
odds ratios (ORs) adjusted for other variables calculated by logistic regression.
Parametric (ANOVA) and non-parametric (Kruskal-Wallis) tests were used to compare the
distribution of LTL across long-lived and not long-lived subjects, and the distribution of the mean
T/S ratio across the various TERT and TERC genotypes. Level of significance was set at p < 0.05. The
relationship between T/S ratio and age was evaluated by regression analysis.
3. Results
To evaluate the involvement of the TERT and TERC polymorphisms in lifespan determination,
genotype frequencies of TERT and TERC SNPs observed in the long-lived subjects were compared
against those observed in the subjects who had died before reaching the age of 90 years (not long-lived)
(Table 1). In both groups, the genotype frequencies of TERT and TERC polymorphisms agreed with
those expected according to Hardy-Weinberg equilibrium. No difference in the distribution of TERC
SNPs and TERT SNPs rs33954691 and rs2736098 genotypes was observed between the long-lived and
the not long-lived (Table 1). By contrast, a significant defect of the TERT VNTR MNS16A L/L genotype
(p = 0.018), and rs2853691 A/G and G/G genotypes (p = 0.01), was found in the long-lived compared
to the not long-lived. The two TERT polymorphisms were found in strict linkage disequilibrium
(p < 0.0001, D = 80% of Dmax), with a trend of the MNS16A L allele to be associated with the rs2853691
G allele and the MNS16A S allele with the rs2853691 A allele.
Table 1. TERT and TERC genotype distribution in long-lived and not long-lived. Percentage is given
in brackets.
Gene/Genotype Not Long-Lived Long-Lived
TERC rs12696304
G/G 11 (12.4) 5 (7.0)
G/C 35 (39.3) 31 (43.7)




C/C 56 (67.5) 40 (58.8)
C/T 22 (26.5) 25 (36.8)




C/C 7 (8.6) 8 (11.9)
C/G 36 (44.4) 34 (50.7)
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Table 1. Cont.
Gene/Genotype Not Long-Lived Long-Lived
TERT rs2853691
A/A 41 (45.1) 48 (67.6)
A/G1 42 (46.2) 22 (31.0)




C/C 77 (85.6) 62 (84.9)
C/T1 11 (12.2) 9 (12.3)




C/C 56 (64.4) 52 (72.2)
C/T1 30 (34.5) 17 (23.6)
T/T1 1 (1.1) 3 (4.2)
TOTAL 87 72
p 0. 29
1 These genotypes were pooled for the analysis.
Logistic regression analysis was then applied to correctly evaluate the effect of TERT genotypes on
longevity. In the analysis, the independent variable was the genotype constituted by the combination
of MNS16A L/L and rs2853691 A/G or G/G genotypes. The dependent variable was having lived to
an age of over 90 years (≥90 years) or not. The results showed that, after adjusting for sex, carrying
MNS16A L/L and rs2853691 A/G or G/G genotypes was associated with a significantly lower
probability of living to more than 90 years of age (odds ratio [OR] 0.34, 95% confidence interval [CI]
0.15–0.79, p = 0.012), or, in other words, a risk of 2.94 (1/0.34) to die before the age of 90 years. Analysis
of the association between TERT MNS16A and rs2853691 genotypes and age at death supported
previous findings, showing that the L/L genotype and carrying G alleles are associated with a lifespan
of less than 90 years (Table 2).
Table 2. Relationship between TERT genotypes and age at death (mean ± SD). In brackets is the
number of subjects.
SNP/Genotypes Age at Death
VNTR MNS16A
L/L 87.6 ± 6.0 (45)
L/S 88.4 ± 5.4 (77)
S/S 90.8 ± 6.2 (36)
p 0.04
rs2853691
A/A 89.9 ± 5.7 (89)
A/G 87.6 ± 5.7 (64)
G/G 85.8 ± 3.7 (9)
p 0.01
Leukocyte telomere length (LTL), expressed as the T/S ratio, was measured in a subgroup of 153
subjects at baseline. The mean LTL value at baseline was 0.69 ± 0.12 T/S (range, 0.49–1.03, median
0.69), with only a slight difference between males and females (males: n = 59, LTL = 0.67 ± 0.11;
females: n = 94, LTL = 0.70 ± 0.12, p = 0.18). Age at baseline was inversely associated with telomere
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length. Linear regression (y = −0.009x + 1.4, p < 0.0001, n = 153) (Figure 1) yielded an estimated
telomere loss rate of about 0.010 T/S ratio/year.
Figure 1. LTL expressed as T/S ratio as a function of age at baseline.
Table 3 lists the estimated haplotype frequencies in the long-lived and the controls. In accordance
with single polymorphism observations, a significant defect of the MNS16A L—rs2853691 G haplotype
was observed in the long-lived compared to the not long-lived to controls (p = 0.03), suggesting that
the presence of the two TERT alleles may prevent attainment of the oldest ages.
Table 3. TERT VNTR MNS16A and TERT rs2853691 haplotype distribution in long-lived and
not long-lived.
VNTR MNS16A/rs2853691 Haplotype Not Long-Lived Long-Lived
L-A 0.294 0.278
L-G 0.301 0.164
S-A 1 0.397 0.548
S-G 1 0.008 0.010
p 0.03
1 These genotypes were pooled for the analysis.
The relationship between LTL at baseline and years of life remaining was analyzed using the
follow-up data on lifespan. A significant positive relation was observed (regression line y = 0.009x
+ 0.6, p = 0.01, n = 99), where the regression coefficient 0.009 T/S provides an estimate of how much
longer the telomeres are at baseline for each additional year of life remaining. We then compared
the baseline LTL values of the subjects still living at follow-up with those no longer living in both
the total sample, and when the sample was divided into three age classes at baseline (70–79, 80–89,
and ≥90 years). The mean LTL values at baseline were significantly higher in those still living than
in those who had died during the follow-up years. Within each age group, the LTL of those still
living was higher than the mean class value and the LTL of those who had died was lower (Table 4).
The difference between those who were still living and those who had died was greater among the
70–79-year-olds than among the 80–89-year-olds (Table 4 and Figure 1). The over 90-year-olds had all
died during the follow-up period.
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Table 4. Mean LTL (T/S ratio) in the total sample, still living and no longer living at follow-up, by age
class (mean ± SD).
All Ages Age 70–79 Years Age 80–89 Years ≥ 90 Years
Total sample 0.69 ± 0.12 (153) 0.72 ± 0.12 (54) 0.73 ± 0.10 (63) 0.57 ± 0.06 (36)
No longer living at follow-up 0.63 ± 0.09 (99) 0.63 ± 0.08 (26) 0.69 ± 0.09 (37) 0.57 ± 0.06 (37)
Still living at follow-up 0.79 ± 0.08 (54) 0.80 ± 0.08 (28) 0.77 ± 0.09 (26) /
p 1 <0.0001 <0.0001 0.0007
1 The p value refers to the comparison between No longer living and Still living at follow-up.
These findings are illustrated in Figure 1: the vast majority of the deceased in the age range
70–79 years had LTL values below the regression line at baseline, whereas those still living had LTL
values above the line. Differently, in the higher age range of 80–90 years, the baseline LTL values of the
no–longer living and the still living were fairly mixed below/above the line. We then compared the
LTL values in the not long-lived (0.67 ± 0.09, n = 56) and the long-lived (0.59 ± 0.08, n = 43, p = 0.003).
The long-lived sample, 84% of which were already 90 years old at baseline, had a lower mean LTL
value than the not-long-lived, who belonged to younger age groups.
Finally, the mean LTL associated with TERT VNTR MNS16A and rs2853691 genotypes involved
with lifespan determination was examined in not long-lived and long-lived subjects. No difference in
mean LTL was observed among TERT VNTR MNS16A and rs2853691 genotypes. However, in subjects
carrying the combined risk genotypes MNS16A L/L + rs2853691 G/G or A/G (Table 5), LTL was found
to be significantly shorter in the Not long-lived than in the Long-lived (p = 0.05). No difference in
mean LTL was observed among the genotypes of the other TERC and TERT SNPs (data not reported).
Table 5. Mean LTL (T/S ratio) associated with the combined genotypes of MNS16A/rs2853691
polymorphisms.
L/L + G/G or A/G L/S or S/S + A/A
Not long-lived 0.63 ± 0.08 (16) 0.64 ± 0.11 (40)
Long-lived 0.72 ± 0.10 (6) 0.66 ± 0.06 (37)
p 0.05 0.57
4. Discussion
Here, we investigated a possible association between TERT and TERC polymorphisms and LTL
and lifespan by means of a follow-up study. This study design allowed us to extend the investigation
to include a sample for which the lifespan was known, and to distinguish between a sample of subjects
definitely not long-lived and a sample of long-lived subjects. Furthermore, all the subjects belonged to
the same birth cohort and had experienced similar social and environmental influences.
Examination of the genetic variation of TERT and TERC genes showed a significant association
between two TERT polymorphisms (the minisatellite MNS16A and the SNP rs2853691) and lifespan.
Carrying the TERT VNTR MNS16A L/L genotype and rs2853691 A/G and G/G genotypes turned out
to be associated with an increased risk (2.94) of dying before the age of 90 years, i.e., below the mean
life expectancy for subjects living in this geographic area, with an average age of about 83 years at
study baseline. The observation was confirmed “in vivo” by mortality data and showed that the same
risk genotypes were associated with the shortest lifespan. An association between VNTR MNS16A
genotypes and longevity has been observed by Concetti et al. [18], whereas rs2853691 SNP has been
reported to belong to a haplotype involved in longevity [13,17]. Our data support these findings
and highlight that the MNS16A L/L genotype and rs2853691 A/G and G/G prevent the attainment
of longevity. Consistent with this result are previous findings that the MNS16A L/L genotype is
associated with an increased risk of Alzheimer’s disease [23] and lower survival in patients with
glioblastoma or lung cancer [31,32], and that rs2853691 A/G and G/G are associated with esophageal
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squamous cell carcinoma [33]. The shorter lifespan associated with TERT genotypes would therefore,
at least in part, be explained by their involvement in the onset of aging-related diseases. We observed
a marginally significant association of the combined risk genotypes of the two TERT polymorphisms
with shorter LTL in the Not long-lived subjects. Although the sample was quite small, this observation
is consistent with a previous work [18] that reported a tendency of greater telomere shortening
in elderly subjects with homozygous VNTR MNS16A L/L as compared with the other MNS16A
genotypes. Considering that the L allele seems to have a negative regulatory role in the expression of
telomerase [20], the overall picture suggests that the relationship of TERT genotypes with lifespan is
mediated by an action of TERT on telomere length. We found no significant relationships of the TERC
SNPs with longevity or telomere length, although the TERC SNPs we examined were often found to
be associated with telomere length [14,16,17,19], and with longevity (rs3772190) [17]. The conflicting
data might depend on diverse factors such as sample size, population examined, and mean age of
the population sample, among others. Telomere length being a complex character, numerous genes
will contribute to its determination, each providing a small contribution that could be difficult to
distinguish. In addition, the interaction of genetic determinants with environmental factors, such as
different population lifestyles, could explain the inconsistencies. Furthermore, the discordant results
might depend on the technique used for LTL measurement as well. In the majority of the population
studies cited above, the average length of telomeres was measured by Real-Time PCR quantitative
analysis (qPCR) or by Southern blot analysis of the terminal restriction fragments, and there is evidence
that intra- and inter-laboratory technical variation severely limits the comparability of telomere length
estimates between laboratories [34].
Here, we also examined the relationships between LTL and lifespan. A significant negative
correlation between age and LTL at baseline was observed, with an estimated telomere loss rate of 0.009
T/S ratio/year. This observation is shared by previous studies [35]; the yearly telomere loss was very
similar to the reported value (0.010 T/S ratio/year) [35]. The mortality data provided by the follow-up
allowed us to evaluate the relationship between LTL at baseline and the number of the remaining years
of life. The positive relationship we observed indicates that the shorter the telomeres at baseline, the
fewer the remaining years of life. In line with this result, analysis of the mean LTL values at baseline
showed that the mean LTL was much shorter in those who had died within nine years of follow-up
than in those still alive at follow-up (Table 4). This is partly due to the fact that among the deceased, all
were already 90 years old at baseline (about 36%), and therefore with reduced telomeres according to
age. The remaining 64% included subjects who had died before the age of 90 and who, as can be seen
from the LTL data in Table 4, had LTL values lower than both the average value of their age class and
the average value of those still living at follow-up. This is illustrated in Figure 1, where the LTL values
for subjects who died during the follow-up are mostly distributed below the regression line. Taking
into account the different age classes (Table 4), a comparison of the mean LTL between those still living
and those no longer living at follow-up, showed a greater difference in the 70-to-79-year olds compared
with the 80-to-90-year-olds, in which the LTL of the no longer living was closer to the LTL of the still
living. Again, this pattern is clearly shown in Figure 1: before the age of 80 years, the LTL values of the
still living and the no longer living are well-separated by the regression line, but they become quite
mixed after the age of 80 years. On the whole the picture provided by our data indicates that telomere
length is related to lifespan. Indeed, it is almost a lifespan biomarker. However, this relationship is
stronger for the younger age group (70–79), and then weakens after 80 years of age.
Despite the mixed results [36] of epidemiologic studies investigating the link between LTL and
lifespan/mortality, accumulating data tend to confirm that shorter baseline TL is a marker of greater
susceptibility to age-related diseases and of higher overall mortality risk [37–39]. Varying sample
sizes and other characteristics, such as age range or the length of the follow-up period, underlie the
conflicting data. In addition, the wide inter-individual variability in telomere length for individuals of
the same chronological age due to inherited and environmental factors may mask any relationships
between LTL and lifespan [40].
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The association between TL and lifespan we observed seemed to weaken in the older age classes.
Several studies have reported that the magnitude of the association of shorter LTL with higher
mortality rates declines with increasing age [4,38–43]. A plausible explanation is the so-called “survival
bias”. In collecting study samples of older individuals, subjects with shorter baseline TL, being more
susceptible to age-related diseases, may be less likely to be included in the study [36,37]. This
would lead to a reduced variability of LTL measurements, shifted towards a longer telomere length.
Furthermore, leukocyte telomere shortening reflects active cell proliferation triggered by factors such
as oxidative stress and chronic systemic inflammation, both of which are aging-related processes.
The overexpression of proinflammatory cytokines and mediators observed in older individuals,
activating leukocyte proliferation, may lead to alterations in the relationship between LTL and age,
and ultimately lifespan [38,44,45]. In this context, it could be hypothesized that, at an age before
80 years, shorter telomere length may indicate a greater susceptibility to aging-related diseases
and therefore be predictive of reduced lifespan, whereas in those older than 80 years of age, chronic
systemic inflammation, together with oxidative stress, could act as prevailing determinants of leukocyte
proliferation and telomere shortening, thus making the relationship between telomere length and
lifespan less linear. LTL therefore seems to be a more reliable lifespan biomarker in a younger age class.
There are indications that the relationship between LTL and age depends on nongenetic factors
such as age, sex, race/ethnicity, lifestyle practices, and dietary patterns [10]. The strength of the present
paper is the examination of a fairly well-defined population sample for ethnicity, age range, lifestyle, and
dietary patterns. This homogeneity allowed us to define a temporal window, the interval of 70–79 years,
in which LTL could be seen as a good lifespan biomarker. These observations provide useful indications
for designing investigations that aim to assess the possible use of LTL as a lifespan predictor.
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Abstract: Biogerontological research highlighted a complex and dynamic connection between
aging, health and longevity, partially determined by genetic factors. Multifunctional proteins with
moonlighting features, by integrating different cellular activities in the space and time, may explain
part of this complexity. Inositol Polyphosphate Multikinase (IPMK) is a potential moonlighting
protein performing multiple unrelated functions. Initially identified as a key enzyme for inositol
phosphates synthesis, small messengers regulating many aspects of cell physiology, IPMK is now
implicated in a number of metabolic pathways affecting the aging process. IPMK regulates basic
transcription, telomere homeostasis, nutrient-sensing, metabolism and oxidative stress. Here, we
tested the hypothesis that the genetic variability of IPMK may affect human longevity. Single-SNP
(single nuclear polymorphism), haplotype-based association tests as well as survival analysis pointed
to the relevance of six out of fourteen genotyped SNPs for female longevity. In particular, haplotype
analysis refined the association highlighting two SNPs, rs2790234 and rs6481383, as major contributing
variants for longevity in women. Our work, the first to investigate the association between variants
of IPMK and longevity, supports IPMK as a novel gender-specific genetic determinant of human
longevity, playing a role in the complex network of genetic factors involved in human survival.
Keywords: aging; longevity; survival; SNP; polymorphism; IPMK; inositol phosphates;
gender-specific association; moonlighting protein
1. Introduction
In the last few decades, research on aging has seen progressive growth due to the social and
medical burden correlated to the increase of the elderly population in developed countries. These
efforts point towards a better understanding of the connections between aging, health, and longevity
as they may provide useful insights for strategies to improve the wellbeing of the elderly. The results
obtained in different research areas underscored the dynamic complexity of such connections [1]. These
studies often identify genes involved in the regulation of the aging process that are also susceptibility
loci of one or multiple age-related diseases. For instance, many genetic variants associated with
increased disease risk are present with high frequency among the oldest individuals: this means
that a disease “risk allele” can also be a pro-longevity variant [2,3]. In some cases, the same variant
exhibits opposite effects on the development of different diseases, with potential differential impact
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on longevity [4,5]. Finally, genetic risk factors may change their impact on mortality risk during
the life course, i.e., from detrimental in middle life to beneficial at advanced ages, very often in
a gender-specific way [6,7]. This makes the identification of genes that robustly associate with
longevity very challenging; in fact, despite the high number of studies aimed at highlighting the
genetic contributors to long-life, only APOE and FOXO3A were consistently replicated in different
populations [8].
Among the mechanisms that may account for this complexity are interactions between
different genes (epistasis) or single nuclear polymorphism (SNP)–SNP interactions at gene level,
gene–environment (internal and external) interactions and pleiotropic (including trade-off-like) effects
of genes on different phenotypes. Alongside this, potential contributing factors could be genes coding
for proteins with different, relevant and often unrelated functions, since they may integrate various
cellular activities in space and time. This special category of multifunctional proteins defined as
moonlighting proteins [9], does not include protein isoforms resulting from different RNA splice
variants, gene fusions or proteins with pleiotropic effects [10]. A protein with potential moonlighting
capability is the inositol polyphosphate multikinase (IPMK).
This protein was initially discovered in budding yeast and named Arg82 for its ability to regulate
arginine metabolism [11,12]. Mammalian IPMK has well-established roles in inositol phosphate
metabolism as it converts inositol (1,4,5)-trisphosphate (IP3) to IP4 and IP4 to IP5 [13,14]. In addition
to its kinase activity, IPMK can function as a nuclear phosphoinositide kinase (PI3-kinase), which
produces PIP3 from PIP2 [15]. Through its PI3-kinase activity, IPMK activates Akt/PKB and its
downstream signaling pathways [16]. In addition, it regulates several protein targets non-catalytically
via protein–protein interactions, including cytosolic signaling factors such as the mammalian target
of rapamycin complex 1 (mTORC1) [17] and the energy-sensing protein kinase AMPK [18]. Recently,
Kim et al. [19] revealed that IPMK acts as an important regulator of Toll-like receptor (TLR)-induced
innate immunity through its interaction with the tumor necrosis factor receptor–associated factor 6
(TRAF6). At the nuclear level, IPMK acts as a transcriptional coactivator for p53 [20] and for serum
response factor (SRF) signaling [21]. Finally, IPMK functions in the export of mRNA from the nucleus
to the cytoplasm [22–24].
To our knowledge, there are no studies investigating the genetic variability of IPMK gene in
human complex phenotypes; just one SNP, rs12570088, near to IPMK locus, was found related to the
susceptibility to Alzheimer’s and Crohn diseases [25].
Given the compelling evidence demonstrating IPMK’s multifunctional nature and thus its
classification as a moonlighting protein, the present paper addresses the hypothesis that IPMK genetic
variability affects human aging and longevity.
2. Materials and Methods
2.1. Population Sample
We analysed five hundred sixty-eight unrelated subjects (252 men and 316 women aged 64–105
years), born in Calabria (South Italy) and recruited in the entire region through several campaigns,
as previously reported [26]. Their Calabrian ancestry was ascertained up to the third generation. At
baseline, all subjects were free of the major age-related pathologies (e.g., cancer, type-2 diabetes and
cardiovascular diseases). The study was approved by the Ethical Committee of the University of
Calabria (on 9-9-2004). Written informed consent was obtained from the subjects in accordance with
institutional requirements and the Declaration of Helsinki principles.
The analyses were performed considering two sex- and age-specific groups obtained according
to the survival functions of the Italian population from 1890 onward [27]. The two “thresholds of
longevity” used to define these age classes were 88 years for men and 91 years for women. These
cut-offs correspond to the point after which a significant negative change in the slope of the survival
curve of the Italian population occurs. In particular, in the present study males younger than 88 and
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females younger than 91 years will be defined as controls (N = 309, mean age 74 years), while males
older than 88 and females older than 91 years will be defined as cases (N = 259, mean age 96.9 years).
2.2. SNP Selection and Genotyping
We performed genotyping of 14 SNPs mapping within and nearby the IPMK gene, prioritized by
a tagging approach. Analysis was performed by SEQUENOM MassArray iPLEX technology according
to the procedure previously reported [28]. Sequenom Typer 4.0 Software was used for the management
and analysis of the collected data. About 10% of the samples were reanalyzed and the concordance
rate of the genotypes was higher than 99%.
2.3. Quality Control
After genotyping, samples were subjected to a battery of quality control (QC) tests. At sample
level, subjects with a proportion of missing genotypes higher than 10% were dropped from the
analysis. At SNP level, SNPs were excluded if they had a significant deviation from Hardy–Weinberg
equilibrium (HWE, p < 0.05) in the control sample, a Missing Frequency (MiF) higher than 10% and a
Minor Allele Frequency (MAF) lower than 5%.
2.4. Functional Parameters
2.4.1. Disability
A modification of the Katz’ Index of activities of daily living (ADL) was used to assess the
management of four everyday activities (toileting, getting up from bed, rising from a chair, walking
around) [29]. For the analysis, ADL scores were dichotomized as 1 if the subject was able to perform
every activity and 0 otherwise.
2.4.2. Physical Performance
Evaluation of Hand Grip strength (HG) was performed through a handheld dynamometer
(SMEDLEY’s dynamometer TTM, Tokyo, Japan) while the subject was sitting with the arm close to
their body, by repeating the measure three times with the stronger hand. The maximum of these values
was used in statistical analyses. When the test was not performed, it was indicated if it was because of
physical disabilities or if the subject refused to participate.
2.4.3. Cognitive Functioning
Screening of cognitive impairment was carried out by MMSE, a 30-point scale able to evaluate
several different cognitive areas including memory, calculation, abstraction, judgment, visual–spatial
ability and language [30]. MMSE scores range from 0 (lowest cognitive function) to 30 (highest
cognitive function). MMSE scores were normalized for age and educational status, variables known to
affect the result of the test.
2.5. Statistical Methods
For each SNP, allele and genotype frequencies were estimated by gene counting from the observed
genotypes. Hardy–Weinberg equilibrium (HWE) was tested by Fisher’s exact test. Pairwise measures
of linkage disequilibrium (LD) between the analyzed loci was estimated by Haploview (https://www.
broadinstitute.org/haploview/haploview). A logistic regression model was also used to evaluate
the effect of genetic variability on the chance to reach very advanced age. Different genetic models
(dominant, additive and recessive) were used to test association, using for each SNP the minor allele
as reference. For each SNP the most likely genetic model was then estimated on the basis of minimum
level of statistical significance (Wald test p-value).
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As this study was exploratory, the p-values are reported without employing conservative statistical
significance thresholding procedure (e.g., Bonferroni correction) as that could eliminate potentially
important findings.
In order to evaluate if the detected effect of the polymorphisms on longevity may result in
differential patterns of survival of the different relevant genotypes, we evaluated survival after 10
years from the baseline visit. Univariate survival analysis was carried out by the Kaplan–Meier method
and survival curves compared by log-rank test. Subjects alive after the follow-up time were considered
as censored, and this time was used as the censoring date in the survival analyses. In addition, hazard
ratios (HR) and 95% confidence intervals (95% CI) were estimated by using Cox proportional hazard
models taking into account age as a confounder variable.
Pairwise measures of linkage disequilibrium (LD) between the analyzed loci were calculated by
Plink 1.9 [31] and plotted with the Haploview version 4.2 [32]. The amount of LD was quantified by
Lewontin’s coefficient (D’). Haplotype-based association analysis within the generalized linear model
(GLM) framework was used to model the effect of haplotypes on the probability to attain longevity, by
the haplo.stats package of R. The haplo.score function of this package has been used to obtain the score
statistics. Permutation-based p-values were used to evaluate the significance of the scores obtained
(10,000 permutations).
Statistical analyses have been performed using SNPassoc and surv packages of R [33].
3. Results
Fourteen SNPs from about 76 kb genomic sequences spanning the IPMK gene were selected for
examination by a tagging approach. The QC phase excluded three SNPs. In particular, two SNP were
excluded due to MiF data higher than 10% (rs1698392, rs2440854) and one because it did not satisfy the
HWE (rs2275443). Figure 1A shows the eleven high quality SNPs that were tested for association with
longevity with their corresponding gene position, while panel B depicts the degree of LD between pairs
of SNPs.
3.1. Association with Longevity
3.1.1. Single SNP Analysis
The general characteristics of the analyzed sample are described in Table 1. Since a number of
studies highlighted gender- and age-specific associations with survival at advanced age, in this work
we analyzed the role of IPMK SNPs in the predisposition to become long-lived in gender subgroups.
Table 1. General characteristics and post-survey mortality in the analyzed sample.
Elderly Subjects Long-Lived Subjects
N (age) 309 (74.06 ± 6.95) 259 (96.92 ± 3.72)
Females % 49.5% 63.0%
Height (cm) 160.6 (9.7) 151.4 (9.5)
BMI 26.9 (4.2) 23.21 (4.1)
HG strength [Kg (SD)] 21.89 (9.9) 13.04 (6.4)
ADL* (% Disabled) 17% 69%
MMSE 23.3 (5.4) 14.0 (6.8)
ADL, Activity Daily Living; HG, Hand Grip; BMI, Body Mass Index; MMSE, Mini Mental State Examination; for
each parameter, mean value and standard deviation, in brackets, are shown. *Participants were defined as “not
disabled” if independent in all items and “disabled” if dependent in at least one item.
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Figure 1. Schematic representation of (A) selected polymorphisms in the Inositol Polyphosphate
Multikinase (IPMK) region; (B) linkage disequilibrium (r2 coefficient) among the single nuclear
polymorphisms (SNPs).
From the results of the logistic regression analysis shown in Table 2, it can be seen that significant
differences between the long-lived subjects and younger controls are present among females only.
In particular, six out of eleven markers (in order: rs2790156-G/A, rs2790234-C/G, rs2590320-C/A,
rs6481383-C/T, rs1832556-G/A, rs2251039-C/T) were significantly associated with the longevity
phenotype under a dominant model of inheritance. For all the SNPs, the presence of the minor allele
conferred decreased odds to reach advanced old age. rs2790234 showed the greatest impact (Odd Ratio,
OR, 0.33; 95% Confidence Interval, CI, 0.16–0.67; P = 0.00225), while association of similar magnitude
was observed for the other five polymorphisms with ORs (95% CI) of 0.62, 0.572, 0.592, 0.592 and 0.612
(all p-values < 0.05) for rs2790156, rs2590320, rs6481383, rs1832556, rs2251039, respectively).
3.1.2. Haplotype-Based Analysis
To further explore the association of the entire region with longevity, we performed a haplotype
analysis among the six SNPs associated with longevity. As shown in Figure 1B, all six SNPs lie in
a large LD block, with rs2790156, rs2590320, rs1832556 and rs2251039 in strong LD and rs2790234
and rs6481383 in a weak linkage. Among all possible haplotypes, we found only four combinations:
G-C-C-C-G-C, 61%; G-C-C-T-G-C, 16%; A-C-A-T-A-T, 14%; A-G-A-T-A-T, 7% (Table 3). In line with the
single locus analysis, we found a negative association of the minor allele combination A-G-A-T-A-T
with longevity in females (p-value = 0.002). On the contrary, a positive association was observed for
the opposite combination G-C-C-C-G-C (p-value = 0.024). A deep analysis of the associated haplotypes
showed that the strength of these associations was influenced by the allelic status at rs2790234 and
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rs6481383. Indeed, while A-G-A-T-A-T is significantly associated, the A-C-A-T-A-T is not; likewise,
while G-C-C-C-G-C showed an effect on longevity, this was not true for G-C-C-T-G-C.
Table 2. Results of the logistic regression models for IPMK SNPs in the sample divided by sex.
(a) Females
SNP (Major/Minor Allele) OR 95% CI p-value
rs17636964 (G/C) 1.48 0.82–2.662 0.185
rs12261547 (G/C) 1.39 0.62–3.11 0.415
rs2790156 (G/A) 0.61 0.38–0.98 0.042
rs16911967 (G/C) 0.40 0.12–1.33 0.136
rs2790234 (C/G) 0.33 0.16–0.67 0.002
rs11006086 (T/C) 0.67 0.34–1.32 0.255
rs2590320 (C/A) 0.57 0.36–0.91 0.019
rs6481383 (C/T) 0.59 0.37–0.94 0.026
rs1832556 (G/A) 0.59 0.37–0.94 0.028
rs11006100 (T/A) 0.69 0.42–1.14 0.154
rs2251039 (C/T) 0.61 0.38–0.97 0.038
(b) Males
SNP OR 95% CI p-value
rs17636964 (G/C) 0.98 0.50–1.94 0.974
rs12261547 (G/C) 0.52 0.16–1.66 0.272
rs2790156 (G/A) 0.79 0.46–1.35 0.397
rs16911967 (G/C) 2.08 0.54–7.96 0.283
rs2790234 (C/G) 0.98 0.49–1.94 0.959
rs11006086 (T/C) 0.76 0.31–1.85 0.550
rs2590320 (C/A) 0.81 0.48–1.37 0.436
rs6481383 (C/T) 1.10 0.65–1.87 0.713
rs1832556 (G/A) 0.81 0.47–1.37 0.436
rs11006100 (T/A) 1.73 0.98–3.04 0.056
rs2251039 (C/T) 0.78 0.46–1.34 0.377
OR: Odd Ratio; CI: Confidence Interval.
Table 3. Estimation of haplotype frequencies in the IPMK SNPs (in order: rs2790156, rs2790234,
rs2590320, rs6481383, rs1832556, rs2251039) and association with longevity in the female sample.
Haplotype Frequency Score p-Value *
A-G-A-T-A-T 0.067 −2.897 0.002
A-C-A-T-A-T 0.138 −0.668 0.483
G-C-C-T-G-C 0.161 −0.353 0.715
G-C-C-C-G-C 0.616 2.155 0.024
* simulated p-value obtained by Monte Carlo replication up to 10,000 bootstraps.
3.2. Association with Survival
By using 10 years of follow-up survival data, we investigated if the single variants associated with
female longevity also influenced the survival of the younger cohort. As shown in Figure 2, consistent
with the detrimental effect on longevity, we found a trend toward significance for three out of six
variants associated with longevity, rs2590320, rs1832556 and rs2251039, with HR values 1.72 (0.91–3.23),
1.75 (0.93–3.28), 1.75 (0.93–3.28) respectively (p < 0.1). we could not perform a haplotype-based survival
analysis because a classification of carriers or non- carriers would reduce the size of the two classes
too much.
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Figure 2. Survival functions of female carriers of minor allele (black) vs non-carriers (grey) of IPMK
variants. (A) rs2790156; (B) rs2790234; (C) rs2590320; (D) rs6481383; (E) rs1832556; (F) rs2251039. Time
is expressed in months, where 0 is considered the time of recruitment and each individual is followed
up for survival status till death. The Cox regression was adjusted for age. Hazard ratio (HR) value,
confidence interval and p-value from Cox regression analysis are reported inside the figure.
3.3. Association with Functional Parameters
To investigate whether the variants in IPMK gene also concur to determine the age-related
physiological decline, we analyzed the SNPs in relation to markers of physical (ADL and Hand
Grip) and cognitive (MMSE) performance. No significant association was detected (data not shown).
As a result, we conclude that IPMK has an effect on survival and longevity independently of the
tested variables.
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4. Discussion
Our study was designed to test the hypothesis that genetic variability at the IPMK locus
contributes to survival to very old age. We provided evidence that polymorphisms in this gene
significantly affect the females’ chance of survival to old age, a result that implicates IPMK,
a multifunctional protein with potential moonlighting functions, as a significant contributor to gender
differences in longevity.
The gender difference in life expectancy and mortality, including survival to extreme age, as
well as prevalence and incidence of the most important age-related diseases, is supported by a
huge amount of clinical and demographic data [1,34]. In almost all modern populations, females
live longer than males and this has been attributed to a particular combination of genetic factors,
environmental factors (nutrition and stress), sex hormones and immunity, along with socio-economic
and cultural factors [35,36]. Gender-specific longevity alleles were identified for a long time [37,38] and
recently confirmed by genome-wide association studies (GWAs) [39,40]. These studies also indicated
that different pathways contribute to longevity in men and women; for instance, paths involved
in inflammation and immunity emerged as male-specific, while those involved in PGC-1α (PPARγ
coactivator-1α) function and tryptophan metabolism emerged as female specific [40]. It is intriguing
that many members of these pathways are known to perform diverse unrelated functions, behaving as
moonlighting proteins [41,42]. As previously discussed, proteins with moonlighting properties may, in
part, explain the complex role of genetic factors in determining the longevity phenotype, including
gender-linked effects. In this sense, IPMK is surely a possible player because of multifunctional
protein feature. IPMK catalyzes key steps leading to the synthesis of inositol pyrophosphates [43].
These molecules, that as the name indicates contain one or more pyrophosphate moiety, control
several aspects of cell physiology essential for cell survival. Inositol pyrophosphate regulate telomere
length [44], vesicular trafficking [45], DNA recombination [46], ROS signaling [47] and energetic
metabolism [48], likely by controlling cellular phosphate homeostasis [49,50]. In fact, these molecules
regulate the pathophysiology of metabolic disorders such diabetes and obesity [51,52]. The numerous
and distinct connections between metabolism and aging that research is highlighting [53,54] suggest
that inositol pyrophosphate might be relevant to the aging process. Remarkably, the knockout of
inositol hexakisphosphate kinase 3 (IP6K3), an essential enzyme for inositol pyrophosphates synthesis,
results in altered metabolism and extends mice lifespan [55]. Furthermore, we associated two SNPs in
the 5′-flanking promoter region of the IP6K3 gene with the susceptibility to late onset Alzheimer’s
disease (LOAD) [28]. Therefore, the catalytic activity of IPMK, indispensable for inositol pyrophosphate
synthesis, could be ultimately important for controlling metabolism and lifespan. Independently from
its enzymatic activity, through protein–protein interaction, IPMK acts as a signaling hub in regulating
nutrient and energetic pathways, including mTOR and AMPK [17,56]. The inhibition of mTORC1
pathway components extends lifespan and confers protection against an increasing list of age-related
diseases, while on the contrary its over-induction leads to a higher risk of age-related diseases and
decreased lifespan [57,58] and references therein]. A role in the control of cell survival and death has
been also highlighted. A small deletion that leads a truncated form of IMPK was found to reduce the
activation of p53 and increase the resistance to apoptosis of cancer cell lines [59]. Moreover, Davey et
al. found that IPMK plays an important role in necroptosis, a form of regulated cell death prompted by
injury and infection [60]. Both apoptosis and necroptosis impact on a variety of processes governing
cell physiology and homeostasis with implications in health and disease [61].
It is interesting to note that many of the processes in which IPMK participates influence aging
in a gender specific manner. For instance, some authors have suggested that gender differences
in lifespan are due to gender-specific susceptibility to oxidative stress [62] and yet gender-specific
survival is associated with sex differences in telomere dynamics [63]. It has also been demonstrated that
rapamycin, the inhibitor of mTOR signaling, extends lifespan in dose- and gender-specific ways [64]
and that there are sex-differences in muscle AMPK activation [65].
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On the whole, these studies corroborate our findings that six IPMK SNPs significantly affect female
longevity. Haplotype analysis confirmed the single SNP analyses, identifying an advantageous effect
in carriers of the haplotype G-C-C-C-G-C; conversely the A-G-A-T-A-T haplotype is a disadvantageous
combination for longevity. Haplotypes analysis allowed us to establish that among the six SNPs, two
SNPs, rs2790234-C/G and rs6481383-C/T, were more likely to have an effect on lifespan, the minor
rs2790234-G allele conferring a longevity disadvantage and the major rs6481383-C allele having a
beneficial effect on the trait. The absence of correlation with survival and parameters of quality of
aging suggests that these SNPs play a major role on the probability to achieve longevity.
Since we have no demonstrable functional explanation for the association as both SNPs occur in
large intronic regions, it is difficult to evaluate their significance at this time. Moreover, both SNPs lie
in a large region of LD, which likely contain hundreds of polymorphisms with one or more others that
may have a direct contribution. Thus, our findings could be relevant for future investigations.
This study has some limitations that merit consideration. First, the sample size is rather small,
which limits its statistical power. The sample size might have influenced the significance of survival
analysis, so only trends have been identified. However, this result may also depend on the follow-up
time of 10 years, not sufficient to draw long-term conclusions on the effect of genetic variants with a
minor effect on survival. Therefore, the sample size should be increased and further explorations in
additional populations and other countries are needed before drawing further conclusions. Another
possible drawback is the lack of a proper correction for multiple testing. However, it should be noted
that this was a pilot study, the first to analyze the association of IPMK variability in human aging and
longevity, so a Bonferroni correction would have eliminated potentially important findings if applied.
Furthermore, because associated SNPs are intronic, experimental evidence in support of the hypothesis
that the detrimental genotypes influence the function of the protein should be carried out.
5. Conclusions
Specific IPMK haplotypes affect lifespan in women. Although our studies do not allow definitive
conclusions, we believe that our findings can provide a basis for future studies to better clarify the
basic mechanisms linking IPMK to female longevity and potential targets for realizing gender-specific
therapeutic interventions. Finally, we believe that proteins with moonlighting capabilities, such as
IPMK, could represent one of the factors that makes it difficult to disentangle the genetic complexity of
the longevity phenotype.
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Abstract: Xenobiotic-metabolizing enzymes (XME) mediate the body’s response to potentially harmful
compounds of exogenous/endogenous origin to which individuals are exposed during their lifetime.
Aging adversely affects such responses, making the elderly more susceptible to toxics. Of note, XME
genetic variability was found to impact the ability to cope with xenobiotics and, consequently, disease
predisposition. We hypothesized that the variability of these genes influencing the interaction with
the exposome could affect the individual chance of becoming long-lived. We tested this hypothesis
by screening a cohort of 1112 individuals aged 20–108 years for 35 variants in 23 XME genes. Four
variants in different genes (CYP2B6/rs3745274-G/T, CYP3A5/rs776746-G/A, COMT/rs4680-G/A and
ABCC2/rs2273697-G/A) differently impacted the longevity phenotype. In particular, the highest
impact was observed in the age group 65–89 years, known to have the highest incidence of age-related
diseases. In fact, genetic variability of these genes we found to account for 7.7% of the chance to
survive beyond the age of 89 years. Results presented herein confirm that XME genes, by mediating
the dynamic and the complex gene–environment interactions, can affect the possibility to reach
advanced ages, pointing to them as novel genes for future studies on genetic determinants for
age-related traits.
Keywords: aging; longevity; survival; SNP; polymorphism; xenobiotic-metabolizing
enzymes; xenobiotics
1. Introduction
Aging is a complex phenotype responding to a plethora of drivers in which genetic, behavioral, and
environmental factors interact with each other. This can be conceptualized in terms of exposome—that
is, the totality of exposures to which an individual is subjected throughout a lifetime and how those
exposures affect health [1].
The exposome basically includes a wide variety of toxic or potentially harmful compounds
of exogenous (environmental pollutants, dietary compounds, drugs) or endogenous (metabolic
by-products such as those resulting from inflammation or lipid peroxidation, oxidative stress, infections,
gut flora) origin and related biological responses during the life course [2].
The individual ability to properly cope with xenobiotic stress can influence susceptibility to
diseases and, thus, the quality and the rate of aging, phenotypes that certainly result from the
cumulative experiences over lifespan. Additionally, in all the different theories proposed to explain the
Genes 2019, 10, 403; doi:10.3390/genes10050403 www.mdpi.com/journal/genes86
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aging process, a common denominator remains the progressive decline of the capacity to deal with
environmental stressors to which the human body is constantly exposed.
In this scenario, a crucial role can be played by the coordinated activity of cellular mechanisms
evolved for reducing the toxicity of endogenous and xenobiotic compounds to which humans
are exposed. These mechanisms comprehend a broad range of reactions of detoxification that
make harmful compounds less toxic, more hydrophilic, and easier to be excreted. The main
effectors of these mechanisms are a large number of enzymes and transporters, collectively
referred to as xenobiotic-metabolizing enzymes (XMEs) or drug metabolizing enzymes (DMEs).
This process occurs in three phases. Phase I enzymes, such as cytochrome P450s (CYPs),
carboxylesterases, and flavin monooxygenases, add reactive groups to the toxin; in phase II, glutathione
S-transferases (GST), UDP-glucuronosyltransferases (UGT), catechol-O-methyltransferases (COMT),
and N-acetyltransferases (NAT) conjugate water-soluble groups onto the molecule; in phase III,
ATP-binding cassette (ABC) transporter proteins facilitate the export of the conjugate out of cells as
well as the import and the efflux of a broad range of substrates [3].
With aging, there is a decline in the ability to mount a robust response to xenobiotic insults. This is
somewhat attributed to the age-related reduction in liver mass, which can result in reduced metabolism
rates and in the decreased kidney and liver blood flows, which can result in reduced excretion and
elimination of xenobiotic and its metabolites [4]. In addition, a reduction in the activity of phase I and II
enzymes and the consequent fall in biotransformation capacity have been reported by several authors
in both old animals and humans [5–7]. As aging is characterized by an increased prevalence of chronic
conditions that require the use of multiple medications, these changes have particular relevance from a
clinical point of view, affecting drug effectiveness and toxicity [8]. Moreover, transcriptional profiling
has revealed the up-regulation of xenobiotic-metabolizing genes in long-lived mutants across diverse
model organisms [9–11], suggesting that the individual ability to modulate xenobiotic responses may
either lead to increased risk of diseases and death or favor longevity.
It is also known that the activity of XME proteins is affected by the variability of the corresponding
genes, whose polymorphisms can account for the inter-individual variability in both xenobiotic
response/toxicity and disease predisposition. In this regard, significant associations of alleles in these
genes (especially in phase II genes) with many forms of cancer [12,13] or coronary heart disease [14]
were found. Moreover, in testing a sample of individuals of different ages, Ketelslegers et al. [15] found
that the prevalence of risk alleles in XME genes decreases with age, suggesting that individuals carrying
a higher number of risk alleles show a higher risk of morbidity and mortality for chronic diseases.
Based on all the above, we reasoned that genetic variants of XME genes might affect the chance to
live a long life. In order to test this hypothesis, we screened a set of 35 SNPs in 23 XME genes and their
association with aging and survival in a cohort of 1112 individuals aged 20–108 years, performing both
case-control and prospective cohort analyses.
2. Materials and Methods
2.1. Study Population
The initial dataset included 1112 unrelated individuals (497 men and 615 women) whose ages
ranged from 20 to 108 years. All subjects were born in Calabria (Southern Italy), and their Calabrian
ancestry was ascertained up to the third generation. Samples were collected within the framework of
several and appropriate recruitment campaigns carried out for monitoring the quality of aging in the
whole of Calabria, as previously reported [16]. In brief, younger subjects were recruited from students
and staff of the University of Calabria; elderly subjects were from people visiting thermal baths, the
Academy of the Elderly, or contacted through general physicians. Very old subjects were selected
through the population registers and then contacted and invited to join the study. Old and very old
subjects underwent a multidimensional geriatric assessment with the aim of collecting clinical history,
anthropometric measures, cognitive functioning, functional activity, and physical performance.
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White blood cells (WBC) from blood buffy coats were used as sources of DNA, while plasma/sera
were used for routine laboratory analyses.
For the analyses, the sample was divided in three specific age classes based on two age thresholds,
65 and 89 years, after which a significant negative change in the slope of the survival curve of the Italian
population occurs [17]. Thus, subjects were classified as younger adults (age class S1, 20–64 years;
n = 330), elderly (age class S2, 65–89 years; n = 433), and very old subjects (age class S3, ≥90 years; n =
349).
For subjects of the 65- to 89-year-old group, vital status was traced after a mean follow-up
time of approximately 10 years through the population registers of the municipalities where the
respondents lived.
2.2. Ethic Statement
The study was approved by the Ethical committee of the University of Calabria (Rende, Italy, on 9
September 2004). All the subjects provided written informed consent in accordance with institutional
requirements and the Declaration of Helsinki principles.
2.3. Cognitive and Physical Assessments
Cognitive status was assessed by age- and education-adjusted Mini Mental State Examination
(MMSE) [18]. The score ranges from 0 to 30, and a score of 23 points or less is usually considered
to indicate cognitive impairment. Hand grip (HG) strength was evaluated by using a handheld
dynamometer (SMEDLEY’s dynamometer TTM) while the subject was sitting with the arm close to the
body. Three consecutive measurements were performed with the stronger hand, and the maximum
value was used for data analysis. The performance of activities of daily living (ADL) (bathing, dressing,
toileting, transfer from bed to chair, and feeding) was assessed using a modification of the Katz
Index [19]. Scores were dichotomized as 1 if the subject was able to perform every activity and
as 0 otherwise. Depressive symptoms were assessed using the 15-item Geriatric Depression Scale
(GDS) [20]. Subjects with GDS scores greater than or equal to 5 were considered to be affected by
depressive symptom.
2.4. SNPs Selection and Primer Design for iPLEX TM Assay
A panel of 35 candidate polymorphisms was selected based on known functional consequence
(exonic, regulatory regions) or prior associations with disease risk, pathology, or drug response. SNPs
were chosen from 23 genes involved in detoxification related pathways of xenobiotic substances.
Supplementary Table S1 reports the complete list of assayed SNPs and their basic features. In summary,
we selected 6 SNPs in 5 genes of phase I, 11 SNPs in 7 genes of phase II, and 13 SNPs in 7 genes of
phase III. Four non-canonical XME genes (indicated as others in Table S1) and relative polymorphisms
(4 SNPs) were selected because they have been deeply studied in relation to drug response, and thus
likely affect the risk or the clinical evolution of several diseases. All SNPs have a reported minor allele
frequency of >0.05 in Europeans. For each polymorphism, PCR and extension primers were designed
using Sequenom MassARRAY Assay Designer 3.0 software (Sequenom, San Diego, CA, USA), resulting
in a 22 plex and a 13 plex.
2.5. Sequenom Mass Spectrometry Genotyping
First, 2 μL of genomic DNA (5 ng/uL) were PCR-amplified in a 5 μL reaction containing 0.8 μL
HPLC grade water, 0.5 μL of 10 × PCR buffer with 20 mM MgCl2, 0.4 μL of 25 mM MgCl2, 0.1 μL of
25 mM dNTP mix, 1 μL of 0.5 μM primer mix, and 0.2 μL Sequenom PCR enzyme. PCR conditions
were: an initial cycle at 94 ◦C for 2 min, 45 cycles at 95 ◦C for 30 s, 56 ◦C for 30 s, 72 ◦C for 60 s, and a
final step at 72 ◦C for 5 min.
Unincorporated dNTPs in the amplification products were dephosphorylated by adding 2 μL of
the shrimp alkaline phosphatase (SAP, Sequenom) mix consisting of 1.53 μL of HPLC grade water,
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0.17 μL of SAP buffer, and 0.3 μL (0.5 U) of SAP enzyme (Sequenom). Each reaction was incubated at
37 ◦C for 40 min, and SAP was then heat inactivated at 85 ◦C for 5 min.
Following SAP treatment, a single base pair extension reaction was performed using Sequenom’s
iPLEX Gold chemistry, where 2 μL of the iPLEX reaction mix was added to the samples. The reaction
mix consisted of 0.62 μL of HPLC grade water, 0.2 μL of iPlex buffer, 0. 2 μL of iPlex terminator mix,
0.94 μL of primer mix, and 0.04 μL of iPlex enzyme. Thermal cycling conditions included an initial
cycle at 94 ◦C for 30 s; 40 cycles at 94 ◦C for 5 s, [52 ◦C for 5 s and 80 ◦C for 5 s (repeat 5 times per cycle)];
and a final step at 72 ◦C for 3 min. The samples were then resin treated and spotted on a SpectroCHIP
using the MassARRAY nanodispenser (Sequenom) and analyzed using the MassARRAY Compact
System matrix-assisted laser desorption/ionization-time-of-flight mass spectrometer (MALDI-TOF)
(Sequenom). Genotypes were assigned in real time using the MassARRAY SpectroTYPER RT v3.4
software (Sequenom) based on the mass peaks present. All results were manually inspected using the
MassARRAY TyperAnalyzer v3.3 software (Sequenom).
2.6. Quality Control
After genotyping, samples were subjected to a battery of quality control (QC) tests. At sample
level, subjects with a proportion of missing genotypes higher than 10% were dropped from the analysis.
At SNP level, SNPs were excluded if they had a significant deviation from Hardy–Weinberg equilibrium
(HWE, p < 0.05) in the younger subgroups, a missing frequency (MiF) higher than 20%, and a minor
allele frequency (MAF) lower than 1%. See Table S1 for details.
2.7. Statistical Analysis
For each SNP, allele and genotype frequencies were estimated by gene counting from the observed
genotypes. HWE was tested by Fisher’s exact test. Logistic regression models were used to evaluate
the effect of genotypes (independent variables) on the probability of belonging to different age groups
(dependent variable). Differences between age groups were tested by comparing two of them at once.
Genetic data were coded with respect to a dominant, a recessive, and an additive model of inheritance.
Then, for each SNP, the most likely genetic model was estimated on the basis of minimum level of
statistical significance (Wald test p-value). In such models, sex was used as a covariate. To capture
sex-dependent effects of the analyzed genetic variants, an additional interaction term was also included.
Finally, to test whether combinations of SNPs might better differentiate between the different age
groups, a multivariate model including the associated SNPs was also fitted. The Nagelkerke index was
then used to compare the obtained models.
Linear and logistic regression models were applied to estimate the impact of genetic variability on
parameters of cognitive (MMSE, GDS) and physical (HG, ADL) performance, including age, gender, and
height as covariates. Continuous and categorical variables were compared by using the independent
samples t-test and the X2 test as appropriate. For evaluating if the effect of the polymorphisms on
longevity phenotype also affected the survival patterns of the different genotypes, we performed a
longitudinal study after 10 years from the baseline visit. Univariate survival analysis was carried
out by the Kaplan–Meier approach, and survival curves were compared by log-rank test. Subjects
were considered as censored if they were alive after the follow-up time, and this time was used as
censoring data in the survival analyses. Moreover, hazard ratios (HR) and 95% CI were estimated by
Cox proportional hazard models using age and gender as confounder variables.
Because this was a hypothesis driven study, a level of significance p-value = 0.05 was considered
for each association test without Bonferroni post hoc correction for multiple comparisons.
Statistical analyses were performed using SNPassoc and surv packages of R (http://www.R-project.org/).
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3. Results
After quality control checks, there were genotyping data on 27 SNPs in a cohort of 981 individuals
aged 20–108 years. Demographic characteristics for the study cohort according to age groups defined
in the Materials and Methods section are presented in Table 1.
Table 1. Demographic characteristics for the analyzed cohort according to age group membership.
Age Class S1 Age Class S2 Age Class S3
n 287 379 315









ADL (% Disabled) - 43.0 69.5
GDS (% Depressed) - 32.3 26.2
HG (Kg; mean, SE) - 22.2 (0.62) 13.1 (0.43)
MMSE < 23 (%) - 9.5 66.5
ADL, activity daily living; GDS, Geriatric Depression Scale; HG, hand grip; MMSE, Mini Mental State Examination;
SE, standard error.
Four SNPs demonstrated a nominally significant association (p-value < 0.05) in at least one
comparison (see Table 2).
Table 2. Multinomial logistic analysis for univariate genetic associations.
* Comparison 1
(Age Class 2 vs. Age Class 1)
Comparison 2
(Age Class 3 vs. Age Class 1)
Comparison 3
(Age Class 3 vs. Age Class 2)
65–89 Years vs. <65 Years 90+ vs. <65 Years 90+ vs. 65–89 Years
Gene OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
rs3745274-G/T CYP2B6 0.97(0.67–1.40) 0.88 0.54 (0.37–0.80) 0.002 0.56 (0.39–0.80) 0.005
rs776746-G/A CYP3A5 1.20(0.65–2.22) 0.57 1.97 (1.08–3.56) 0.022 1.66 (0.99–2.79) 0.054
rs4680-G/A COMT 1.67(1.10–2.54) 0.016 2.43 (1.58–3.73) <0.001 1.47 (1.10–2.15) 0.046
rs2273697-G/A ABCC2 0.87(0.61–1.23) 0.44 1.26 (0.89–1.79) 0.18 1.45 (1.03–2.05) 0.030
* In each comparison, the youngest group was considered as the reference category. For both comparisons 1 and 2
(both using the youngest group as reference category), odd ratios (ORs) were obtained directly from the equations
included in the models; for comparison 3 (90+ years vs. <65 years), ORs were obtained by difference of equations
included in the models.
Two of them (rs3745274-G/T and rs776746-G/A) belonged to genes for phase I enzymes (CYP2B6 and
CYP3A5, respectively), one (rs4680-G/A) was within the phase II COMT gene, and one (rs2273697-G/A)
was within the phase III ABCC2 gene. The best-fitting genetic model for three of them was dominant,
while rs4680-G/A best fit a recessive genetic model. As Figure 1 shows, these variants had different
gene frequency trajectories over the three examined age intervals.
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Figure 1. Gene frequencies across the three age classes S1 (20–64 years), S2 (65–89 years), and S3
(90–108 years) of: (A) T allele carriers of rs3745274 in CYP2B6; (B) A allele carriers of rs776746 in
CYP3A5; (C) AA carriers of rs4680 in COMT; (D) A allele carriers of rs2273697 in ABCC2.
We found a significant decrease in the proportion of carriers of the CYP2B6 rs3745274-T allele
in the oldest sample (S3 group) with respect to the youngest S1 and S2 [odds ratio (OR) = 0.547 CI
95% 0.373–0.803, p-value = 0.002 for comparison 2; OR = 0.563 CI 95% 0.395–0.803, p-value = 0.005 for
comparison 3), consistent with a detrimental effect of this allele on longevity (Table 2 and Figure 1A).
An opposite effect was observed for rs776746, being carriers of the A allele significantly overrepresented
in the S3 group as compared to S1 (OR = 1.97 CI 95% 1.08–3.56; p-value = 0.022) and S2 group. In this
last case, however, only a trend toward significance was detected (OR = 1.66 CI 95% 0.99–2.79;
p-value = 0.054) (Table 2 and Figure 1B). For both SNPs, we did not find differences between age
groups in comparison 1, indicating that carrying of the above alleles confers a disadvantageous or an
advantageous effect on lifespan only in the last part of life. A different trajectory was observed for
the COMT rs4680 variant (Figure 1C). Indeed, in all the comparisons, we found that the proportion
of homozygous AA individuals was always significantly higher in the oldest than in the younger
subjects (OR = 1.67 CI 95% 1.10–2.54, p-value = 0.016 for comparison 1; OR = 2.43 CI 95% 1.58–3.73,
p-value <0.001 for comparison 2; OR = 1.47CI 95% 1.10–2.15, p-value = 0.046 for comparison 3),
consistent with a linear trend towards a positive effect of the rs4680-AA genotype on longevity. As
for the rs2273697 variant in ABCC2, a significantly higher prevalence of carriers of the minor allele
A in subjects belonging to the S3 group in comparison to the younger age group S2 (comparison 3)
(OR = 1.459 CI 95% 1.038–2.051; p-value = 0.030) was observed (Figure 1D), thus indicating a beneficial
impact of this allele for reaching longevity. No statistically significant evidence for genotype-by-sex
interactions was observed.
Next, to evaluate the overall effect of the multivariate model on the total phenotypic variance, we
estimated Nagelkerke indexes for comparisons 1 and 3; we found that the variance explained by the
combined genetic data was 0.7% in comparison 1 and 7.7% in comparison 3. Finally, we evaluated
the combined effect of the variability of genes listed in Table 2 at different ages. As Table S2 shows,
we detected an approximately similar effect size to that seen in univariate analysis, suggesting an
independent effect of each SNP. In comparison 3, three out of four SNPs included in the genetic profile
remained substantially associated with the phenotype and significantly associated with the age-group
membership (rs3745274-G/T, rs776746-G/A, rs4680-G/A), thus significantly discriminating very long
lived (90+) from younger elderly (65–89 years old) subjects.
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Since the weight of genetic factors increases starting from 65 years of age, we investigated the
association of the above variants with biomarkers of age-associated changes in physical (HG and
ADL) and cognitive (MMSE and GDS) abilities. A significant association was found between COMT
rs4680 and ADL performance (p-value = 0.03) with subjects homozygous for the allele A showing
significantly lower probability to be disabled than those carrying at least one G allele (60.7% of AA
among the non-disabled vs. 39.3% of AA among the disabled). In addition, we found that the same
variant significantly influenced the GDS performance in females. Subjects with the AA genotype were
more represented among non-depressed than depressed individuals (78.9% vs. 51.6%; p-value = 0.017).
No other significant association between these SNPs and geriatric parameters was observed.
Finally, by using 10-year follow-up survival data, we assessed whether the variants we found
associated with the longevity phenotype also influenced the survival of the elderly cohort (age
65–89 years). Kaplan–Meier survival analysis showed a trend for a positive association with survival
for carriers of the minor allele (A) of rs2273697 in ABCC2 (p-value = 0.054; see Figure 2), a result
consistent with the positive effect on longevity. However, the association did not hold significance
when multivariate Cox proportional hazard regression analysis was performed (HR = 0.63, 95% CI:
0.35–1.16; p-value = 0.143).
Figure 2. Kaplan–Meier survival functions relative to carriers of the minor allele A (black) vs. non
carriers (gray) of the ABCC2 variant rs2273697. Time is expressed in months, where zero is considered
the time of recruitment, and each individual is followed up for survival status until death.
4. Discussion
In this study, we show that genetic variants of genes related to xenobiotic metabolism, such
as those of phases I-III, have an influence on the chance of reaching old and very old ages beyond
100 years. Among the 27 genetic variants analyzed, four (rs3745274, rs776746, rs4680, and rs2273697)
have shown to exert significantly different and age-specific effects on longevity, with changes of gene
frequencies following either linear or non-linear trajectories. In particular, except for rs4680, which
showed a significant linear change across the age classes, we observed major frequency changes in the
other SNPs in passing from 65–89 to 90–108 age-range. In fact, the genetic variability of these genes
showed to account for 7.7% of the chance to survive beyond the age of 89 years. This figure is quite
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important if we take into account that genetics is believed to account for 25% of the individual chance
to be long-lived.
Age-specific gene effects have already been reported in literature for genetic variants in other genes
thought to shape the dynamic and the complex gene–environment interactions, which profoundly
change during human lifespan [21]. Genes encoding for xenobiotic metabolizing enzymes surely have
these characteristics.
Completely opposite effects on longevity were observed for rs3745274-T (negative effect) and
rs776746-A carriers (positive effect) located respectively in CYP2B6 and CYP3A5 genes that function
in biotransformation reactions (phase I). Substrates for both isoenzymes include not only clinically
used drugs but also a large number of environmental toxic and carcinogenic chemicals (pollutants,
pesticides), as well as endogenous compounds such as steroid hormones and fatty acids [22,23].
The CYP2B6 protein makes up roughly 2–6% of total liver CYP content [24]. There is a remarkable
inter-individual variability in its expression partly due to transcriptional regulation and genetic
variations [22]. The rs3745274-G/T, herein found to affect the likelihood of becoming long-lived, is a
missense variant (Gly516His) in exon 4. A study by Hofmann et al. [25] reported evidence that the T
allele is responsible for aberrant splicing, resulting in a shorter variant lacking exon 4, 5, and 6 and
decreased expression and enzymatic activity. Notably, relevant studies have established a link between
this variant and a higher risk of multiple cancers [26–28]. Therefore, it is likely that individuals carrying
the T allele, because of a lower detoxifying capability, have a higher susceptibility to cancer compared
to non-carriers and thus a decreased probability of reaching advanced ages.
Emerging evidence also suggests that the rs776746-G/A variant in intron 3 of the CYP3A5 gene may
affect the individual’s risk of cancer development. The presence of the G allele creates a cryptic splice site
that determines a truncated non-functional protein. Therefore, subjects carrying the GG genotype are
considered to be CYP3A5 non-expressors [29]. Very interestingly, the frequency of the rs776746-G allele
varies markedly across ethnic groups, ranging from about 18% in Africans to 94% in Europeans (data
from 1000 genome) and is significantly correlated with population distance from the equator [30], thus
suggesting considerable interaction between genotype and environment. Notably, current literature
supports a relationship between the G allele and cancer risk [31,32], suggesting that a protective
effect of the expressor A-allele may allow individuals to better cope with dangerous compounds
potentially promoting cancer development. Consistently, we found that elderly subjects carrying the
rs776746-A have a higher likelihood of becoming long-lived than non-carrying ones. Interestingly, for
both rs3745274 and rs776746, changes in gene frequencies start to occur in the middle-aged group (S2),
i.e., the one characterized by a higher incidence of cancer and other age-related diseases.
Moreover, the polymorphism rs2273697-G/A appeared to modulate the probability of obtaining
longevity by mainly acting in the 65–89 years age group. This is a missense variant (Val417Ile) in exon 10
of the ABCC2 gene, encoding for the multidrug resistance-associated protein 2 (MRP2), a member of the
ABC transporter superfamily. This phase III protein, which is expressed in hepatocytes, renal proximal
tubular cells, and enterocytes, is involved in the removal of many toxic chemicals, nutraceuticals,
drugs, and their conjugates, as well as endogenous compounds (e.g., bilirubin-glucuronides) [33]. A
recent finding by Wei and colleagues provided direct evidence that the rs2273697-A allele increases
the ATPase and the efflux activity of the MRP2 protein [34]. Our survival analysis showed that the
presence of the A allele decreases the risk of death in subjects aged 65–89 years, and that carriers of this
allele are more represented in the 90+ cohort. Based on the above evidence, it seems plausible that
rs2273697-A promotes increased survival at old age through an enhanced MRP2 efflux capacity, which
likely results in a better protection against cytotoxic effects of toxic compounds.
Finally, we observed a significant linear increase in frequency for the COMT rs4680-AA genotype
across the different age groups, suggesting a positive effect on survival at both old and very old ages.
The rs4680 polymorphism lies in exon 4 and determines either a valine (Val; G allele) or a methionine
(Met; A allele) at amino acid 158. This SNP has been reported to significantly affect enzyme activity;
for instance, the Val allele has a four-fold higher enzyme activity than the Met allele [35]. COMT is
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an important phase II enzyme, which, by methylation, inactivates biologically active catechols (i.e.,
catecholamines, catecholestrogens) and toxic catechol-based molecules [36]. In recent years, COMT
has become intensively studied, largely due to its role in regulation of the dopamine level in the brain.
In Caucasians, the Met allele is reported to be associated with better cognitive function [37], while Val
carriers tend to have a greater likelihood of becoming depressed [38]. It is well known that depression
as well as cognition impairment represent major risk factors for disability, often associated with worse
health outcomes and increased risk of death, especially in later life [39]. All of the above is in line
with our data showing a positive effect on longevity of the A (Met) allele, moreover, confirmed by
the association of the same allele with a lower depressive status and a better physical performance in
elderly subjects.
On the whole, the different trends in XME gene frequencies we observed in population age once
again highlight the complexity in gene–longevity associations. In fact, we found two associated SNPs
behaving as pro-longevity variants (rs776746-A and rs4680-AA), one as a killing variant (rs3745274-T),
while the rs2273697-A allele showed a U-like frequency curve that was higher at younger ages,
decreased in early old, and then increased in exceptionally old. Such a behavior is typical of a buffered
variant, in accordance with the buffering mechanism in aging hypothesis suggested by Bergman [40],
which states that a deleterious variant can be neutralized by the protective effect of pro-longevity genes.
5. Conclusions
The present study—the first to our knowledge to investigate the association between SNPs in
XME genes and human longevity—found that their variability conditions the chance to reach very
old age by affecting survival in an age-specific way. This is a novel finding considering that the
variability of XME genes has been extensively investigated in relation to drug metabolism and response
to treatment. However, drugs are only a limited kind of substrate that XME proteins can metabolize;
their detoxification function might rather modulate the dynamic and the complex biological response
to the exposome, thus representing a potential determinant of longevity. We are aware that the study is
not conclusive and deserves future investigations. Because the genetic variability of all the XME genes
herein analyzed show population specificity, it could be very interesting to test the association with
longevity in other ethnic groups. Moreover, a longer follow up time and the knowledge of specific
causes of death could further support our conclusions, allowing us to better understand the specific
pathological phenotype affected by the variants analyzed in this study. Nevertheless, the associations
here reported may contribute to our understanding of the genetic determinants of human longevity,
supporting future studies in the role of xenobiotic metabolism in quality of aging and extreme survival.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/5/403/s1,
Table S1: List of genes and SNPs considered in the present study. Table S2. Multinomial logistic analysis for
multivariate genetic associations.
Author Contributions: Conceptualization, G.R., A.M., P.C. and S.D.; methodology, P.C., S.G. and F.I.; formal
analysis, A.M.; data curation, A.M. and S.G.; writing—original draft preparation, G.R.; writing—review and
editing, G.R., S.D., G.P., P.C. and A.M.; funding acquisition, G.R.
Funding: This research was funded by the Italian Ministry of University and Research (PRIN: Progetti di Ricerca
di rilevante Interesse Nazionale—2015, Prot. 20157ATSLF) to G.R.
Acknowledgments: The work has been made possible by the collaboration with Gruppo Baffa (Sadel Spa, Sadel
San Teodoro srl, Sadel CS srl, Casa di Cura Madonna dello Scoglio, AGI srl, Casa di Cura Villa del Rosario srl,
Savelli Hospital srl, Casa di Cura Villa Ermelinda).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Wild, C.P. Complementing the genome with an “exposome”: The outstanding challenge of environmental
exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomark. Prev. 2005, 14, 1847–1850.
[CrossRef] [PubMed]
94
Genes 2019, 10, 403
2. Escher, B.I.; Hackermüller, J.; Polte, T.; Scholz, S.; Aigner, A.; Altenburger, R.; Böhme, A.; Bopp, S.K.; Brack, W.;
Busch, W.; et al. From the exposome to mechanistic understanding of chemical-induced adverse effects.
Environ. Int. 2017, 99, 97–106. [PubMed]
3. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch.
Pharm. Res. 2005, 28, 249–268. [CrossRef]
4. Klotz, U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab. Rev. 2009, 41, 67–76. [CrossRef]
[PubMed]
5. Wauthier, V.; Verbeeck, R.K.; Calderon, P.B. The effect of ageing on cytochrome P450 enzymes: Consequences
for drug biotransformation in the elderly. Curr. Med. Chem. 2007, 14, 745–757. [CrossRef]
6. Yun, K.U.; Oh, S.J.; Oh, J.M.; Kang, K.W.; Myung, C.S.; Song, G.Y.; Kim, B.H.; Kim, S.K. Age-related changes in
hepatic expression and activity of cytochrome P450 in male rats. Arch. Toxicol. 2010, 84, 939–946. [CrossRef]
[PubMed]
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Abstract: Studies investigating exceptionally long-lived (ELL) individuals, including genetic
studies, have linked cardiovascular-related pathways, particularly lipid and cholesterol homeostasis,
with longevity. This study explored the genetic profiles of ELL individuals (cases: n = 294,
95–106 years; controls: n = 1105, 55–65 years) by assessing their polygenic risk scores (PRS) based on
a genome wide association study (GWAS) threshold of p < 5 × 10−5. PRS were constructed using
GWAS summary data from two exceptional longevity (EL) analyses and eight cardiovascular-related
risk factors (lipids) and disease (myocardial infarction, coronary artery disease, stroke) analyses.
A higher genetic risk for exceptional longevity (EL) was significantly associated with longevity in
our sample (odds ratio (OR) = 1.19–1.20, p = 0.00804 and 0.00758, respectively). Two cardiovascular
health PRS were nominally significant with longevity (HDL cholesterol, triglycerides), with higher
PRS associated with EL, but these relationships did not survive correction for multiple testing.
In conclusion, ELL individuals did not have significantly lower polygenic risk for the majority of the
investigated cardiovascular health traits. Future work in larger cohorts is required to further explore
the role of cardiovascular-related genetic variants in EL.
Keywords: polygenic risk score; cardiovascular health; exceptional longevity; lipid profile
1. Introduction
The human life span has significantly increased over the last century with many individuals
surpassing 80 years of age in developed countries due to factors such as improved healthcare and
favourable lifestyle choices [1]. Exceptional longevity, defined as exceeding the average life expectancy,
is multifaceted with genetic, environmental and epigenetic factors all playing a role. Exceptionally
long-lived (ELL) individuals are examples of successful ageing with a proportion demonstrating
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compression of morbidity [2]. Thus, ELL individuals have been described as “super controls” for
studies on age-related decline and disease [3]. It is important to study these models of successful ageing,
as these rare individuals may reveal novel longevity-associated pathways, which may ultimately
translate into strategies to promote health in our ageing population.
There is evidence linking healthier cardiovascular risk profiles and lower incidence of
cardiovascular disease with longevity [4]. Analysis of lipid metabolism in longevous families
identified changes in lipid concentration, specifically a smaller total cholesterol to high-density
lipoprotein-cholesterol (TC/HDL-C) ratio and lower triglycerides levels, in the offspring of
nonagenarians [5]. Lipid profiling in the Leiden Longevity Study established larger low-density
lipoprotein particles as major predictors of longevity [5]. Similarly, Barzilai et al. (2015) suggested that
healthy ageing is promoted by a unique lipoprotein profile [6]. Levels of apolipoproteins, important
lipid transporters in the circulatory system, have been observed to decline with age. However, higher
apolipoprotein levels in the exceptionally long lived have been reported, suggesting a younger
apolipoprotein profile that may promote longevity [7].
Further evidence from candidate and genome-wide association longevity studies indicates
that cardiovascular pathways are involved in successful ageing. In a parental longevity genome
wide association study (GWAS) examining 75,000 participants, the authors concluded that
cardiovascular-related pathways are important contributors in attaining exceptional longevity [8].
In a recent meta-analysis examining longevity genetic polymorphisms, all significant genes
(APOE, FOXO3A, ACE, Klotho and IL6) play roles in cardiovascular pathways, such as lipid metabolism,
or have been previously linked to cardiovascular disease [9]. The genetic variants with the largest effect
sizes in this meta-analysis were located in the APOE and FOXO3A genes. The product of the APOE
gene transports lipids in the blood and is consequently critical in cholesterol metabolism. Any loss
of cholesterol homeostasis may increase the risk of cardiovascular disease, obesity and diabetes [10].
In addition, cardiovascular diseases (heart attack and stroke) have been strongly linked to APOE [11].
FOXO3A is an evolutionary conserved transcription factor and has been consistently and independently
replicated with longevity in many ethnically diverse cohorts [12]. Recently, the longevity-associated G
allele of FOXO3 rs2802292 in older Japanese and Caucasians was associated with decreased risk of
coronary artery disease mortality [13]. Interestingly, both Ashkenazi Jewish and Italian centenarians
genotyped for an isoleucine to valine variation at codon 405 in the cholesteryl ester transfer protein
(CETP) gene had a higher frequency of the VV genotype, which has been associated with larger
low-density lipoprotein particle sizes and lower CETP serum levels. The authors deduced that
lipoprotein particle size is heritable and encourages healthy aging [6,14]. Similarly, homozygosity
for the -641 C allele in the APOC3 promoter (rs2542052) was 25% higher in centenarians and linked
with pro-longevity lipoprotein levels and sizes [15]. Additional prior studies investigating genetic
vascular factors involved in human longevity have described variants in genes involved in blood
pressure regulation such as methyltetrahydrofolatereductase (MTHFR), paraoxonase 1 (PON1) and
plasminogen activator inhibitor type I (PAI-1) [16]; however, further studies are still needed to confirm
these suggested associations.
Polygenic risk scores (PRS) for cardiovascular-related phenotypes can now be calculated due to
the availability of summary data from GWAS examining a broad range of traits from lipids to coronary
artery disease. This facilitates the evaluation of the contribution of polygenic risk for cardiovascular
risk factors and disease to exceptional longevity and successful ageing. Thus, the purpose of this study
was to explore the genetic profiles of ELL individuals aged (≥95 years) by assessing their polygenic
risk for cardiovascular-related risk and disease phenotypes relative to middle-aged controls. This study
tests the hypothesis that ELL individuals have lower polygenic risk for cardiovascular health-related
traits and disease compared to controls, which may give them a survival advantage.
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2. Materials and Methods
2.1. Participants
ELL individuals were recruited from two Sydney-based Australian studies: The Sydney
Centenarian Study (SCS) [17] and the Sydney Memory and Ageing Study (Sydney MAS) [18].
Both studies recruited participants using the compulsory electoral roll and Medicare lists from
New South Wales, Australia. A subsample from SCS with available genetic data provided 256
long-lived cases with a European background (age range 95–106, mean age 97.5 years, 31% male).
This sample was enriched by the addition of 38 individuals from Sydney MAS (≥95 years,
mean age 86.7 years, 26% male). Ethics approval was granted from the relevant Human Research
Ethics Committees for each study. SCS and Sydney MAS were approved by the Human Research
Ethics Committees of UNSW Sydney and the South Eastern Sydney and Illawarra Area Health
Service (ethics approvals HC17251 and HC14327, respectively). The Hunter Community Study (HCS)
was approved by the University of Newcastle and Hunter New England Human Research Ethics
Committees (HREC 03/12/10/3.26). Written informed consent was obtained from all participants or if
unable to consent, proxy consent was obtained from the nearest of kin.
Controls were obtained from the Hunter Community Study (HCS) in Newcastle, New South
Wales [19]. These participants have a similar ethnic background to the long-lived cases and Newcastle
is geographically close to Sydney (160 km). The HCS is a cohort of 3253 individuals (age range 55–85,
mean age 66.3 years, 46% male). For the purpose of this investigation a subsample of 1105 individuals
aged 55–65 (mean age 60.3 years, 47% male) were used as controls.
Fasting blood samples from each cohort were collected for DNA and biochemistry analyses.
Biological measures assessed included total cholesterol, as well as low-density lipids (LDL) and
high-density lipids (HDL), and triglycerides as described in [20,21].
2.2. Genotyping
DNA was extracted using standard methods. SCS cases were genotyped using the Illumina
OmniExpress array (California, USA), whereas the HCS cases were genotyped using the Affymetrix
Axiom Kaiser array (California, USA) and the Sydney MAS samples were genotyped using the
Affymetrix Genome-wide Human SNP Array 6.0 according to the manufacturer’s instructions. In all
three cohorts, genotyped single nucleotide polymorphisms (SNPs) were excluded if the following
criteria were observed: (i) The call rate was <95%, (ii) p-value for Hardy-Weinberg equilibrium
was <10−6, (iii) minor allele frequency was <0.01% and (iv) the strand ambiguous (A/T and C/G).
If first- or second-degree relatives were identified, only one family member was retained for analysis.
EIGENSTRAT analysis [22] allowed for the detection and removal of any ethnic outliers. After quality
control (QC) checks, for SCS and Sydney MAS there were genotyping data on 640,355 and 734,550 SNPs,
respectively, whilst for HCS there were data on 739,276 SNPs. As part of the QC checks, the reported
sex of the participants was verified using genotyped data and samples with sex discrepancies
were discarded. The quality controlled genotype data were imputed in the Michigan imputation
server (https://imputationserver.sph.umich.edu) [23] using the Haplotype Reference Consortium
reference panel (v3.20101123). Similar to the genotyped data, QC steps in the imputed data were
implemented (minor allele frequency (MAF) > 0.05, imputation quality score >0.6, call rate >0.95, HWE
p-value >10−6). The SNPs with high quality dosage scores were converted to best-guess genotypes
using PLINK and were used in the calculation of the PRS. The genotypes for the APOE single nucleotide
polymorphisms (SNPs) rs7412 and rs429358 were extracted from the imputed dosage using PLINK.
Both the SNPs were imputed with high accuracy in all the three cohorts (r2 > 0.80) and the APOE
ε2/3/4 haplotypes were inferred using these two SNPs [24].
Genotyping availability: Due to ethical concerns, genotyping data have not been deposited in
a public repository. However, genotyping data can be requested via a formal review process to the
relevant studies.
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2.3. Polygenic Risk Scores (PRS)
PRS were generated by using the PRSice program [25] from summary statistics obtained from
previous GWAS studies. The following phenotypes were examined: Longevity, cardiovascular disease
(myocardial infarction, all stroke and coronary artery disease) and cardiovascular disease-related
risk factors (cholesterol, triglycerides, high- and low-density lipoproteins and essential hypertension).
Details regarding each GWAS utilised, including links to the summary data are provided in the
Supplementary (Tables S1 and S2). Linkage disequilibrium pruning was performed using the clumping
option (r2 > 0.25 and physical distance threshold of 250 kb KB). PRS were calculated for each of the
phenotypes using different p-value significance cut-offs for the SNPs included from each of the
GWAS, ranging from p = 5 × 10−8 to 1. We only present the results for the PRS p-value threshold of
5 × 10−5 in the main text. Due to the strong associations between longevity and (i) the APOE locus
(chromosome 19, base pair 45,393,826–45,422,606) and (ii) the FOXO3A locus (chromosome 6, base pair
108,881,038–109,005,977), longevity PRS were also calculated after removing these loci.
2.4. Statistical Analyses
All analyses were performed using R version 3.4.3 [26]. Chi-squared tests were utilised to
determine differences in proportions between groups. To achieve normality of the lipid variables,
inverse normal transformations were performed. Independent sample t tests were used to compare
the means between the cases and controls.
To demonstrate that the PRS were associated with their respective phenotypes in our sample,
analyses were undertaken investigating the relationships between (a) PRS for EL phenotypes (+/−APOE,
FOXO3A and APOC3 loci) and EL in our sample using logistic regression, controlling for sex and where
appropriate APOE ε4 or APOC3 (rs2542052) C homozygotes; (b) cardiovascular risk factor (lipids) PRS
and measured lipid levels using linear regression, adjusting for age and sex and where appropriate
APOE ε4 or APOC3 (rs2542052) C homozygotes. Lastly, logistic regressions were used to investigate
associations between cardiovascular health PRS and EL in our sample, controlling for sex.
The variance explained by the PRS using logistic regression was calculated using the Nagelkerke
method [27] as implemented in the R package rsq [28] and power calculation was performed using
WebPower [29]. Correlation analyses between the different PRS were undertaken to examine genetic
overlap, using the PRS calculated at the nominated GWAS threshold p-value cut-off of 5 × 10−5.
3. Results
3.1. Sample Characteristics
The sample characteristics are described in Table 1. As expected, there were fewer APOE ε4 carriers
in the ELL cases compared to the younger controls, 14.6% versus 30.8%, respectively (p = 1.49 × 10−8).
LDL and total cholesterol levels were statistically different, with controls displaying higher lipid levels
than EL cases (Table 1). The frequency of APOC3 (rs2542052) C homozygotes did not differ significantly
in the cases and the controls (p = 0.503564).
Table 1. Sample characteristics of long-lived cases (≥95 years) and younger controls (55–65 years).
Cases Controls p-Value
Cohort SCS/Sydney MAS HCS
Sample size (n) 294 1105 N/A
Age range (mean ± SD) 95–106 (96.1 ± 4.1) 55–65 (60.3 ± 2.8) N/A
N (%) males 90 (31) 518 (47) N/A
APOC3 a C homozygotes, n (%) 120 (40.1) 475 (42.9) 0.503564
APOE ε4 carrier, n (%) 43 (14.6) 340 (30.8) 1.49 × 10−8
HDL (mean ± SD) (% missing) 1.47 ± 0.45 (17.1) 1.36 ± 0.37 (0.6) 0.148557
LDL (mean ± SD) (% missing) 2.69 ± 1.02 (17.3) 3.25 ± 0.91 (12.3) 1.23 × 10−19
TC (mean ± SD) (% missing) 4.75 ± 1.16 (17.0) 5.24 ± 1.03 (0) 6.37 × 10−15
TG (mean ± SD) (% missing) 1.31 ± 0.63 (17.0) 1.41 ± 1.12 (0.6) 0.492286
Notes: HDL = high-density lipoprotein, LDL = low-density lipoprotein, TC = total cholesterol, TG = total triglyceride.
Raw mean values are reported. a, APOC3 SNP rs2542052.
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3.2. Polygenic Risk Scores (PRS)
The exceptional longevity and cardiovascular risk and disease phenotypes used for calculation
of the PRS are shown in Table 2. The total number of SNPs included from each GWAS for the PRS
calculations are listed for two GWAS p-thresholds (genome-wide significance p < 5 × 10−8, suggestive
p < 5 × 10−5). Details for all other calculated PRS calculated (at different p-value cut-offs) are available
in the Supplementary (Table S3).
Table 2. Longevity and cardiovascular-related risk and disease phenotypes examined, with the number




p < 5 × 10−8
N SNPs
p < 5 × 10−5
Total Number of GWAS
SNPs Available
Exceptional longevity
Exceptional longevity [30] 0 32 184,562
Exceptional parental longevity [8] 0 123 476,093
Cardiovascular health
Myocardial infarction [31] 35 107 19,607
Stroke [32] 11 226 471,632
Coronary artery disease [33] 96 447 460,589
Essential hypertension (http://www.nealelab.is) 2 107 476,069
HDL [34] 318 685 204,118
LDL [34] 301 652 202,316
Cholesterol [34] 367 797 204,123
Triglycerides [34] 238 592 201,879
Notes: SNP numbers are after QC steps for the PRS calculation, including removal of any SNPs with a
poor imputation quality score (≤0.6) and linkage disequilibrium pruning. HDL = high-density lipoprotein,
LDL = low-density lipoprotein.
3.3. PRS Associations with Measured Phenotypes
3.3.1. Longevity PRS with Exceptional Longevity
As expected, higher longevity PRS from either Broer et al. [30] (EL, ≥90 cases vs. controls)
or Pilling et al. [8] (exceptional parental longevity—EPL cases had a mother who lived ≥98 years
and a father ≥95 years vs. controls) were significantly associated with longevity in our sample
(Table 3, Figure 1). Results from both analyses suggest individuals carrying pro-longevity variants
were 1.19–1.20 times more likely (per standard deviation increase in PRS) to survive to an exceptional
age (≥95 years) or to have both parents that were ELL. PRS calculated at other p-value thresholds
were all statistically significant (Table S4). For example, at a p-value threshold of 0.05, the EL PRS
had an OR of 1.79 (p = 2.29 × 10−17), and the PRS for exceptional parental longevity had an OR of
2.01 (p = 6.34 × 10−23). Sex was also found to be significant. Figure 1 shows that within the ELL cases,
there is a subsample that have low-longevity PRS (i.e., for both EL and EPL) and yet have survived
to 95 years old and over. The PRS explained 0.7%–10% of the phenotype variance depending on the
GWAS p-value threshold (Table S4).
Table 3. Associations between longevity EL and EPL PRS (p-value threshold < 5 × 10−5) and
exceptionally long-lived cases versus controls.
Odds Ratio (OR) Standard Error [8] p-Value
PRSEL [30] 1.20 0.068 0.00758
PRSEPL [8] 1.19 0.067 0.00804
Notes: EPL = exceptional parental longevity, defined as participants with a mother who lived ≥98 years and a
father ≥95 years. EL = exceptional longevity, defined as participants who lived ≥90 years. Logistic regressions
were adjusted for sex, comparing differences in PRS for ELL vs. controls. ORs expressed in PRS SD units.
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Figure 1. Density plots visualizing the standardised PRS distributions for EL (exceptional longevity,
PRSEL) and EPL (exceptional parental longevity, PRSEPL) in the entire sample and the corresponding
box plots in the long-lived cases (95+ years) versus controls (55–65 years).
Additional analyses excluding the TOMM40/APOE/APOC1 locus (Table S5), the FOXO3A locus
(Table S6) and the APOC3 locus (Table S7) did not markedly change the results. When adjusting for ε4
carrier status or APOC3 C homozygotes, the results did not change noticeably (Tables S8 and S9).
3.3.2. Association of Cardiovascular Risk Factor (Lipids) PRS with Measured Lipid Levels
Linear regressions were performed to ascertain whether the PRS for the lipid cardiovascular risk
factors were associated with actual lipid levels in the current study. As expected, (Table 4), the PRS
were positively associated with the measured lipid levels in our cohorts. The results for all lipid
PRS calculated at additional p-value thresholds and additionally adjusted for APOE ε4 or APOC3 C
homozygotes are available in the Supplementary (Tables S10, S11 and S12, respectively) The additional
adjustments did not change the results significantly.
3.3.3. Cardiovascular Health PRS and Exceptional Longevity
As shown in Figure 2, only two cardiovascular health PRS (HDL and TG) at the chosen
p-value threshold of < 5 × 10−5 were nominally significant with exceptional longevity, with higher
PRS associated with exceptional longevity. However, after Bonferroni correction for multiple
testing, assuming eight independent tests, they no longer remained significant. The results
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for all cardiovascular health PRS calculated at additional p-value thresholds are available in
the Supplementary (Table S13). Analyses were also adjusted for APOE ε4 and APOC3 C
homozygotes (Tables S14 and S15; when adjusting for APOE ε4, three cardiovascular health PRS
(HDL, TG and myocardial infarction (MI)) were marginally significant but would not survive multiple
testing correction.
 
Figure 2. Forest plot showing the associations of different cardiovascular PRS with exceptional
longevity. Notes. MI = myocardial infarction [31], AS = all stroke [32], CAD = coronary artery
disease [33], EssHT = essential hypertension [www.nealelab.is], HDL = high-density lipoprotein,
LDL = low-density lipoprotein, TC = total cholesterol, TG = total triglyceride [34]. Logistic regression
analyses were adjusted for sex, comparing differences in PRS for ELL vs. controls. PRS were calculated
using the relevant GWAS summary results with a p-value threshold < 5 × 10−5.
Table 4. Associations of different PRS (p-value < 5 × 10−5) for lipid cardiovascular risk factors with
measured lipid levels in the combined sample (55–106 years).
Sample Size (n) Beta (β) Standard Error [8] p-Value
PRSHDL 1331 0.261 0.024 3.94 × 10−26
PRSLDL 1196 0.200 0.028 3.81 × 10−13
PRSTC 1336 0.176 0.026 1.66 × 10−11
PRSTG 1335 0.254 0.026 2.63 × 10−21
Notes. HDL = high-density lipoprotein, LDL = low-density lipoprotein, TC = total cholesterol, TG = total triglyceride.
Linear regression adjusted for age and sex, independent variable = PRS, dependent variable = lipid level. All lipid
PRS were generated using summary results from Willer et al. [34].
PRS Genetic Overlap
Figure 3 explores the genetic overlap between the investigated PRS. Exceptional parental longevity
overlaps with the exceptional longevity PRS, although the correlation coefficient is small (r = 0.07,
p = 0.009). P-values for the entire correlation matrix are provided in Table S16. Interestingly, LDL
overlaps with both exceptional longevity (r = −0.06, p = 0.03) and exceptional parental longevity
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(r = −0.05, p = 0.04) in the expected direction. Myocardial infarction (MI) overlaps with exceptional
longevity (r = −0.06, p = 0.03) but not exceptional parental longevity. Other significant correlations
were observed between the cardiovascular risk factors and/or cardiovascular disease. For example,
the MI PRS was correlated with the PRS for stroke, coronary artery disease, HDL, LDL, total cholesterol
and triglycerides.
Figure 3. Pearson’s r correlation matrix comparing the genetic overlap between the investigated PRS.
Note: EL = exceptional longevity [30], EPL = exceptional parental longevity [8], MI = myocardial
infarction [31]; AS = all stroke, CAD = coronary artery disease [33], EssHT = essential hypertension
[www.nealelab.is], HDL = high-density lipoprotein, LDL = low-density lipoprotein, TC = total
cholesterol and TG = total triglyceride [34]. PRS were calculated using a p-value threshold of
p < 5 × 10−5.
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4. Discussion
In summary, this study did not confirm the hypothesis that ELL individuals have lower polygenic
risk scores for cardiovascular-related phenotypes. Only the HDL cholesterol and triglyceride PRS were
nominally significantly associated with ELL participants. In contrast and as expected, ELL individuals
had higher polygenic risk scores for EL.
In regards to the associations of the various cardiovascular PRS with EL, no findings survived
correction for multiple testing. This is despite validating the utility of the lipid PRS by confirming
positive associations with measured lipid levels in our sample. Interestingly, the different lipid
PRS were based on GWAS that found a large number of genome-wide significant loci (Table 1).
ELL individuals had lower LDL and total cholesterol levels than controls in this study, but they did not
differ on their respective PRS. This may suggest that environmental factors, perhaps lifestyle-related,
influenced these lipid levels, which possibly promote longevity. The most significant finding in our
study was for the HDL PRS, with higher scores associated with EL, which was in the expected direction
(OR = 1.15, p = 0.034). Other findings that were nominally significant, or approached significance,
that were also in the expected direction were the PRS for essential hypertension (OR = 0.89, p = 0.068)
and LDL (OR = 0.89, p = 0.077). However, the direction of the relationship between the triglyceride
PRS and EL was contrary to expectations (OR = 1.14, p = 0.050). Moreover, the relationships between
EL and cardiovascular PRS constructed at less stringent GWAS p-value thresholds reached statistical
significance with EL, although not always in the expected direction. In contrast, the UK Biobank study
observed that extreme parental longevity (defined as at least one parent who survived to the top 1% of
age at death) had lower polygenic risk for several cardiovascular health measures. Namely coronary
artery disease, systolic blood pressure, body mass index, high-density lipoproteins, low-density
lipoproteins and triglycerides. A similar result for HDL cholesterol and extreme parental longevity
(EPL) by the UK Biobank to the current study was reported (OR = 1.08) [8]. Again, similar results
were reported by the UK Biobank for LDL (OR = 0.89). However, the observed discrepancies between
our analysis and the UK Biobank were most likely due to methodological differences, including the
use of PRS that were based on different GWAS and p-value thresholds (p < 5 × 10−5 vs. p < 5 × 10−8,
respectively). Additionally, sample sizes varied (e.g., cases: n = 294 vs. n = 1339, respectively) and there
were differences in the definitions of EL (≥95 years vs. participants with at least one long-lived parent).
This study confirmed significant associations between higher-longevity PRS and EL in our
cohort using summary data from two different GWAS studies, Broer et al. [30] (≥90 years cases)
and Pilling et al. [8] (cases had a mother who lived ≥98 and a father ≥95 years), with the results in
the expected direction. Despite both of the longevity PRS not including any genome-wide significant
variants (p < 5 × 10−8), PRS scores were significantly associated with EL in our sample. It should be
noted that Pilling et al. [8], examining EPL, observed two genome-wide significant hits; however, they
were not used in our PRS due to the quality control steps undertaken. Interestingly, 32 SNPs from the
EL overlap with 123 SNPs in the EPL at the suggestive threshold of p < 5 × 10−5. EL PRS calculated at
other GWAS p-value thresholds were all statistically significant with EL in our sample and showed
strengthened associations (e.g., EL: OR increased from 1.2 to 1.8 at a threshold of p < 5 × 10−5 to <0.05).
A significant but modest correlation between EL and EPL PRS suggests there is a slight overlap in
genetic risk between these two longevity phenotypes. Moreover, when the whole genome (p ≤ 1) was
considered for calculation of the EL and EPL PRS, the correlation coefficient increased to 0.46.
Limitations of this investigation include the relatively small sample size of the current study,
which could result in low statistical power. This is demonstrated by a post hoc power analysis based on
our observed sample sizes and parameters, which showed that an OR above 1.26 would have provided
80% power, assuming eight independent tests. However, some of the observed ORs were below 1.26
(GWAS p-value threshold < 5 × 10−5), which may have contributed to the observed non-significant
results. This study did not examine sex differences, which may influence EL [9]. The other issue is the
appropriate GWAS p-value threshold cut-off to use for the analyses. As can be seen from the results
described, there is great variation in the results at different thresholds for the same PRS, with some
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findings in the expected direction, whilst others were contrary. Currently, there is no consensus
regarding the use of thresholds, which can have a great influence on the interpretation of the results.
5. Conclusions
Using the current GWAS data available, polygenic risk for cardiovascular-related phenotypes
and disease calculated at the 5 × 10−5 threshold appear not to play a strong role in achieving EL.
This is despite some evidence that cardiovascular pathways are involved, including lower prevalence
of APOE ε4 carriers in ELL individuals [9,16]. On the other hand, at less stringent GWAS p-value
thresholds, there were significant results observed but these were not always in the expected direction.
Therefore, studies enrolling larger sample sizes are required to further explore the role of CVD-related
genetic variants in EL. Sex and ethnic differences should also be examined. Other EL phenotypes could
be investigated, including healthy EL and the use of more extremes of EL (e.g., supercentenarians),
which may further reveal the extent of the contribution of cardiovascular genetic determinants to
ageing successfully.
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